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ABSTRACT 
"TUMOR-TARGETING APTAMERS FOR THE TREATMENT 
OF PROSTATE CANCER" 
Enid W. Choi, B.S. 
December 2011 
Prostate cancer is the most common type diagnosed among men in the United States. 
Random oligodeoxynucleotide (ODN) libraries are used to generate DNA aptamers by 
systematic evolution of ligands by exponential enrichment (SELEX). We explored the 
utility of guanine-rich libraries, and found that some had cancer-selective antiproliferative 
activity that generally correlated with G-quadruplex formation, nuclease resistance, and 
enhanced cellular uptake. We identified several proteins by mass spectrometry that bind 
to GC and cytosine ODNs. We compared the GT library with the classic random library 
for SELEX of whole prostate cancer cells and identified a new aptamer from the GT 
library with enhanced nuclease resistance and antiproliferative activity. We present 
evidence that ASI411, a known G-rich anticancer aptamer, inhibits prostate tumor 
initiating cells. This body of work supports the hypothesis that G-rich ODNs are well 
suited to the development of new aptamers in the treatment of cancer. 
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CHAPTERl 
INTRODUCTION TO NOVEL CONCEPTS IN ONCOLOGY RESEARCH: 
APTAMERS AND TUMOR INITIATING CELLS 
BACKGROUND 
Prostate cancer and the need for new therapies 
Cancer is responsible for one out of every four deaths and ranks as the second 
leading cause of death in the United States (1). More than 11 million people were 
estimated to be living with a history of cancer as of 2005 (the most recent statistic) (6.,J.). 
In 2008, The National Institute of Health estimated the cost of cancer to the nation at over 
$228 billion for the year (6.,1). Although the five year survival rate for cancers of all types 
has improved from 50% (1975-1977) to 66% (1996-2004), the persistently high impact of 
cancer on the American population, including patients, their families, and the economy, 
make further endeavors in cancer prevention, detection, and treatment a necessity in this 
country. In addition, according to the World Health Organization, cancer rates in the 
world are on the rise. Reasons underlying this statistic include a longer-lived - and thus 
increasingly aged - population and changes in lifestyle, such as Westernization of the diet 
and increased rates of smoking, in areas with previously low cancer incidence. It is clear 
that cancer is a serious problem that affects a large portion of the world's population and 
will continue to do so for years to come. 
Prostate cancer is the most common non-cutaneous cancer type diagnosed among 
men in the Western world. After lung cancer, it is the second leading cause of male 
cancer-related death in the United States (J). In 2010, approximately 217 thousand men 
were diagnosed with prostate cancer and 32 thousand died from this cancer (the 
approximate capacity of 68 jumbo jets). African American men are particularly 
vulnerable to prostate cancer with a death rate more than double that of white men (J). 
The reasons behind this discrepancy are incompletely understood at this time, but merit 
further investigation. The yearly cost of treating prostate cancer has been estimated at 
$2.3 billion, making it the most expensive cancer to treat among men (followed by lung 
and then colorectal) (1). Prostate cancer patients who undergo androgen ablation 
generally experience initial regression of their disease which may last for several years. 
However, with time, most patients will go on to develop castration-resistant prostate 
cancer (CRPC) that must then be treated with chemotherapy. The current first line 
chemotherapy for such patients is largely ineffective, improving overall survival by only 
a few months (1,1). In the last year, four new drugs have been approved as second line 
chemotherapy for CRPC (one for palliation of bony metastases), but again the increase in 
survival is a few months at best (§). Additionally, chemotherapy drugs are generally 
poorly selective, causing serious side effects due to damage to non-cancer cells. The 
average age at diagnosis for men with prostate cancer is 70 years of age (J). Therefore, 
developing more specific therapies is especially important for geriatric patients who often 
cannot tolerate highly toxic regimens. 
Although early stage prostate cancer typically has a high survival rate, there 
remains a clear need for better treatments. Surgical prostatectomy involves significant 
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risk of major side effects like impotence and incontinence. These adversely impact 
quality of life, highlighting the need for new medical technologies that lessen the risk to 
patients. Moreover, advanced prostate cancer is generally insensitive to chemotherapy 
and has a particularly poor prognosis, so novel agents are sorely needed. 
Oligonucleotides as medicines 
Small pieces of synthetic nucleic acid (oligonucleotides or nucleic acid oligomers) 
are now commonly used in a number of different ways as tools for laboratory research. 
Interest is also growing in the possible applications of oligonucleotides as medically 
useful agents. Strategies utilizing oligonucleotides (both in the laboratory and in the 
clinic) are many: 
• Antigene - a synthetic DNA oligomer targets a portion of the genomic double-helix 
DNA to form a triple helix and block transcription of that region (7-9). 
• Antisen,se - a DNA oligomer is designed to be complementary to mRNA encoding a 
specific protein. Base-pairing between the oligomer and the mRNA results in a 
double-stranded molecule which is degraded by the cell, blocking translation of the 
protein of interest (lQ,ll). 
• RNA interference - the oligomer is a double-stranded RNA that is processed 
intracellularly to single-stranded molecules. The RNA-induced silencing complex 
(RISC) pathway is activated, causing degradation of a specific endogenous mRNA 
species (1). 
• Transcription decoy - a double-stranded DNA oligomer mimics the target of a 
specific transcription factor, but does not result in production of protein. The decoy 
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thus decreases the expression of the endogenous sequence eU). 
• Immunostimulating - DNA oligomers containing the CpG (i.e. cytosine-guanine) 
motif act as agonists of Toll-like receptor 9 (TLR9), causing activation of dendritic 
cells and B cells (H,U). 
• Aptamer - a single-stranded DNA or RNA oligomer folds into a sequence-determined 
three dimensional shape that binds specifically to a molecular target and (generally) 
inhibits its function (16-20). 
Though the field of nucleic acid oligomers as clinically useful medications has 
immense potential, the major hurdle of nucleic acid oligomer therapeutics of all types is 
whether or not the drug actually reaches its intended human cellular target. Optimally, 
any such therapy would be given in a systemic fashion and thus must have enough 
molecular stability to withstand degradation while traveling through the patient's 
circulation. Unfortunately, oligonucleotides by nature are particularly vulnerable to 
degradation by serum nucleases such that the half-life of most oligonucleotides after 
systemic administration is on the order of minutes. Another limitation of oligonucleotides 
with intracellular targets (including all those that act via RNA interference) is the low 
degree of intrinsic cellular uptake. Many bacteria utilize uptake of extrinsic DNA 
fragments as an important method to maintain genetic variability within the species, and 
have evolved cellular mechanisms for competency. In contrast, eukaryotic cells have 
protective mechanisms against competency, which in nature act to defend the cell against 
viral infection. 
Several methods have been attempted to address these two major challenges 
(stability and uptake) in the clinical use of nucleic acid oligomers. One strategy is by 
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enhancing resistance to degradation by modifying the nucleotides that make up the 
oligomer, such as substitution of an amine of fluorine group at the 2' position of the 
ribose ring. The phosphodiester linkage of the oligomer backbone may also be modified 
by replacing a non-binding oxygen with a sulfur atom to form a phosphorothioate bond. 
While these changes do achieve the intended effect of increasing the molecular stability 
of the oligomer, they may have detrimental effects such as decreased activity or increased 
toxicity. In terms of the poor delivery of oligonucleotides to the intracellular 
compartment, researchers have employed various vehicles such as liposomes, polymer 
vesicles, genetically engineered viruses, and nanoparticles (21-28). These methods work 
very well in vitro, and are invaluable tools in laboratories worldwide, but translation into 
practical clinical use is limited at this time. 
In summary, although a number of methods designed to enhance oligomer 
stability and/or cellular uptake exist, they all generally decrease the ability of the 
molecule to act at its intended target and/or increase the toxicity of the agent. 
G-rich oligodeoxynucleotides and guanine quadruplexes 
It is well-established that oligodeoxynucleotides (ODNs) enriched in guanine 
bases (guanine-rich oligodeoxynucleotides, or GROs) have distinct properties. Via 
hydrogen bonding, the guanines facilitate the formation of folded three-dimensional 
structures, namely the G-quadruplex (29). This structure is by nature highly stable, with a 
melting point well above physiologic temperatures and a high degree of intrinsic 
resistance to both serum and intracellular digestive enzymes that is much greater than 
typical single- or double-stranded oligomers (days vs. hours). In addition, GROs have 
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been reported as having enhanced cellular uptake in a number of different settings, even 
without any of the chemical modifications or convoluted delivery systems that classic 
oligomer therapy requires (l~,30). The specific mechanism behind the increased uptake 
of GROs is unclear despite decades of research, but may be at least in part secondary to 
the molecular stability of the higher order structure. 
Aptamers: a new class of cancer drug 
Of the different types of nucleic acid oligomer therapeutics, our laboratory is 
focused on the study of aptamers. Aptamer therapeutics are particularly pertinent to the 
field of medical oncology. Currently available chemotherapy drugs can be generally 
divided into two categories: small molecules or monoclonal antibodies. Small molecules 
are typically toxic chemicals, and were the first type of pharmaceutical used to treat 
cancer. Examples include cyclophosphamide, a nitrogen mustard, and cisplatin, a 
platinum derivative. Both these and other drugs nonspecifically kill cells by causing DNA 
damage, and like most small molecule therapeutics, have considerable toxicity to non-
malignant cells. This non-specificity is responsible for the classic chemotherapy side 
effects, including hair loss, gastrointestinal upset, and bone marrow suppression. Therapy 
is based on the rationale that cancer cells are more vulnerable to DNA damage than 
healthy cells. 
Monoclonal antibodies are much larger than small molecules, being comprised of 
four large protein chains. Antibody therapy operates on the premise that tumor-specific 
antigens exist which can be used to distinguish cancer versus normal cells (e.g., 
trastuzumab, which binds the signaling molecule HER2/neu that is overexpressed in 
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many breast cancers, or to target processes that are critically important for tumor growth 
(e.g. bevacizumab, an anti-VEGF antibody that inhibits angiogenesis). Antibodies are a 
much more recent addition to the chemotherapy pharmacopeia, with the first anticancer 
antibody approved in 1997 for the treatment of non-Hodgkin lymphoma Cll). The major 
advantage of anticancer monoclonal antibodies is the high degree of specificity with 
which they bind their antigen target, making them as selective as the antigen against 
which they were raised. 
Each of the two classes described thus far has its own intrinsic advantages and 
disadvantages in terms of clinical use. Aptamers, made of synthetic DNA or RNA that 
bind to specific targets, comprise an entirely new class of cancer drug. An aptamer's 
function lies beyond the traditional paradigm of DNA and RNA acting as passive 
blueprints for proteins or binding in a Watson-Crick sequence-dependent manner as 
required for RNA interference therapies. Instead, the basis for aptamer binding is the 
molecule's specific three-dimensional shape. Just as proteins have a specific structure 
determined primarily by the amino acid sequence, aptamers often contain secondary 
structure motifs (e.g. hairpins, G-quartets) determined by the sequence oftheir nucleotide 
bases. The mechanism of action for aptamers is, in essence, like that of monoclonal 
antibodies. 
In terms of size, aptamers fall between traditional small molecules and large 
antibody proteins, and they have advantages of both of these classic drug types. Aptamers 
are specific for their molecular targets and less likely to cause toxic side effects than 
small molecules. Functionally, in terms of target-binding, aptamers are on par with 
monoclonal antibodies, yet aptamers have additional desirable characteristics including 
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ease of manufacture, molecular stability (i.e. longer shelf life), and lower 
immunogenicity. In addition to frank therapeutic effects, aptamers may also be utilized as 
vectors for targeted drug delivery or for imaging. The same intrinsic characteristics that 
make aptamers appealing as pharmaceuticals also allow them to be easily employed for 
these ancillary purposes; attaching a highly specific aptamer to a drug or radionuclide 
that lacks cancer cell specificity would result in targeted delivery of the non-specific 
molecule. Aptamers lend themselves easily to these types of chemical modifications. 
Compared to most other nucleic acid therapies, aptamers do not necessarily require 
cellular uptake in order to function and need not be limited by transmembrane transport. 
Aptamers are also being explored for non-oncologic purposes. Essentially any 
application that currently uses monoclonal antibodies could be performed with a less 
expensive, more stable, and similarly target-specific aptamer. This includes many 
research assays such as Western blotting, flow cytometry, immunohistochemistry, and 
ELISA. Several aptamers are also in different stages of human clinical trial, particularly 
for anticoagulation (12,20). The first aptamer to be approved for clinical use is 
pegaptanib, an intraorbital injection for the treatment of wet macular degeneration, which 
targets vascular endothelial growth factor (VEGF). It was approved by the Food and 
Drug Administration in 2004 (32). 
SELEX (systematic evolution of ligands by exponential enrichment) 
Aptamers may be engineered through a process called SELEX (Figure 1), an 
iterative procedure of approximately 10-20 cycles. The SELEX technology uses intrinsic 
binding affinity to isolate candidate aptamer sequences that bind to a target of interest 
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Repeat 
up to 20x 
-Remove unbound oligos 
-Capture bound oligos 
-Amplify by PCR 
-Isolate single-strand oligos 
-Sequence 
-Test 
Figure 1: Schematic of SELEX workflow. An oligonucleotide 
library containing a mixed population of billions of sequences is 
applied to a specific target. Sequences that bind are retained and 
amplified by peR. The new pool enriched in target-binding 
sequences is reapplied to the target, and the cycles repeated 
until aptamer sequences become prominent. 
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(typically a purified protein) from an oligonucleotide library of millions of individual 
species. Briefly, a library of single-stranded DNA or RNA molecules of different random 
sequences flanked by known primer-binding regions is applied to the target. For a library 
of 26 unknown bases between the primer-binding regions, the number of possible 
different species is on the order of 1015 (26 positions, with each position having equal 
likelihood of being A, C, T, or G; 426 = 4.5 X 1015 possible sequences (Chapter 2)). Some 
sequences will bind to the target. The unbound sequences are removed, and those 
remaining are detached and amplified by PCR. The PCR product, now enriched in target-
binding sequences, is purified and then reapplied to fresh target for the next round of 
SELEX. As these steps are repeated, the sequences that bind with greatest affinity will 
become increasingly prominent, and candidate aptamers can be identified. 
Aptamers generated by SELEX have the same problems with molecular stability 
(i.e. resistance to degradation) and cellular uptake as other therapeutic nucleic acid 
oligomers. In addition to the previously discussed standard oligomer modifications to 
enhance stability, SELEX may address this issue "upstream" with the use of chemically 
modified or L-configuration nucleotide bases in the starting libraries and PCR reactions 
such that the selected aptamers have intrinsic stability and do not require downstream 
modifications that may adversely affect their activity or safety profile. 
In this project, two upstream SELEX variations to improve molecular stability 
and cellular uptake are described and will be discussed fully in Chapter 4. The first is the 
utilization of a starting oligomer library that is G-rich. We propose that such a library will 
contain fewer sequences, with a higher proportion of molecules that can form G-
quadruplexes. The library will thus have more molecules with the naturally enhanced 
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stability and uptake associated with this tertiary structure. This hypothesis is strengthened 
by the observation that many aptamers produced by SELEX using the standard (non-G-
rich) starting library have been reported to be able to form G-quadruplexes. Our second 
variation is to perform whole-cell SELEX; but, instead of simply selecting sequences that 
bind to the cells, we select for those that have been internalized by the cell. Rather than 
attempting to target a particular mechanism to transport the oligomer across the cell 
membrane, we propose to let the cell determine which sequences are able to do so. This 
method could handily address the issue of poor cellular uptake of oligomers, allowing us 
to generate efficiently internalized aptamers that would be ideal for drug delivery of 
molecules such as siRNAs for which transport across the cellular membrane is an 
effective-dose-limiting hurdle. 
"AS1411" is the first anticancer aptamer in human trials 
Dr. Paula J. Bates (the mentor for this proposal) and her colleagues have already 
discovered aptamers that selectively kill cancer cells (33-37). One of these, a G-rich 
oligodeoxynucleotide (ODN) called AS 1411 (previously known as AGRO 1 00), is the 
first anticancer aptamer to enter human clinical trials (ll.). AS 1411 was initially 
discovered following a chance observation that a particular DNA sequence had 
significant antiproliferative activity against the DU145 prostate cancer cell line. F,urther 
studies on AS 1411 proved that it binds to nucleolin, a protein that is highly expressed on 
the surface of cancer cells but not normal cells. Dr. Bates' work thus not only led to a 




Phase I and Phase II clinical trials of AS1411 have shown promising results that 
are remarkable for the lack of major side effects (11,38). AS1411 has been tested against 
metastatic renal cell carcinoma (MRCC) and acute myelocytic leukemia, and may 
ultimately prove useful in treating other metastatic cancers such as prostate. Of twelve 
MRCC patients in the Phase I trial, one had a complete response, one had a partial 
response (70% tumor shrinkage) and seven more had disease stabilization ranging from 2 
to 15 months. This aptamer clinical trial is the first of its type, indicating an almost 
wholly unexplored niche for new, more specific anticancer aptamers. 
The clinical response to AS 1411 is very unusual in that a single treatment may 
have no immediate effect, but over several months may cause complete tumor regression 
with no additional treatment. Due to this curious effect, one hypothesis of this project is 
that AS 1411 and other aptamers may act by targeting cancer stem cells. 
Tissue stem cells, cancer stem cells, and tumor initiating cells 
Tissue stem cells (also known as "adult stem cells" or "somatic stem cells") are 
capable of both differentiation and long-term self-renewal. They are now believed to exist 
in most if not all organs of the human body, remaining quiescent until signaled to divide 
for tissue maintenance or repair. Though elusive, the definitive identification of tissue 
stem cells is slowly being pinpointed in many different systems such as the bone marrow, 
skin, gastrointestinal tract, bronchial epithelium, and prostate gland (39-42). These stem 
cells are also responsible for common hyperproliferative disease states such as 
hyperkeratosis and benign prostatic hyperplasia (BPH). In the prostate, the malignant 
version of such over proliferation is prostate cancer. 
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It has long been recognized that cancers have diversity within their cell 
populations (e.g. stromal, immune cells), but until recent years, the extreme diversity of 
the cancer cell population itself within a single malignancy has been largely overlooked. 
Many recent publications report a rare subgroup, dubbed cancer stem cells (CSCs), which 
appear to divide and differentiate to make a tumor just as benign stem cells do to make a 
healthy tissue (43-46). CSCs were first detailed in the context of acute myelocytic 
leukemia (AML) (47,48). Cells were isolated from human patients based on cell surface 
marker profiles and injected into mice. These cells proliferated and repopulated in the 
mice into AML pathologically identical to the disease in the original human patients. 
Other cells without this surface marker profile were wholly unable to cause cancer in the 
mice. Since this first report, CSC populations have been characterized in breast, brain, 
prostate, ovary, colon, and other solid tumors. In these organs, it may be only this small 
population (generally between 0.01 and 5% of the total cancer cells) that is able to 
establish and perpetuate a tumor. 
Current anticancer therapies focus on rapid shrinkage of tumor volume, and 
indeed this is the primary objective of most cancer research models. However, the 
majority of cancer patients who enter remission will eventually suffer a relapse of their 
disease. The concept of CSCs could explain this sad phenomenon. If CSCs comprise only 
a tiny percentage of the total tumor, divide slowly, are resistant to chemotherapy, and are 
responsible for the perpetuation of the tumor, then even those cancer therapies that cause 
dramatic clinical responses may leave the CSCs unscathed (49). The surviving CSCs 
would reestablish the disease in time. On the other hand, a therapy that selectively targets 
CSCs may initially appear to have no effect on tumor growth, but over time the tumor 
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would shrink and finally disappear. (Figure 2) This is precisely the effect shown by 
AS 1411. Furthermore, most of the morbidity and mortality associated with cancer is due 
to distant metastases. If only CSCs are able to form a metastasis, then anti-CSC therapies 
could potentially be used as prophylaxis for cancer spread. 
The nascent field of CSC research is fraught with conflicting reports as the 
methodology slowly becomes established. One confounding element is the inconsistency 
of the very definition of "cancer stem cell." In 2006 the American Association of Cancer 
Research convened a CSC workshop to discuss guidelines for this rapidly growing area 
of study. At that time a CSC was defined as "a cell within a tumor that possess[ es] the 
capacity to self-renew and to cause the heterogeneous lineages of cancer cells that 
comprise the tumor" (50). Despite this guideline, many researchers use the term CSC for 
subgroups of cancer cells that can reproducibly grow a tumor; the feature of self-renewal 
is often not addressed. For this situation, the term tumor initiating cell (TIC) is preferable, 
and this term will be used throughout this body of work. 
Different research groups propose varying and overlapping properties for TICs: 
TICs alone are sufficient for the formation of cancer, there are different types of TICs 
which may have varying tumor-forming capacities, TICs might make up the bulk of the 
tumor rather than comprising a rare subpopulation, and many cells (both benign and 
malignant) have to potential to become a TIC. Whether or not a true self-renewing CSC 
compartment exists, within a given malignancy there is a high degree of cellular 
heterogeneity that has been largely ignored in the development of new cancer therapies. 
Certain subpopulations of cells are known to be markedly more invasive, proliferative, 
and/or stem-like (i.e. having stem cell markers and features). Therefore, despite the 
14 

























Figure 2: Cancer stem cells (green) and clinical implications. 
Treatments that spare cancer stem cells may initially have a 
dramatic clinical response, but given time the intact stem cell 
compartment will repopulate the tumor. Conversely, treatments 
that destroy the cancer stem cell subpopulation may appear to 
have limited initial effect, but with time the tumor spontaneously 
regresses. 
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controversy surrounding the study and terminology of CSCs, TICs, and different cancer 
cell subtypes, the basic concept of a subpopulation of cancer cells that is particularly 
responsible for tumorigenicity is becoming widely accepted and must be addressed in 
cancer drug development. 
Aptamers and cancer stem cells 
Upon further consideration, aptamers and CSCs have many additional aligning 
features that make the study of their relationship even more compelling: 
• CSCs are largely quiescent, making them less vulnerable to chemotherapies that 
target rapidly proliferating cells (51-53). Unlike most chemotherapy drugs, aptamers 
do not require cycling cells for activity. 
• CSCs have been shown to express multi-drug resistance efflux pumps that non-
specifically remove small molecules from the cell (g,54,~. Aptamers are not small 
molecules and would likely be unaffected by these pumps. 
• CSCs may have highly activated DNA damage responses, making ionizing radiation 
therapy and many anticancer drugs less effective (43,52). Aptamers do not appear to 
damage DNA as part of their mechanism of action. 
• CSCs may prove to be difficult to access, either embedded deep within a tumor or 
within a protected stem cell "niche" (43,56). Aptamers have better tissue penetration 
compared to monoclonal antibodies, and may be able physically to reach CSCs more 
readily (TI,58). 
RATIONALE AND PURPOSE 
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We believe the field of anticancer aptamers is worthy of further investigation. The 
initial intention of this body of work was the isolation of new cancer-specific aptamer 
sequences via whole-cell SELEX for potential use in clinical oncology. AS 1411 was 
discovered by a chance observation. It is therefore likely that a deliberate approach to 
find new aptamers for specific cancer types will lead to even more promising anticancer 
molecules that may be used for drug-delivery, imaging, and even veritable 
pharmaceuticals. 
We hypothesized that G-rich aptamers are likely to form G-quaduplexes, and may 
be particularly appropriate due to naturally enhanced molecular stability and ability to 
enter cells. We planned to test the utility of a G-rich, non-classical library (specifically, 
comprised of only G and T bases) compared with the classic random N library as the 
starting point for SELEX. To better understand the intrinsic characteristics of G-rich 
libraries in general, we studied the anticancer activity of a number of G-rich libraries in 
comparison with non-G-rich libraries. The unexpected observation that robust anticancer 
activity was exhibited by certain G-rich libraries, without the isolation of a unique 
aptamer sequence, led us to explore biological and biophysical characteristics and attempt 
to relate them to this intrinsic activity. 
With respect to cancer stem cells, elimination of CSCs and TICs may prove to be 
the key to curing cancer and aptamers may be an effective way to target them. A second 
project goal of studying the ability of a G-rich aptamer to target cancer stem cells arose 
from observation of the clinical effects of AS 1411. Though high risk, a positive result 
indicating that AS 1411 is able to selectively target and destroy or neutralize CSCs would 
contribute greatly to the scientific bodies of knowledge of both aptamers and CSCs. 
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Thus, this hypothesis-driven project was planned to explore the potential interactions 
between a G-rich aptamer and CSCITICs, and possibly elucidate a key ability of a known 
G-quaduplex-forming anticancer molecule. To our knowledge, the project described here 
is the first to investigate the relationship between aptamers, a new class of cancer drug, 
and cancer stem cells, a revolutionary new cancer theory. 
HYPOTHESIS AND OBJECTIVE 
• Our hypothesis is that guanine-rich oligonucleotides are optimal for the development 
of new aptamers for use in the treatment of cancer, and may have particular utility in 
the treatment of cancer stem cells. 
• Our objective is to develop new targeted aptamers specific for the treatment of 
prostate cancer. 
SPECIFIC AIMS 
Aim I: Study guanine-rich oligodeoxynucleotide libraries for use in whole cell-SELEX. 
Aim 2: Use non-conventional (G-rich) oligodeoxynucleotide library to identify aptamer 
candidates specific for prostate cancer cells and characterize selected aptamer 
candidates. 
Aim 3: Test the hypothesis that a model aptamer (ASI411) targets CSC/TICs. 
18 
CHAPTER 2 
CANCER-SELECTIVE ANTIPROLIFERATIVE ACTIVITY IS A GENERAL 
PROPERTY OF SOME G-RICH OLIGODEOXYNUCLEOTIDES 
INTRODUCTION 
The appended manuscript describes the characterization of general properties of 
G-rich and non-G-rich libraries of single-stranded oligodeoxynucleotides (ODNs). This 
report has been published in the peer-reviewed journal Nucleic Acids Research (59; 
Appendix A). As discussed, the underlying hypothesis of this body of work is that G-rich 
ODNs are particularly suited for development as new medical therapies due to naturally 
enhanced molecular stability and cellular uptake. We performed a number of experiments 
to establish baseline characteristics of G-rich versus non-G-rich ODN libraries, including 
anti proliferative effects upon a variety of cell lines. We did this in preparation of the 
SELEX project described in Chapter 4, in which we attempt the generation of cancer-
specific aptamers from a non-traditional, G-rich ODN library. The purpose of these 
experiments was initially to test our hypothesis that G-rich libraries would be enriched in 
G-quadruplex forming sequences, which would have increased nuclease resistance and 
cellular uptake compared to traditional libraries. 
Briefly, eleven libraries and three monobasic ODNs of varying lengths and 
nucleotide compositions were studied. We originally anticipated a lack of 
antiproliferative activity (as well as lack of molecular stability and cellular uptake) in the 
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libraries, whereas after isolating candidate aptamer sequences via SELEX we expected to 
demonstrate an enhancement in activity. Although we postulated that G-rich libraries 
would contain a higher proportion of biologically active molecules, we presumed that the 
effects of any such molecules would be masked by the remaining millions of different 
sequences that comprise even a smaller, sequence-constrained library. On the contrary, 
however, we observed that G-rich libraries comprised of G+ T or G+C 
oligodeoxynucleotides exhibited robust inhibition of cancer cell growth while having 
little to no effect on the non-cancerous fibroblast cell line. Interestingly, the library 
comprised of G+A bases did not have this effect. This manuscript is the first to report 
cancer-specific antiproliferative activity exhibited by a library of ODNs rather than a 
single, carefully isolated sequence. 
Based on these unexpected results, a complete scientific project evolved. Our 
experimental ODN samples were divided into those that inhibited the growth of cancer 
calls and those that did not. The two groups were then compared for biophysical and 
biological characteristics, namely higher order structure, molecular stability, cellular 
uptake, and protein binding, in an attempt to correlate these features with this cancer-
specific activity. 
CONCLUSIONS 
In this manuscript, we conclude that cancer-selective anti proliferative activity 
requires "nuclease-resistance, efficient cellular uptake, and binding to specific 
protein(s)." Though we observed some exceptions, as a general rule we showed that the 
libraries that have these biological and biophysical characteristics appear to form G-
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quadruplexes. It is noteworthy that, although G-quadruplex formation appears to be a 
prerequisite for cancer-selective antiproliferative activity, quadruplex formation alone is 
insufficient for this activity. This conclusion has also been reported by previous 
researchers in our group (36). 
Our results, as well as any other elucidation of features that confer anticancer 
activity may aid in the isolation of new cancer-targeting aptamers via the SELEX 
procedure. For example, the identification of a sequence motif (e.g. GGTGGT) that 
correlates with cancer-selectivity if found specifically at the 3' end suggests the utility of 
a starting library in which every sequence ends with this motif. The starting SELEX 
library would be enriched in potential anticancer molecules from the outset, and the 
SELEX evolution process would select for target specificity. 
Additionally, any constraint on the sequence or composition of an ODN pool of a 
given length yields a library that contains fewer molecules. Minimizing the length of the 
starting library while maintaining optimal biological activity would also reduce the 
number of molecules. A library that contains fewer sequences may translate into a 
decrease in the number of cycles required before candidate aptamer sequences become 
prominent enough to be identified, with potential corresponding effects on the costs of 
discovery and manufacture. For these reasons we studied both nucleotide composition 
and library length, and observed that a library with as few as eighteen nucleotide bases in 
length exhibited virtually the same inhibition of cancer cell growth as one nearly twice as 
long (34 bases). 
We concluded that, in general, the "active" anticancer libraries showed evidence 
of G-quadruplex formation and that this feature was critical to the intrinsic activity of the 
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library. We thus pursued the possibility of using a G-rich ODN library, smaller and 
enriched in G-quadruplex forming sequences, as the starting point for SELEX rather than 
the classic, larger, random N library (Chapter 4). 
Regarding the GA 26mer ODN library, we observed that this library had a unique 
CD spectrum that is consistent with data previously reported by other researchers for 
G+A ODNs. The spectrum is believed to signifY stacked guanine bases, but whether or 
not this translates into a G-quadruplex is uncertain at this time. It has been reported that a 
GA aptamer that binds to the bovine prion protein does form a G-quadruplex (60,Q.l) but 
perhaps the majority of species within the GA 26mer library are unable to form this 
structure due to the relatively bulkiness of the adenine base compared to the pyrimidines 
(thymine and cytosine). If it is indeed formation of G-quadruplexes that is ultimately 
responsible for selective antiproliferative activity against cancer cells, it is likely that the 
percentage of G-quadruplex-forming sequences within the library determines the net 
presence or lack of antiproliferative activity of the library en masse. Therefore, if fewer 
quadruplexes are present in the GA library, it follows that the library would not exhibit 
this activity, along with the corresponding lack of the characteristic G-quadruplex protein 
binding and cellular uptake. This does not rule out the possibility of potential GA-
anticancer aptamers. However, regarding SELEX, we conclude that a GA starting library 
offers little benefit over the classic N library. 
In our EMSA data, we observed unique protein bands in the GC 26mer and C 
26mer samples. The identification of the protein targets of the GC 26mer library may be 
particularly significant in the development of new aptamers as cancer therapeutics, as this 
library had a unique profile of antiproliferative activity against the various cancer cell 
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lines (Appendix A, manuscript, Figure 3E). The C 26mer did not exhibit cancer-selective 
antiproliferative activity, but had a unique CD spectrum suggestive of the i-motif tertiary 
structure (Appendix A, manuscript, Figure 4B) in addition to its unique protein band. 
Studies that identifY GC- and/or and C-binding proteins would therefore be a contribution 
to the body of knowledge ofaptamers and ODN therapies. 
In the following chapter (Chapter 3), we discuss GC and C ODNs in greater 
detail. We describe additional experiments that we performed to identifY proteins from 
cancer cell extracts that bind to the GC 26mer library and the C 26mer ODN. We discuss 
the implications of the identified proteins, including possible mechanisms of action. We 
close Chapter 3 with a description of future experiments and directions, especially the 
validation of proteins identified as binding to these ODNs of particular interest. 
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CHAPTER 3 
PROTEIN TARGETS OF THE GC OLIGODEOXYNUCLEOTIDE 26MER 
LIBRARY AND POLY-DEOXYCYTOSINE 26MER MOLECULE 
INTRODUCTION 
The significance of nucleic acid-binding molecules 
It was at one time accepted that the role of nucleic acid within a cell was largely 
passive. According to the central dogma of molecular biology, DNA acts as an 
information repository that is passed down during cell division and contains instructions 
to make proteins. Proteins were thought to be the active components of biology that 
perform virtually all essential cellular functions. RNA was believed to be little more than 
the machinery that translates the DNA information into the final functional protein end 
product. 
While the central dogma still holds true, it is now known that the nucleic acids of 
the cellular genome playa more nuanced and dynamic role that first envisioned. DNA in 
and of itself has intrinsic functional activity including regulation of gene expression and 
intracellular signaling. Epigenetic modifications have been implicated in a number of 
disease states including Alzheimer's disease, rheumatoid arthritis, and several kinds of 
cancer (62-64). RNA comes in a variety of subspecies with different functions such as 
riboswitches, ribozymes, and microRNAs, in addition to the classic mRNA, tRNA, and 
rRNA types (65,66). Clearly, nucleic acids are both more complex and much more 
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biologically active than was once postulated, and will require further investigation in 
order to be fully appreciated. It follows that identifying and elucidating molecules that 
bind to nucleic acids, including both endogenous and synthetic aptamer species, will have 
important implications not only in the development of medical therapeutics (the goal of 
this project), but also in fundamental molecular biology. 
Treatment strategies in the development of new pharmaceutical agents that utilize 
nucleic acid binding may thus be designed in two different ways. The first is by 
engineering synthetic nucleic acid aptamer therapeutics to bind to clinically. relevant 
targets. The second is by identifying endogenous nucleic acid structures that play 
important roles in disease states and designing small molecules, or monoclonal 
antibodies, or even nucleic acid aptamers that target them. 
Rationale for studying GC ODN library- and dC-binding proteins 
Our manuscript (Appendix A) makes the following observation regarding protein 
binding using radiolabeled ODN libraries and monobasic samples and a whole cell lysate 
from prostate cancer cells: that the GC 26mer library (which has intrinsic and selective 
antiproliferative activity against cancer cells) and the C 26mer ODN «dCb, which does 
not have antiproliferative activity at all) each exhibit unique protein bands that differ both 
from one another and from all the other libraries and monobasic ODNs that we studied 
(Appendix A, Figure 7, B3 and B4, respectively). 
These unique protein binding data are of particular scientific interest for the GC 
library, as this library has different cancer type selectivity than the GT libraries 
(Appendix A, Figure 3A); while the GT libraries inhibited the growth of every cancer cell 
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line tested, the GC library exhibited antiproliferative activity similar to the GT libraries 
against the lung and prostate cancer cell lines, but only moderate activity against breast 
cancer cells. Correspondingly, the fluorescently-Iabeled GC 26mer library exhibited 
cellular uptake that was comparable to the GT library in lung and prostate cancer cells, 
but relatively reduced in breast cancer cells. [t may be that the GT and GC libraries act by 
distinct mechanisms of action and through distinct molecular targets, and that the target 
of the GC library is expressed at different levels in the breast cancer cells compared to the 
other cancer cell types tested. Identification of such a target would shed light upon a 
possible tumor specific target as well as the mechanism of the cancer-selective 
antiproliferative effect of the GC ODN library. Such data would also suggest the 
possibility of using an ODN library containing only guanine and cytosine as a starting 
point for SELEX to generate aptamers against specific cancer types known to be enriched 
in that target molecule. As discussed in Chapter I, we hypothesize that guanine-rich 
oligonucleotides are optimal for the development of new aptamers for the treatment of 
cancer and one of our specific aims is to study guanine-rich ODN libraries for use in 
SELEX against cancer cells. The study of proteins that bind to the GC library therefore 
furthers the goals of our project. 
The primary aim of this body of work is to develop new aptamers for use as 
oncology therapeutics. Although the poly-C ODN exhibited no intrinsic anticancer 
activity, cytosine-rich stretches of DNA are able to form a highly dynamic, pH-dependent 
quadruplex structure called the "i-motif' (discussed further below). This non-canonical 
nucleic acid structure may playa regulatory role by acting as a biological switch in the 
activity and/or expression of guanine-rich areas, as a cytosine-rich strand is the natural 
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complement of such regions. Guanine-rich regions (that may themselves form G-
quadruplexes) are prevalent throughout the human genome, and include centromeres, 
chromosome 19, immunoglobulin switch regions, and disease states involving the X 
chromosome (Fragile X) (67,68). G-rich regions are also seen in the promoters of many 
genes important in cancer biology, such as c-myc, c-kit, VEGF, HIF-l, KRAS, MEN-I, 
RET, and RB (69). Perhaps the most well-known G-rich area of the human genome is the 
telomere, which has far-reaching implications and effects on the biologies of cancer and 
of aging, and is an attractive therapeutic target of much pharmaceutical interest. Several 
citations in the literature report that the corresponding C-rich telomere strand forms i-
motifs that may eventually be shown to act in the regulation of the telomere, and thereby 
impact in the field of oncology (70-72). 
Only a handful of proteins that specifically bind to poly-C ODNs and/or the i-
motif have been identified (lQ). Therefore, the identification of a new i-motif-binding 
protein, though perhaps not overtly pertinent to the development of new anticancer 
aptamers, would be a contribution to the scientific field of aptamers and their targets and 
could eventually be significant in the development of cancer therapeutics. 
We chose not to characterize proteins binding to the GT library because we 
suspected that such proteins would have a high degree of redundancy with the proteomic 
analysis of AS 1411, ODN comprised solely of guanine and thymine bases that has been 
extensively characterized by our laboratory previously (37). As expected, each library 
exhibited a high number of protein bands; we focused our efforts only on the bands in the 




Endogenously, stretches of nucleic acid that are especially GC-poor or GC-rich 
have been reported to have important biologic functions. The guanine-cytosine base pair 
is joined by three hydrogen bonds, while the adenine-thymine bond is joined by only two. 
Therefore, sections of genomic DNA that require frequent separation, such as promoter 
regions, tend to have low GC content. Conversely, nucleic acids with high GC content 
may form higher order structures that depend on this strong complementary base pairing. 
For example, structured RNA species (e.g. tRNAs, rRNAs, ribozymes) often contain a 
high percentage of G + C bases which incur molecular stability to the fragile RNA 
molecule by forming shapes such as stem-loops and cloverleaves (73). Riboswitches are 
a type of structured RNA that are common in bacterial species, and denote an 
untranslated portion of an mRNA molecule that may bind to proteins that regulate 
expression of that mRNA - in other words, an endogenous RNA aptamer. One recent 
report describes a new class of riboswitch that binds to the biologically important 
molecule S-adenosylmethionine which was identified by analyzing regions of genomic 
DNA with relatively high GC content that did not contain known genes, but did precede 
metabolic genes. The authors' rationale was that stretches of DNA with these features 
were likely to be enriched in such metabolically active RNA species (74). 
Another role of GC-rich stretches of DNA involves epigenetic modifications. 
Epigenetic methylation occurs most often upon cytosine bases that are immediately 
followed by a guanine (CpG). The term "CpG island" is defined as a region that 1) is 
greater than or equal to 200 bases, 2) is comprised of at least 50% cytosines and guanines 
(i.e. GC-rich), and 3) has an observed to expected G+C ratio of at least 0.6. Given this 
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definition, CpG islands are found in the 5' promoter region of approximately 60% of 
human coding genes, and methylation at or around the CpG islands can block 
transcription of those genes. Aberrant methylation of promoters has been implicated in a 
number of disease states; global hypomethylation is a known feature of cancerous cells, 
as is hypermethylation of important tumor suppressor genes (62). The study of GC-rich 
nucleic acids may therefore impact the study of oncology. 
In addition to sequences containing approximately equal numbers of Gs and Cs, 
individual molecules within the GC library may contain either relatively more guanines 
or relatively more cytosines. Guanine-rich molecules may form the highly stable G-
quadruplex, while cytosine-rich molecules may form the i-motif. One must also consider 
the possibility that multiple molecules within the library may assemble into a multiplex, 
forming not only secondary and tertiary, but also quaternary structures with or without 
complementary base pairing. It may be that the GC library exhibits its distinct profile of 
anti proliferative activity and unique protein binding pattern due to the prevalence of all 
three structural features: GC-base pairing, G-quaduplex, and i-motif, and that the 
structures may be formed by one or more individual ODN molecules. 
poly-de ODN and the i-motif 
Although C-rich stretches of nucleic acid are relatively less well-studied than 
many other nucleic acid motifs, there exists a small, highly conserved family of 
molecules known as poly-C binding proteins (PCBPs) that playa role in posttranslational 
regulation as well as acting as transcription factors. Certain PCBPs have been shown to 
act in the transcription and posttranscriptional regulation of the androgen receptor, an 
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important signaling pathway in prostate cancer (]2,76). An increase in PCBPI levels was 
associated with a decrease in AR expression, and knockdown of PCBPI caused an 
increase in AR. As AR is not expressed in prostate cancer stem-like cells, PCBPs may be 
a potential therapeutic target. The C-rich telomere strand is also known to bind PCBPs. 
In addition to the study of PCBPs and their targets, there is a growing field of 
study concerning the "i-motif," a higher-order nucleic acid structure based upon the 
binding of cytosine residues. The i-motif was first described as "two parallel duplexes 
(antiparallel to one another) with .. .intercalating base pairs," i.e., the i-motif is a cytosine 
based four-stranded tertiary nucleic acid structure (77). The i-motif has been reported 
with both DNA and RNA species, though the RNA structure is much less stable (78). 
The i-motif is pH dependent, and is widely believed to require slightly acidic 
conditions in order to be formed. However, in our manuscript (Appendix A) we 
demonstrate a series of CD spectra of the C 26mer ODN at a range of pH that suggest the 
formation of the i-motif up to a pH of 7; other researchers report similar observations at 
neutral and even somewhat alkaline pH (59,79). If the i-motif is able to be formed at 
physiologic pH, then it is likely to be biologically relevant. Alternatively, the i-motif is 
known to be highly dynamic and readily affected by the nucleic acid's microenvironment 
(pH, ion concentration) (2009, Zhou et al.), and therefore could function as a regulatory 
switch. Manipulation of the i-motif formation and stability could then be used to exploit 
biologic function. As an example, single-walled carbon nanotubes have been shown to 
induce the formation of the i-motif in telomeric DNA and to stabilize this structure, 
enabling the S 1 nuclease to cleave the single-stranded hairpin loops resulting in 
degradation of the telomere (IDl). This phenomenon may potentially be exploited for 
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therapeutic purposes in the investigation of cancer and also of aging. 
Identification of GC- and C-ODN-binding proteins 
After submission of our manuscript describing cancer-selective anti proliferative 
activity of certain guanine-rich ODN libraries, we subsequently pursued the identification 
of proteins that bind to the GC and C ODNs. We studied these ODNs in comparison with 
the Nand GT libraries, reasoning that the unique bands seen in the EMS A data 
(Appendix A, Figure 7) should be present in samples containing cellular lysate and GC 
library or poly-dC ODN, and absent in the Nand GT libraries. The methods and results 
from this preliminary experiment identifying GC- and C-ODN-binding proteins are 
included here. 
METHODS 
Pull down of GC 26mer- and C 26mer-binding proteins 
Three libraries and one monobasic ODN were ordered with biotin attached to the 
5' end: N 26mer, GT 26mer, GC 26mer, and C 26mer. Whole cell lysate of DUl45 cells 
was prepared using RIPA buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.02% 
sodium azide, 1 % NP-40, 0.5% sodium deoxychol, 0.5 mM DTT, 1 Ilg / mL aprotinin,) 
containing 2 mM PMSF and Ix protease inhibitor cocktail (Sigma, St. Louis). One mg of 
cell lysate was preincubated with 10 11M biotinylated ODN, then incubated with 
Neutravidin (a streptavidin analogue) agarose resin (Thermo Scientific). Beads 
containing bound ODN-protein complexes were washed thrice. Bound proteins were 
eluted in 2x SDS-PAGE loading buffer containing 5% (3-mercaptoethanol. 
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Separation of pull down samples 
Samples were subjected to SOS-PAGE using an 8% polyacrylamide gel. The gel 
was washed thrice in water, stained with Simply Blue Safe Stain (Invitrogen) for one 
hour, and destained in water overnight at room temperature. The binding, elution, and 
SOS-PAGE was repeated once, and the samples in the second gel allowed to 
electrophorese for a longer period of time in order to achieve better resolution of the 
higher molecular weight proteins. 
Mass spectroscopy analysis of unique protein bands 
Candidate bands from the GC 26mer and C 26mer lanes (e.g. uniquely present in 
these samples versus N 26mer and GT 26mer) were excised and digested using a 
commercial trypsin-based kit (Trypsin Profile IGO Kit, Sigma). Samples were sent for 
mass spectroscopy analysis at the University of Louisville core facility. 
RESULTS 
GC library and C 26mer bind unique proteins 
Based on the EMSA data, we used biotinylated OONs (GC 26mer library and 
poly-dC monobasic 26mer) to pull down proteins from OU145 whole cell lysate. Proteins 
were eluted from streptavidin beads, run on acrylamide gels, and stained with Coomassie 
blue (Figure 1). We then examined the gel for bands unique to either the GC 26mer 
sample or the C 26mer sample. Though complicated by the presence of a high number of 
bands in the GT library (comparable to the pattern seen with AS 1411), we identified a 
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1. ATP-dependent DNA helicase 2, subunit 2 
2. Isoform 2 of heterogeneous nuclear ribonucleoprotein K 





25~"~~~" ____ ~~~~" 
3. Cd002 protein 
4. cDNA FLJ45706 clone FEBRA2028457, highly similar 
to nucleolin 
5. Hypothetical protein XRCC5 
6. 70 kD protein 
7 -9. Keratin or trypsin 
10. Isoform 2 of ATP binding cassette family F member 1 
11. Isoform 2 of nucleolin 
Figure 1: Precipitation of proteins from DU145 whole cell lysate 
with biotinylated oligodeoxynucleotide librares. DONs with 
bound proteins were separated using agarose beads with a 
streptavidin analog. Excised proteins marked with arrowheads. 
Identified proteins as listed. (-) no library, N 26mer, GT 26mer, GC 
26mer, and C 26mer monobasic DON. 
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number of unique bands in each sample which were excised. Upon analysis by mass 
spectroscopy, identifications were made for all eleven bands. The significant 
identifications are discussed below: 
GC library-bindin2 proteins: 
ATP-dependent DNA helicase 2 subunit 2 (Ku80), IPI00220834.8 
Hypothetical protein XRCC5 (Ku80), IPI00791570.1 
70 kDa protein (Ku70), IPI00465430.5 
Cd002 protein, IPI00216746.1 
cDNA FLJ45706 fis, clone FEBRA2028457 (highly similar to nucleolin), 
IPI00444262.3 
Ku80 and Ku70 
These proteins are the two subunits that form the heterodimer eukaryotic DNA 
repair protein Ku. Ku was originally discovered in the context of autoimmune disease, 
and notably is involved in the genetic recombination responsible for the development of 
the humoral immune system and the vast variety of antibody species (ill. 
Ku plays a critical role in double-strand break repair, both homologous repair and 
non-homologous end joining. It acts by binding to the free ends of linear, duplex DNA, 
and physically juxtaposing the two ends. Ku may then recruit other proteins into an active 
complex called DNA-dependent protein kinase (DNA-PK) to perform the necessary 
repair. The activity of the DNA-PK complex is regulated by the Ku protein. Ku therefore 
has wide ranging effects on cell proliferation, apoptosis versus tumorigenesis, 
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chromosomal stability, and telomere maintenance (ll,83). Mutations in either Ku80 or 
Ku70 have been implicated in a variety of cancer types, including gastrointestinal and 
hematologic. 
In addition to their function as the Ku heterodimer, the subunits Ku80 and Ku70 
may act as unique entities with their own specific functions. Data suggest that Ku80 and 
Ku70 may be active at many different subcellular locations. Though primarily nuclear, 
both subunits have been shown to trans locate into the cytoplasm and to the cell surface. 
The impetus, regulation, and significance of these translocations are poorly elucidated at 
this time. 
Though Ku has not been shown to bind to particular sequences of nucleic acid, it 
is known to bind to free ends of duplex DNA including blunt ends, ends with overhangs, 
hairpins, and telomeres (which contain a G-rich motif and a correspondingly C-rich 
complementary strand) ~). Because guanines and cytosines are natural complements, 
the GC 26mer library likely contains molecules that either self-contain or assemble to 
form duplex DNA structures. It is therefore logical and exciting that molecules within our 
GC library bind to the Ku subunit proteins. 
If compromised in either activity or expression, lack of Ku may lead to 
tumorigenesis due to its role in DNA repair. Conversely, if overactive, excessive DNA 
repair/end-joining may translate into resistance to chemotherapies. Ku could potentially 
be manipulated as therapeutic target, and aptamers evolved from a GC ODN library may 
be a good way to target this fundamentally important protein complex. 
Cd002 protein 
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This ubiquitously expressed human protein has been identified in a number of 
different contexts. Cd002 is officially known as endoplasmic reticulum-golgi 
intermediate compartment (ERGIC)-2, but is also known as Erv41, PTXI, and CDAI4. 
The specific function of this protein is unknown. 
As ERGIC2, this protein is reported to play a role in intracellular transport 
between the endoplasmic reticulum and the Golgi apparatus. The yeast homologue is 
called Erv41. As PTX I, this protein was first identified in 2001 via subtractive 
hybridization, i.e. expressed in normal prostate tissue but not in prostate cancer tissue. 
(W Cd002 has been shown to be upregulated in nasopharyngeal carcinoma and 
downregulated in prostate cancer cells (84,85). PTXI is located on chromosome 12, a 
common site for mutations in advanced prostate cancer. When expressed in a prostate 
cancer cell line, PTXI induced senescence. When downregulated in the same cell line, 
the cells exhibited increased tumorigenicity and invasiveness compared to control 
prostate cancer cells ~. As CDAI4, this protein was shown to have similar effects on a 
different prostate cancer cell line as well as being downregulated in three liver cancer cell 
lines, and to interact with human EF -I ex (W. 
Nucleolin 
Nucleolin was first described in 1973. It is a large protein that is ubiquitously and 
abundantly expressed with a diverse array of cellular functions. It is intimately involved 
in the formation of nucleolus, but is also found in the nucleoplasm, cytoplasm and on the 
cell surface. Nucleolin is purported to play myriad roles in RNA transcription, rRNA 
folding and ribosome formation, intracellular transport of molecules, mRNA stabilization, 
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calcium homeostasis, cell adhesion, and response to viral infections. Nucleolin may be 
heavily modified with phosphate and methyl groups in response to different extracellular 
signals, and as protein synthesis is a critical element in cell growth, nucleolin acts as part 
of the pathways responsible for cellular proliferation. Nucleolin is also known to bind 
directly to oncologically important proteins such as c-myc, VEGF, and topoisomerase 
(88-90). 
As one may expect given nucleolin's role in different aspects of RNA function, 
nucleolin is a known generic nucleic acid binding protein. Among other nucleic acid 
species (including RNA) to which it binds, nucleolin has been shown specifically to bind 
guanine-rich oligonucleotides and G-quadruplexes, including the telomerase sequence 
and ribosomal genes 00. We believe nucleolin is involved in the mechanism of action of 
AS 1411, the G-rich aptamer discovered by Dr. Bates et al. that has been studied as a 
potential therapy for patients with acute myelocytic leukemia. Previous reports from our 
laboratory show that AS 1411 binds to nucleolin, and that anti proliferative effect of 
AS 1411 on cancer cells is correlated with the formation of a protein complex containing 
nucleolin, and that inhibiting nucleolin expression by siRNAs can inhibit certain 
biological activities of AS 1411 (.2.l,92). 
C 26mer-binding proteins: 
• Isoform 2 of heterogeneous nuclear ribonucleoprotein K (hnRNP K), IPI00216746.1 
• Isoform 2 ofATP-binding cassette sub-family F member 1, IPI00013495.1 
• Isoform 2 ofnucleolin, IPI00827674.1 
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hnRNPK 
Heterogenous nuclear ribonucleoprotein K was first described in 1992 as a 
subunit of the hnRNP complex. The protein K element in particular is highly conserved 
across species and is found in multiple subcellular compartments (nucleus, cytoplasm, 
mitochondria). This protein has been shown to bind to a vast array of molecular targets 
including DNA, RNA, kinases, transcription factors, translation factors, splicing proteins, 
a methyltransferase, and a helicase. Like Cd002 (one of the GC-binding proteins that we 
identified), hnRNP K is able to bind eF-la and plays a role in translation (2J,W. It has 
been shown to bind the promoter region of c-myc and to regulate its transcription. hnRNP 
K is dysregulated in a number of different cancer types, and it has been reported as a 
prognostic indicator for colorectal cancer (95-100). It also may be involved in viral 
infection. In one specific example, the FLIP antiapoptotic protein is believed to be a 
prognostic indicator for nasopharyngeal carcinoma; hnRNP K and nucleolin appear to 
work together to regulate the transcription of FLIP (100). Isoform 2 (along with isoform 
1) is the most abundant species and appears to be the predominant form of hnRNP K 
found in the cytoplasm, though distinct properties for this isoform are unknown QQl). 
Due to the diversity of molecules to which it binds, the hnRNP K protein is 
believed to be involved in a wide array of cellular processes. One role that is postulated is 
that hnRNP K acts as a docking platform, able to bind to a variety of players in multiple 
pathways and integrate their intracellular signals into a single downstream effect to the 
maximal benefit of the cell or organism (102). 
One specific capability of hnRNP K is "tenacious" binding to single-stranded 
poly-dC nucleic acids, and not to other monobasic nucleic acid polymers - in other 
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words, hnRNP K is one of the few known PCBPs, and the identification of hnRNP K 
helps to validate our pull-down assay (103, 104). PCBPs are classically believed to bind 
to C-rich RNA species, and it is not yet proven whether or not hnNRP K binds 
particularly the i-motif structure of poly-cytosine nucleic acid, but if so it may playa role 
in any biological switch functions of such structures. 
ABCFI 
The ATP-binding cassette family is a fundamental class of proteins that is 
conserved across species and widely expressed in human cells. Many of these proteins act 
as transmembrane pumps, using energy from the hydrolysis of ATP for active transport of 
many different molecules. There are seven distinct classes that have been identified. 
ABCF is the sixth class, also known as the GCN20 class (54). 
ABCFI, a member of the ABCF class, is also known as ABC27 and ABC50, and 
was first identified as a protein that is upregulated in response to tumor-necrosis factor 
alpha (TNF-a) (lli). It is found in the cytoplasm and the nucleus, but not the nucleolus. 
Unlike other members of the ABC superfamily, ABCF 1 lacks a transmembrane region, 
and is not believed to function as a transmembrane pump. Rather, ABCFI has been 
shown to playa critical role in protein synthesis and cell proliferation. It forms a complex 
with eIF2, GTP, and methionyl-tRNA (the initiator tRNA), and is believed to be critical 
to translation, initiation, elongation, and the formation of polyribosomes (106,107). It is a 
substrate for phosphorylation by CK2 which affects the formation of the polyribosomes 
with eIF2, and thus may act in the regulation of ABCF 1 activity (106). 
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Nucleolin 
A known generic nucleic acid binding protein. Described above as an identified GC 
ODN-binding protein 
CONCLUSIONS 
With this study, we have identified a number of proteins that bind to our GC ODN 
library and C monobasic ODN. Some of these proteins (nucleolin, hnRNP K) are known 
to bind to guanine and/or cytosine rich nucleic acid molecules. Others, although known to 
bind to different types of nucleic acid, have never before been implicated for these 
particular subtypes (Ku, ABCFl). One identified protein (Cd002) has not previously been 
reported to bind to nucleic acid. Many of these protein targets are important in a wide 
array of biologic functions and have potentially major implications in cellular 
proliferation and tumor biology. The use of GC and C ODNs to target these proteins 
could therefore further the development of novel aptamer cancer therapeutics. 
While we have identified several protein candidates, additional studies would be 
required in order to confirm their binding and to test for any role in biological activity. 
The most immediate future experiments for the completion of this project involve the 
verification of the protein targets identified by mass spectroscopy. We must study 
whether or not these protein targets are biologically pertinent by targeting living cells 
(both cancerous and non-malignant) rather than purified protein lysate. Cells growing in 
vitro would be treated with biotinylated experimental and control ODNs, then lysed and 
bound proteins purified via biotin-streptavidin association as before. Following this, we 
would perform Western blotting with target-specific antibodies against the proteins 
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identified by mass spectroscopy. In this way we could assure that the proteins previously 
isolated from the whole cell lysate are indeed targeted by our ODNs of interest within the 
context of a living cell and may potentially play a role in their mechanism of action or 
lack thereof. 
The following step would be to examine the relevance of the identified protein 
targets of the GC library to its profile of anti proliferative activity across different cancer 
types. We are particularly curious about the GC library's markedly attenuated 
antiproliferative activity against the MCF7 breast cancer cell line (manuscript, Appendix 
A). An important question to answer is whether or not the proteins of interest are present 
in differing levels in the growth-inhibited lung and prostate cancer cells versus the less 
responsive breast cancer and virtually unresponsive fibroblast cells. If so, these data 
could shed light on the mechanism of the antiproliferative activity of GC ODNs. The 
specific experiments would depend on the particular protein target and its pathways, but 
could include such classic molecular biology techniques such as analysis of gene 
expression, a functional assay if one exists, and gene silencing or upregulation of the 
purported target to see if the antiproliferative activity can be modulated. 
For example, a possible experimental plan to study the GC library targeting of the 
Ku proteins is as follows: 
• Determine baseline levels of Ku70 and Ku80 in untreated DU145, MCF7, and Hs27 
cells by Western blotting and/or qPCR. Treat cells with GC 26mer, N26mer, AS1411, 
and no ODN, and repeat experiment to determine effect on Ku70 and Ku80 
expression. 
• Treat DU145 prostate cancer cells in culture with biotinylated GC 26mer, N 26mer, 
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AS 1411, and no ODN. Control cell lines (Hs27 and/or MCF7) may also be employed. 
• Make cell extracts from treated cells and isolate proteins bound to biotinylated ODNs 
as before. 
• Perform Western blotting for Ku70 and Ku80 to validate our previous identification 
of these proteins and determine variations in extracted protein levels. 
• Decrease and increase expression levels of Ku70 and Ku80 in DU145 cells using 
siRNA and expression plasmids (with control molecules) 
• Perform MIT antiproliferative and flow cytometry on these modulated cells to 
determine the effect of levels of Ku70 and Ku80 on GC 26mer activity and uptake. 
Use appropriate control ODNs and cells. 
Another interesting follow-up project would be to determine what specific 
sequence(s) within the GC 26mer library bind to these identified GC-binding proteins. 
The most logical course is to perform SELEX with the GC 26mer library upon the 
identified protein target and isolate unique sequences that bind it. We would screen these 
candidate aptamers for high affinity binding to the protein target. The evolved sequences 
that are in fact aptamers for our target could then be taken through the same biophysical 
and biological studies as for the parent library to determine the antiproliferative activity, 
structure, stability, cellular uptake, and protein binding of these new potential 
therapeutics. 
A final possible study could be to test the G-rich GC 26mer library in comparison 
with the G-rich GT library for whole cell SELEX. It would be interesting to compare the 
candidate aptamers evolved from the GC library versus both the classic N library and the 
GT library. Outcomes could include the speed (i.e. number of SELEX cycles) with which 
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candidate aptamers are identified, location and prevalence of guanines within the 
candidates, and increases in cellular uptake and antiproliferative activity relative to the 
parent libraries. Given the attenuated activity of the GC library in breast cancer cells, one 
could argue that GC aptamers are therefore ill-suited for SELEX to find aptamers specific 
for that tumor type. However, the partial anti proliferative activity of the GC library 
against that cell line suggests that it does indeed contain sequences that inhibit the growth 
of those cells. Perhaps the GC library contains more potential anti-breast cancer 
sequences than the N library, but fewer than the GT library. We could perform whole cell 
SELEX with these three libraries on breast cancer cells to study how the antiproliferative 
activity of the parent library affects the SELEX outcomes. 
With the data we have generated from this project involving ODN libraries 
(Chapters 2 and 3), there are a plethora of possible experiments we could perform that 
would help elucidate the nature of G-rich libraries, G-rich ODNs, proteins that bind to 
them, and their mechanisms of action. We decided instead to refocus our efforts on the 




IDENTIFICATION OF A NEW ANTI-PROSTATE CANCER 
APTAMER BY SELEX 
INTRODUCTION 
Therapeutic applications of aptamers 
The field of aptamers (oligonucleotides that form specific three-dimensional 
structures and have target-binding specificity) is new and largely untapped. In terms of 
clinical use, aptamers could potentially be used in a multitude of ways: as imaging 
agents, as vectors for the targeted delivery of drugs, as histology stains for tissue 
specimens, and as bona fide pharmaceuticals. Relative to monoclonal antibodies, 
aptamers are inexpensive and simple to manufacture. Relative to small molecule drugs, 
they are target-specific and because of this have few side effects. Aptamers are more 
easily modified than either of these two other classes of drugs such that the development 
of one target-specific aptamer could easily result in more than one application simply by 
the affixation of different molecules; an aptamer that binds to cancer cells could both be 
tagged with a radionuclide for use in tumor imaging and be conjugated to a drug with 
poor tumor specificity resulting in targeted delivery of that drug: 
Aptamers as chemotherapy 
We believe there is immense potential in the development of new aptamers for 
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clinical use, especially in the management and treatment of cancer. Chemotherapy 
regimens are notoriously difficult for cancer patients to tolerate. The side effects of these 
treatments can be so debilitating that doses must be limited to less than the recommended 
therapeutic level with correspondingly less anticancer efficacy. Consideration for 
nonspecific toxicities is particularly important in patients with poor reserves, such as 
those who are elderly or have other comorbidities (e.g. obesity, heart failure, chronic 
obstructive pulmonary disease, high blood pressure). In today's aging and increasingly 
inactive American society, an ever higher percentage of patients are clinically 
compromised in these ways. Physicians, patients, and patients' caretakers together must 
consider the impact of chemotherapy on the patients' quality of life versus any possible 
extension of life, and strike a careful balance between maximizing the treatment for the 
malignancy while keeping the side effects to a tolerable level. 
Even when the recommended doses of chemotherapy are able to be administered, 
there remains much room for improvement in the generally poor efficacy of most 
chemotherapy regimens. For example, almost half of young patients with early stage 
breast cancer (age less than 50 years; disease restricted to the breast and locoregional 
lymph nodes such that surgery can be curative) will die from their malignancy within 
fifteen years. Adjuvant chemotherapy has been shown to decrease the likelihood of 
recurrence in these patients, but there has been only a modest effect on overall survival 
(42.4% vs. 32.4% mortality at 15 years). The effect is even less robust in older patients 
(50-69 years old; 50.4 vs. 47.4% mortality at 15 years) (108). For metastatic castration 
resistant prostate cancer (CRPC), two landmark clinical trials reported a significant 
increase in survival with docetaxel in 2004. The findings were so compelling that the 
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standard of care for CRPC was quickly revised to incorporate the new data. While any 
improvement in overall survival is good news, the sad fact remains that even this high 
profile, high impact result translates to an increase of only 2-3 months of life (18.9 
months vs. 16.4 months) (1,~). Three new drugs for the definitive treatment of metastatic 
CRPC have been approved in the last year, each of which may confer an additional few 
months' survival (§). These drugs provide important further opportunities for CRPC 
patients, but it is clear that although progress is being made, we must strive for even 
greater advancements in the treatment of patients with cancer. 
The goals in the development of new cancer drugs must therefore be twofold: first 
and foremost, treatments should positively and significantly impact patient survival. 
Second, treatments must have tolerable side effects that have been minimized as much as 
possible. Aptamer drugs may be particularly well suited to meet these two criteria. In 
terms of efficacy, aptamers may be engineered against virtually any target, including any 
identified tumor specific antigen. If such an antigen is truly a valid target in the treatment 
of cancer, an aptamer that is able to be delivered to that target and specifically bind it will 
be a valuable pharmaceutical tool. Aptamers also typically have very few side effects, 
likely for multiple reasons including target specificity, lack of immunogenicity, small 
size, and rapid systemic clearance. In clinical trials, aptamers consistently exhibit large 
therapeutic windows and comfortable safety margins (11, 1 09, 11 0). The Phase I clinical 
trials of AS 1411 were remarkable not only for the tumor regression seen in multiple 
patients, but also for the virtual absence of major adverse events such that no maximum 
tolerated dose (the dose at which toxicities are no longer acceptable) was seen; in other 
words, all the patients were easily able to tolerate even high doses of AS 1411 (11JID. 
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Selective evolution of ligands by exponential enrichment (SELEX) on whole prostate 
cancer cells 
As discussed in Chapter 1, aptamers have an additional advantage over both 
antibodies and small molecules (i.e. traditional classes of chemotherapy) in that they may 
be engineered to bind specific targets with relative ease. The most powerful aptamer-
generating technology is SELEX, an iterative and evolutionary method to screen large 
pools of billions of different sequences for aptamers that specifically bind a target of 
interest (for a more detailed description of the basic SELEX methodology, see Chapter 1, 
Figure 1). Many features of SELEX may be fine-tuned by the user. For example, the 
lengths of the variable and the primer-binding regions may be adjusted as shorter 
aptamers are less expensive to manufacture. It has also been postulated that minimizing 
the lengths of the primer regions reduces non-specific binding and experimental artifact 
(111). For the critical step of purification of single-strand molecules from the PCR 
product, different methods have been described including asymmetric PCR, biotinylated 
primers and streptavidin beads or fixed matrix, gel electrophoresis, and lambda 
exonuclease digestion, each with different advantages and disadvantages (112). 
In the years since its inception in 1990, a plethora of major variations of the basic SELEX 
procedure have been developed (113): 
Library modifications 
• Tailored SELEX - To reduce primer-based artifact, primer binding regions are ligated 
to primerless ODNs before the PCR reaction, then removed from the amplified 
product before the next round of selection (114, 115). 
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• Genomic SELEX - To identify endogenous RNA aptamers and the proteins that bind 
to them, the starting library is based upon the genome of the organism of interest. 
This method can identify protein-binding RNAs and elucidate significant nucleic acid 
regulatory pathways (116, 117). 
Separation of bound versus unbound ODNs 
• Capillary electrophoresis (CE) SELEX - Sequences that bind the target of interest 
experience a motility shift which is exploited during the separation of bound versus 
unbound ODN s using capillary electrophoresis (118-120). 
• Micromagnetic separation (MMS) SELEX - Disposable microchips with large 
magnetic field gradients are used to separate sequences bound to targets affixed to 
magnetic beads (121, 122). 
• Monolex - ODNs are passed through an affinity column and sorted into unbound, low 
affinity and high affinity fractions. The fraction containing the highest affinity 
sequences are amplified once and tested (123). 
Types oftargets (124) 
• Counter SELEX - Many targets are only subtly distinguishable from a related 
counterpart (e.g. disease prion protein vs. endogenous prion protein, ATP vs. ADP). 
To increase target-specificity, the ODN pool is applied to the negative target to 
remove sequences that are able to bind to this undesired target. Unbound ODNs are 
recovered and then applied to the positive target (125, 126). 
• Toggle SELEX - The ODN pool is applied to different protein targets in alternation, 
for example human vs. murine epitopes, to select for aptamers that will have cross-
reactivity (127). 
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• Cell-SELEX - Discussed in greater detail below. 
Cell-SELEX, the variation that may prove particularly relevant for the generation 
of clinically useful aptamers, involves the nature of the target. Rather than using a 
purified molecule as the substrate upon which the ODN library is applied, the target is 
whole cells in culture (128-130). Both prokaryotic and eukaryotic cells have been 
targeted. The method of cell-SELEX has the advantage of applicability; instead of 
targeting a molecule that mayor may not ultimately prove to be clinically useful, the cell 
itself is targeted. With proper selection, the evolved aptamers are able to bind target cell-
specific antigens. It is not necessary to know the identity of the antigen; indeed, cell-
SELEX may very well result in the identification of a novel biomarker. Moreover, the 
aptamers are selected to bind the antigens in their native configuration in their natural in 
situ environment. Experiments may be performed in serum-containing cell-culture 
medium such that sequences are automatically selected for nuclease resistance as well as 
target specificity. Cell-SELEX has been used to identify aptamers that bind to such 
targets as S. aureus bacterium, T. brucei parasite, influenza virus, endothelial cells, 
leukemia cells, and glioblastoma cells (1.2, 125, 130-132). 
We have undertaken two particular innovations to the cell-SELEX technique. The 
first is to amplify only those sequences internalized by the cell as opposed to simply 
binding to the cell surface. The overall objective of this project is to develop new targeted 
aptamers specific for the treatment of prostate cancer, and the major goal of this portion 
of the project is to identify aptamers that are efficiently able to enter prostate cancer cells. 
One of the major hurdles of nucleic acid therapies of all types is poor cellular uptake. 
Although aptamers don't necessarily require uptake in order to function, any aptamer 
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than binds an intracellular target requires a mechanism to cross the cell membrane. An 
exciting potential utility for aptamers with naturally high levels of intracellular uptake is 
as vehicles for other drugs with poor uptake, including almost all other oligonucleotide 
therapies (antigene, antisense, RNA silencing, and transcription decoy strategies, 
discussed in Chapter 1). For therapies that do not require a vector to become internalized, 
a targeted aptamer that is able to achieve high levels inside a cell may still enhance their 
delivery and result in higher cellular concentration. Additionally, should the aptamer be 
cancer-selective, then the appended drug need not be. Identification of cancer-selective 
aptamers with high levels of cellular uptake may thus both allow the introduction of 
molecules that are limited by uptake and confer specificity to molecules that lack it. 
Rather than identifying aptamers against prostate cancer cells and then modifying them 
downstream to enhance cellular uptake, we propose to let evolution determine from the 
start which of the millions of sequences within the library are most able to enter the cells. 
We describe our protocol for isolating only the internalized sequences in some detail 
below, including verification that we discarded both the unbound ODNs from the cell 
media and the ODNs bound to the cell surface. 
Our second SELEX innovation is to test our GT library in parallel with the classic 
random N library. By starting with a library that is smaller (i.e. contains fewer different 
sequences) and is already enriched in molecules that can form G-quadruplexes with the 
desirable characteristics of thermal stability, antiproliferative activity, nuclease resistance, 
and enhanced cellular uptake, we hypothesized that the SELEX procedure would be more 
efficient and require fewer cycles before aptamers sequences can be isolated, and that the 
resultant aptamers would be less likely to require chemical modifications for clinical use. 
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MATERIALS AND METHODS 
Oligodeoxynucleotides 
Oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville, 
IA) or from Invitrogen (Carlsbad, CA): 
• N library (5' - GCG TCA TCA TCG GCT T (Nh6 ACG ACG ATA CTC 
ACG AGC - 3') where N has equal probability of being A, C, G, or T 
• GT library (5' - GCG TCA TCA TCG GCT T (K)26 ACG ACG ATA CTC 
ACG AGC - 3') where K has equal probability of being G or T 
• 5' primer 
• 3' primer 
(5'-GCGTCA TCA TCG GCTT-3') 
(5' - GCT CGT GAG TAT CGT CGT- 3') 
• N cap (5' - ACT ACG GAG GGG CTA GAG CAA CAA GT - 3') 
• N 60cap ( 5' - GCG TCA TCA TCG GCT TAC TAC GGA GGG GCT AGA 
GCAACAAGT ACG ACG ATA CTC ACG AGC - 3') 
• N 26mer (5' - (Nb - 3') where N has equal probability of being A, C, G, or 
T 
• GTcap (5' - GGG TGG GGG TGT TGG GTG ITG GTT TG - 3') 
• GT60cap (5' - GCG TCA TCA TCG GCT TGG GTG GGG GTG ITG GGT 
GTT GGT TTG GCT CGT GAG TAT CGT CGT - 3') 
• GT 26mer (5' - (Kb - 3') where K has equal probability of being G or T 
• AS1411 (5'-GGTGGTGGTGGTTGTGGTGGTGGTGG-3') 
Lyophilized libraries were resuspended in filtered-sterilized water, then heated at 65°C 
for 10 minutes and vortexed vigorously to dissolve. For uptake studies, three thymidine 
bases (TTT) were added to the 5' end of the library sequence to avoid quenching the 5' 
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fluorophore (FAM for flow cytometry and Alexa 488 for confocal microscopy), which 
occurs when immediately proximal to a G-quartet (37). 
Cells 
Four cell lines were used in this study: PC3 and DU145 prostate adenocarcinoma, A549 
lung adenocarcinoma, and Hs27 non-malignant skin fibroblasts. All cell lines were 
acquired from ATCC. Cells were grown in complete cell culture medium of F-12K (for 
PC3) or DMEM (for all others) supplemented with 10% heat-inactivated (15 minutes at 
65°C) FBS and 1 % penicillin/streptomycin. All cells were cultured at 37°C in 5% C02. 
SELEX, selecting for sequences internalized by whole cancer cells 
In a 6-well tissue culture plate, 4 x 105 PC3 prostate cancer cells per well were 
plated in a volume of 1.2 mL complete medium and incubated overnight. For the first 
round of SELEX on the following day, the medium was removed, fresh complete cell 
culture medium was added, and ODN library synthesized with primer binding regions (N 
library, GT library, or no library) was added to a final concentration of 10 f.lM. Cells were 
incubated with the ODN library for one hour, then washed with PBS to remove any 
unbound ODNs. The cells were harvested by scraping in PBS, spinning down, and 
removing the supernatant. To strip away surface proteins and any surface-bound (i.e. not 
internalized) ODNs, cells were incubated with 0.5 mL of glycine-HCI (pH 5.0) for 5 
minutes. Cells were washed thrice with PBS, and finally incubated overnight at 55°C with 
Proteinase K (0.1 mg / mL, Invitrogen) in PK buffer (15 mM Tris-HCI, (pH 8.0), 50 mM 
KCI, 2.5 mM MgCh, 0.5% Tween 20)). The following day, samples were spun down to 
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pellet cell debris and the cell lysate supernatant transferred to fresh tubes, completing the 
first round of SELEX. 
In preparation for the second round, the lysate was used as template for PCR to 
amplify the internalized sequences. PCR reaction tubes were set up using a PCR 
supermix containing enzyme and dNTPs (Invitrogen). In order to produce an excess of 
ssDNA product, the primers corresponding to the ODN libraries' primer binding regions 
were added at a ratio of 20: 1 (4 )lM vs. 200 nM). The deficient primer was manufactured 
with a biotin tag for subsequent removal of dsDNA species from the PCR product. Five 
IlL of lysate or water for negative control were added last. The PCR program began with 
2 minutes at 94°C before going through 25 cycles of 25 sec at 94°C, 25 sec at 55°C, 30 
sec at noc. 
To separate dsDNA from the PCR product, samples were combined with magnetic 
streptavidin beads (Thermo Scientific) for one hour. The supernatant containing unbound, 
unbiotinylated, ssDNA PCR product was removed to fresh tubes. Approximately one 
tenth of this purified product (5 IlL) was added to new cells for the subsequent round of 
SELEX. The remaining cell lysate was stored at -20°C. 
Radioactive peR to detect effectiveness of final wash before lysis 
To ensure that we enrich the sequences that have been internalized by the cells, we 
performed PCR to detect ODNs in the cell culture medium after the addition of ODN, in 
the final wash before lysing the cells, and in the cell lysate. The PCR reactions were set 
up as described above with the addition of 2 microcuries of radio labeled guanine 
nucleotide ([a)2P]-dGTP). Unincorporated nucleotide was removed with TE-Midi 
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SELECT-D G-25 columns (Shelton Scientific, Shelton, CT) according to manufacturer's 
directions, then electrophoresed on denaturing 12% polyacrylamide gels. Gels were 
exposed to film overnight at -80°C and the films developed the following day. 
Sequencing and selection of candidate aptamers 
To identify internalized sequences from each round of SELEX, a portion of the SELEX 
cell lysates were used for sequencing. PCR reaction tubes were set up using a PCR 
supermix containing enzyme and dNTPs (Invitrogen), SELEX primers (not biotinylated; 
Integrated DNA Technologies) at a final concentration of 200 nM each, and 5 )..lL of 
lysate or water for negative control. The PCR program was as described for SELEX with 
the addition of a final step of 10 minutes at n°c. The PCR reactions were used directly 
for cloning using a TOPO vector cloning kit (Invitrogen) according to manufacturer's 
direction and transforming into chemically competent E. Coli. Colonies containing the 
plasmid with the PCR product insert were selected for ampicillin resistance and identified 
by loss of j3-galactosidase function in X-gal screening. Plasm ids from positive colonies 
were purified using a vacuum manifold 96-well high-throughput miniprep system 
(QIAGEN QIAprep Spin Miniprep Kit) according to manufacturer's direction which 
yielded approximately 250 ng/)..lL of plasmid per sample. Plasmids were sequenced at the 
University of Louisville Center for Genetics and Molecular Medicine Nucleic Acid Core 
facility. Approximately twenty sequences were identified from each round of SELEX. 
Sequences were organized by SELEX round, and analyzed for increasing prevalence of 
sequences and/or motifs of nucleotide bases across multiple rounds. 
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Cellular uptake of candidate aptamers 
Flow cytometry 
Uptake experiments were performed with the two candidate aptamers (N cap and GT cap) 
versus the respective parent libraries (N 26mer and GT 26mer). All ODNs were labeled at 
the 5' end with FAM (6-carboxyfluorescein). Four cell lines were studied (PC3, DU145, 
A549, and Hs27). For each sample, 4 x 105 cells were plated and incubated overnight. 
The following day, FAM-Iabeled ODNs were added to make a final concentration of 10 
~M and plates were incubated for one hour. The medium containing unbound ODN was 
removed. Cells were washed thrice and treated with trypsin or TrypLE (Invitrogen) to 
remove surface-bound oligonucleotides and to harvest cells. Cells were kept on ice and 
protected from light until analysis. Propidium iodide (2 ~g per sample) was added as a 
marker of viability. Ten thousand cells were counted after gating to exclude PI-positive 
(non-viable) cells from analysis. Cells were analyzed using a FACScan cytometer. The 
mean fluorescence of cells for each sample was determined using the FlowJo software 
program. 
Confocal microscopy 
Three ODNs samples were manufactured with conjugated Alexa 488: N 26mer, GT 
26mer, and GT cap. Thirty thousand PC3 cells were plated in each chamber of four-
chambered microscopy slides and incubated overnight. The following day, Alexa 488 
ODNs were added to a final concentration of 10 ~M and incubated at 37°C for 2 hours. 
Cells were washed thrice, fixed with 4% paraformaldehyde for 25 minutes, and washed 
thrice more. Coverslips were applied to chambers with a drop of Antifade containing 
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OAPI (Millipore). Cells were analyzed by confocal microscopy using a LSM 510 
inverted confocal laser scanning microscope (Carl Zeiss). 
Quantitative peR of lysa tes of cells exposed to ODNs 
PCR requires the use of primer binding regions. Therefore, candidate aptamers 
were ordered as 60mers (N 60cap, GT 6Ocap) comprised of the captamer sequence (N cap 
or GT cap) with flanking primer binding regions as for the parent 60mer OON libraries. 
To prepare cell Iysates for qPCR analysis for OON uptake: In a 6-well tissue 
culture plate, 4 x 105 PC3 prostate cancer cells per well were plated in a volume of 1.2 
mL complete medium and incubated overnight. On the following day, the medium was 
changed and OONs added (N 60mer, N 60cap, GT 60mer, or GT 60cap) to a final 
concentration of 10 ).lM. Cells were incubated with the OON library for one hour, then 
washed with PBS to remove unbound OONs. The cells were harvested by scraping in 
PBS, spinning down, and removing the supernatant. To strip away surface proteins and 
any surface-bound (i.e. not internalized) OONs, cells were incubated with 0.5 mL of 
glycine-HCI (pH 5.0) for 5 minutes. Cells were washed thrice with PBS, and finally 
incubated overnight at 55°C with Proteinase K (0.1 mg / mL, Invitrogen) in PK buffer (15 
mM Tris-HCI, (pH 8.0), 50 mM KCI, 2.5 mM MgCb, 0.5% Tween 20)). The following 
day, samples were spun down to pellet cell debris and the cell lysate supernatant 
transferred to fresh tubes. 
For the qPCR reactions, Iysates were prepared at six ten-fold dilutions (neat -
1: 1 05) and plated in triplicate with appropriate negative controls in a 96-well qPCR plate. 
Reactions were set up using a 2x SYBR PCR master mix (Applied Biosystems) 
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according to manufacturer's directions. Samples were run on an Applied Biosystems 
7500 Real-Time PCR System machine. 
Mechanistic studies of candidate aptamers (GT cap and N cap) 
MTT anti-proliferative assay 
The candidate aptamers and their parent libraries were tested in triplicate at eight 
concentrations (0, 2, 4, 6, 8, 10, 12, 14 11M) in four cell lines: PC3, OU145, A549, and 
non-cancerous Hs27. We modified previously published MTT [3- (4,5-0imethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assay protocol (16). Briefly, cells were seeded in 
96-well tissue culture plates and incubated overnight. To account for intrinsic differences 
in growth rate, the A549 and OU145 lines were plated at 1000 cells per well, PC3 at 2000 
per well, and Hs27 at 3000 per well. OON stock solutions were then added to each well 
to yield the desired final concentration. Plates were incubated with the OON for five 
days, during which the cell culture medium was not changed. On day five, cell viability 
was determined and the background corresponding to medium alone (no cells) was 
subtracted. For each concentration, the average of the three wells was calculated and 
plotted. Assays were repeated to ensure reproducibility. 
Circular dichroism spectroscopy 
Candidate aptamers and their parent libraries were diluted to a concentration of 5 11M in 
1.5 mL of either water, or 100 mM sodium chloride, or 100 mM potassium chloride. 
Samples were incubated at 95°C for 5 minutes, then cooled on ice until analysis. CO 
spectra were collected at 20°C using a Jasco J-715 spectropolarimeter between 340 and 
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220 nm wavelengths, using 200 nm/min scanning speed, 2 s response time, 5 nm 
bandwidth, and 1 cm pathlength. For each set of samples, the same solution used to 
prepare the ODNs was used as the reference. 
Protein binding to whole cell lysate using electromotility shift assay (EMSA) 
Candidate aptamers were tested in comparison with their parent libraries. Each ODN was 
5'-end-Iabeled with 32p using T4 kinase (Invitrogen). Unbound isotope was removed 
from samples using TE-Midi SELECT-D G-25 columns (Shelton Scientific, Shelton, CT) 
according to manufacturer's directions. Collection tubes containing end-labeled libraries 
were kept on ice, or stored at -20°C for up to one day. The radioactivity of end-labeled 
libraries was measured in a scintillation counter on the day of the experiment. Whole cell 
Iysates from PC3 cells were prepared as follows: Cells were grown till confluent, then 
washed and scraped with HEDG buffer (20 mM HEPES-NaOH, pH 7.8, 0.5 mM EDTA, 
0.5 mM dithiothreitol (DTT)) containing 1 0 % glycerol, Ix protease inhibitor cocktail 
(Sigma, st. Louis) and 0.42 M NaCI at a ratio of 100 f.lL per 75 cm2 culture area. The 
solution was harvested and subjected to three freeze-thaw cycles (liquid nitrogen versus 
room temperature). Samples were centrifuged at 16,000 x g at 4°C for 45 minutes to 
pellet cell debris. An equal volume of HEDG with glycerol and protease inhibitor but 
without NaCI was added to reach a final concentration of 0.21 M NaC!. Fifty thousand 
cpm of radiolabeled-ODN were combined with 2.5 f.lg of cell extract and 5x protein 
binding buffer (Ix is 20 mM Tris-HCI, pH 7.4, 140 mM KI, 2.5 mM MgCh, 1 mM 
dithiothreitol, 0.2 mM PMSF [phenylmethylsulfonyl fluoride D. Samples were incubated 
at 37°C for 15 minutes, then run on a 5% non-denaturing polyacrylamide gel. The gel 
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was fixed in a solution of 10% (v/v) methanol + 10% (v/v) glacial acetic acid in water for 
10 min at room temperature, then exposed to a storage phosphor screen for 2 hours at 
room temperature before scanning. 
Nuclease-resistance in serum-containing medium and PC3 cytoplasmic extract 
Four ODN samples were studied: N 26mer, N cap, GT 26mer, and GT cap. The ODNs 
were 5'-end-Iabeled with 32p using T4 kinase (Promega) and unincorporated y_32p_ATP 
was removed from samples using TE-Midi SELECT-D G-25 columns (Shelton Scientific, 
Shelton, CT, USA) according to manufacturers' directions. Collection tubes containing 
end-labeled samples were stored at -20°C. The radioactivity of end-labeled samples was 
measured in a scintillation counter on the day of the experiment. For each ODN or library 
to be tested, four reaction tubes containing complete cell culture medium without 
antibiotics and four reaction tubes containing 2.5 ).lg PC3 cytoplasmic extract in DMEM 
were prepared. Fifty thousand counts per minute of end-labeled ODN were added to each 
of four tubes. Samples were incubated at 37°C, and tubes were flash-frozen in a dry 
ice/ethanol bath at 0, 1, 4 and 24 h. Frozen samples were stored at -80°C until all samples 
had been harvested. Samples were then thawed on ice and run on 12% denaturing 
polyacrylamide gels. Band density was measured using the UN-SCAN-IT gel 
densitometry application (Silk Scientific, Orem, UT, USA). The percent sample 
remaining was calculated taking the signal of the zero time point lane to be 100%. 
RESULTS AND DISCUSSION 
Radioactive peR indicates success of washes and isolation of internalized ODNs 
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Our goal was to isolate aptamers that were efficiently able to enter the cell. Our 
cell-SELEX protocol must therefore include not only washing unbound ODNs away from 
the prostate cancer cells, but also stripping away any surface bound molecules. Different 
methods have been employed for this purpose. At the beginning of this project, we tested 
both the glycine method described above (harvesting cells by scraping and treating with 
glycine HCl) and a standard trypsin digestion to both digest surface epitopes (along with 
any bound ODNs) and resuspend the cells. An initial round of cell-SELEX was 
performed and the final wash and the cell lysate from both methods tested by radioactive 
PCR for the presence of ODNs. Samples were run on denaturing polyacrylamide gels 
(Figure 1). A detectable band was amplified from the cell lysate but not the final wash for 
the samples from the glycine-treated cells, indicating that ODNs were present in the cell 
lysate after removing cell debris, and that the washing process was effective at removing 
all detectable ODNs after incubation with glycine. The converse was true for samples 
from the trypsin digest, indicating the presence of ODNs in the final wash and a dearth of 
ODNs in the cell lysate. A possible reason for these data is that that the trypsin 
permeabilizes the cells such that internalized ODNs are able to leak out, thus increasing 
the amount of amplifiable ODNs in the wash and decreasing the amount in the lysate. We 
concluded that the trypsin digest was not optimal for our purposes, and utilized the 
glycine stripping method for the isolation of internalized aptamers using the cell-SELEX 
procedure. 
Candidate aptamers identified from both the N library and the GT library 




Figure 1: Radioactive PCR of final wash and lysate. In optimizing our 
SELEX protocol to select for internalized ~ONs, we tested two different 
methods to strip away surface-bound molecules (glycine vs. trypsin). The final 
wash after stripping was clean of OONs for the glycine strip, but not for the 
trypsin. The crude cell lysate contained detectable ~ONs for the glycine-
treated cells, but not the trypsin-treated cells. 
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Figure 2: Radioactive PCR from sequential rounds of SELEX. In round 
one, a 26mer band (the length of the OON starting library) was detectable in 
the cell culture media after adding the OON library, and in the cell lysate after 
1 hour incubation. In later cycles, bands of much higher molecular weight 
were strongly present while the 26mer band was undetectable. These data 
suggest the production of experimental artifact with subsequent cycles. 
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sequenced, yielding a long but by no means exhaustive list of ODNs (Appendix B). As 
expected, in the first two rounds of SELEX for the N library there were few sequences 
that appeared more than once, implying that many more ODN species were present that 
were not selected for sequencing, and that no particular sequence was yet enriched. We 
were surprised to see some sequences repeated from multiple bacterial clones as early as 
round 3, indicating that those sequences were becoming more prevalent in the ODN pool. 
By rounds 4 and 5, the N library candidate aptamer (N cap: 5' - ACT ACG GAG GGG 
CTA GAG CAA CAA GT - 3 ') was virtually the only 26mer that was present. 
It was more difficult to identify candidates from the GT library; as every sequence 
is made of combinations of G and T bases, patterns of bases are more inscrutable. We 
identified some common base motifs among the sequences that appeared to become 
enriched over subsequent cycles. From these, we composed a candidate aptamer (GT cap: 
5' - GGG TGG GGG TGT TGG GTG TTG GTT TG - 3'). These two candidate 
aptamers, N cap and GT cap, were characterized using the same panel of assays we 
utilized for our ODN libraries study and tested for our SELEX selection criterion of 
enhanced cellular uptake in comparison with the parent libraries. 
As N cap was the only candidate seen with the N library SELEX by round 5, we 
discontinued further SELEX cycles for both libraries. For both the N and the GT SELEX, 
we noted some obvious artifacts. An example includes an approximately 400 base 
sequence that evolved clearly in a textbook SELEX manner, becoming increasingly 
prominent with subsequent rounds (Appendix B, Round 3, Sequence 2). There were no 
obvious difference in either frequency or size of artifacts between the Nand GT SELEX. 
Radioactive PCR was performed with media, final wash, and lysates from sequential 
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rounds of N library SELEX (Figure 2). Bands at the 26mer location were seen in the 
media and lysates for the first two rounds, but from round 3 onward we observed several 
bands of much higher molecular weight in all samples. The smaller 26mer band was not 
seen, and we postulate that the larger molecular weight species are preferentially 
amplified resulting in loss or obscuration of the 26mer species. This could explain the 
relative lack of 26mers in the cell lysates as identified by sequencing. The denaturing gel 
data are largely consistent with the sequencing data. 
Candidate aptamers do not exhibit enhanced cellular uptake as compared to parent 
libraries 
Consistent with the SELEX literature, we initially focused our studies on our 
candidate sequences without the primer binding regions. We acquired the candidates and 
their parent libraries without the primer binding regions and with FAM-fluorophore 
tagged at the 5' end: N cap, GT cap, N 26mer, and GT 26mer. To avoid quenching, we 
added three thymidine bases at the 5' end between the sequence of interest and the 
fluorophore for all four OON samples. This modification has previously been shown to 
have no effect on anti proliferative activity for AS 1411 and is standard operating 
procedure in our laboratory. PC3 prostate cancer cells were treated with these OONs and 
then subjected to flow cytometry. To our chagrin, we did not see any enhancement in 
fluorescence with the candidate aptamers relative to their parent libraries (Figure 3A). We 
repeated the experiment using other cell lines (OU145 prostate cancer, A549 lung 
adenocarinoma, and Hs27 non-malignant fibroblasts). We also ordered fluorescent 
libraries and candidate aptamers synthesized with the primer binding regions, reasoning 
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Figure 3: Cellular uptake of FAM-Iabeled oligodeoxynucleotides. 
A) Mean fluoresence in PC3 prostate cancer cells. No enhanced 
uptake seen by candidate aptamers. 8) Confocal microscopy of PC3 
cells. GT cap has less fluorescence than parent library. C) 
Fluorescence of OON stocks alone show a high degree of variation. 0) 
Cellular uptake as measured by corrected mean fluorescence in 
different cell lines. Correction factor based on relative fluorescence of 
OON stock samples. Candidate aptamers have higher uptake than 
parent libraries in all cell lines. GT samples have higher fluorescence 
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that the candidates' selection was performed with these additional bases and that perhaps 
the primer binding regions are required for cellular uptake. Even with these additional 
attempts, we were still unable to demonstrate enhanced cellular uptake (data not shown). 
We also performed confocal microscopy with the fluorophore-tagged 29mer libraries and 
GT cap (N cap was omitted due to consideration of cost and our particular interest in G-
rich ODNs), and again did not observe any enhanced activity (Figure 3B). Relative to its 
parent library, the GT cap sequence actually appeared to have decreased internalization as 
visualized by fluorescence. 
We then examined the ODN stocks themselves. We observed a confounding 
difference in the relative fluorescence of the commercial ODN stock solutions even 
before applying to cells in culture (Figure 3C). In other words, some ODN stocks were 
inherently more fluorescent than others. This difference in relative fluorescence was most 
pronounced in the GT cap sample and could be due to multiple reasons including varying 
degrees of quenching of the fluorophore by higher order structures of the ODNs or 
simply to differences in coupling efficiency during synthesis. To correct for this, in 
parallel with the flow cytometry experiment, FAM-Iabeled ODNs were added in triplicate 
to a 96-well plate containing cell culture medium to make a final concentration of 10 11M 
and incubated for one hour. The relative fluorescence of the samples was measured, and 
applied as correction factors to the measured mean fluorescence observed by flow 
cytometry (Figure 3D). When this method of data analysis was utilized, there was in fact 
enhancement of cellular uptake seen with GT cap relative to the GT 26mer parent library. 
This enhancement was not exclusive to the PC3 cells, but was most marked in this line. N 
cap also had a modest degree of enhancement relative to the N 26mer library in all four 
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cell lines. These data were consistent with MTT data from experiments performed in 
parallel (described below), and indicated that our SELEX protocol did indeed evolve 
aptamers with cellular uptake and that this uptake correlated well with the degree of 
enhancement of antiproliferative activity seen with the candidate aptamers relative to 
their parent libraries. 
We therefore attempted to standardize both fluorescence and ODN concentration 
by measuring fluorescence before treating cells, ensuring that cells were treated with the 
same amount of measured fluorescence (E530 = 100,000), then standardizing the ODN 
concentration by adding unlabeled ODN as needed to a final concentration of 10 f..lM. 
Unfortunately, with this method we were again unable to show enhanced cellular uptake 
by our candidates (data not shown). 
An alternate method to show cellular uptake of aptamers that does not require 
fluorescent ODNs is quantitative PCR. Cells were treated with candidate aptamers and 
their parent libraries, all necessarily with the primer binding regions affixed (i.e. 60mers). 
Cell lysates were prepared, and the lysates used as template in a range of dilutions for 
quantitative PCR using the SYBR green technology. With this protocol, sequences 
internalized by the cell should amplify, and a higher number of ODNs in the lysates 
should require fewer PCR cycles before the SYBR green signal exceeds the background 
threshold. Despite multiple attempts, we were unable to get reproducible data (data not 
shown). One replicate showed increased levels of ODN in the lysates of cells treated with 
GT cap relative to those treated with the GT library, but other replicates showed no 
difference between the samples. Other molecules within the cell lysate may have 
disrupted the PCR reaction. We reasoned that with increasing dilutions (1 part lysate in 
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105 parts water), any disrupting molecules would become so sparse as to be essentially 
absent, but in retrospect perhaps the lack of reproducibility was due to this factor. For 
further attempts one should consider the purification of ODNs from the crude cell lysate. 
However, we did not undertake this task because of the unavoidable issue of the primer 
binding regions. The qPCR required the use of the primer binding regions in order to 
amplifY the ODNs in the template sample. This may ablate any enhanced uptake of the 
candidate aptamers. We have performed anti proliferative MIT assays using our candidate 
aptamers with primer binding regions and found the GT cap had cancer-selective 
antiproliferative activity only without these regions (data not shown). We therefore 
concluded that the aptamer sequence is in fact the 26mer, not the 60mer, and did not 
further optimize this qPCR assay which would require the primer binding regions. 
In summary, despite employing a number of methods, we were unable to 
consistently demonstrate enhanced cellular uptake by our candidates. 
GT cap selectively inhibits the growth of cancer cells with greater potency than the 
GT library 
In parallel with the cellular uptake experiments, we also undertook 
characterization of the candidates with the assays described in our ODN libraries 
manuscript (Appendix A). To assess antiproliferative activity we employed the MTT 
assay. We did not necessarily expect any enhancement in antiproliferative activity in our 
candidates relative to the parent libraries, but believed that the GT cap would likely have 
cancer-selective antiproliferative activity as its parent library does, while the N cap, as a 
non-G-rich sequence from a non-G-rich library, would not. A difference in 
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antiproliferative activity with GT cap versus N cap would illustrate the possibility of 
different utilities for two ODN libraries in SELEX: 1) starting with a GT library and 
selecting for cellular uptake to identifY aptamers that may be used as cancer drugs by 
entering cells and haIting their growth, or 2) starting with the N library and selecting for 
cellular uptake to identifY aptamers that may be used as vehicles but have no intrinsic 
anticancer activity oftheir own. 
We tested our ODNs on four different cell lines: two prostate cancer, one lung 
cancer to study organ specificity, and one non-malignant fibroblast to study cancer 
selectivity (Figure 4, A-D). Consistent with the SELEX literature, we focused our studies 
on our candidate sequences without the primer binding regions (N cap and GT cap). The 
two parent libraries without primer binding regions (N 26mer and GT 26mer) and 
AS1411 were included for comparison. As before (Chapter 2), to illustrate the relative 
activities of the samples, we tabulate the percentage reduction in cell number at 6 f.lM 
oligonucleotide concentration (Figure 4E). For stratification, we consider a reduction of 
30-50% as intermediate antiproliferative activity, and greater than 50% as high. 
We observed an enhancement of antiproliferative activity with the N cap sequence 
relative to the N library in the PC3 cells (28% versus 9% growth inhibition respectively). 
While the change in activity is substantial, the N cap sequence still had only a modest 
absolute effect. Additionally, the antiproliferative effect of the N cap ODN in the non-
malignant fibroblast line was comparable to the effects seen in the prostate cancer cells. 
Both the N cap and the N library had negligible effects on the growth of the lung cancer 
cells which may imply a degree of specificity for prostate cancer cells. We conclude that 
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Figure 4: MTT assay of candidate aptamers compared to parent 
library and AS1411 on different cell types. A) PC3 prostate cancer 
cells. 8) DU 145 prostate cancer cells. C) A549 lung cancer cells. D) 
Hs27 nonmalignant fibroblasts. E) Tabulation of percent inhibition of cell 
growth at 6 ~M DON. Light grey: 30-50% growth inhibition. Dark grey: 
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In contrast, the GT cap sequence exhibited a substantial inhibition of cell 
proliferation that was more potent than the parent library for both prostate cancer cell 
lines. The fold-change was most pronounced in the PC3 cells that were used as the target 
of the SELEX protocol (3-fold for PC3 versus 2-fold for DUI45). Despite selecting our 
GT candidate using prostate cancer cells, the antiproliferative effect was not limited to 
that organ; a similar observation was made upon testing our ODNs on lung cancer cells. 
Though the GT cap had the highest absolute inhibition of proliferation in the A549 lung 
cancer cells, the parent GT library itself has high antiproliferative activity in these cells 
making the fold-change seen with the selected GT cap ODN less than one. Both the GT 
cap and library had virtually no effect on the non-malignant fibroblasts. Excitingly, until 
this study we have not seen an ODN with antiproliferative activity to equal AS 1411. We 
observe that the GT cap sequence is on par with the activity of ASI411 in both DU145 
and A549 cells. 
The data for the parent libraries (N and GT 26mers) in the DU145 and A549 cells 
were largely consistent with our previous findings (Chapter 2). As before, all libraries and 
ODNs have little effect on the growth of the non-malignant cells and all dose-dependence 
curves plateau at a non-zero value implying that the ODNs are inducing a cytostatic 
rather than a cytotoxic effect. We did also assay our candidates and libraries as 60mers 
that included the flanking primer binding regions and tested them for antiproliferative 
activity in the four cell lines. No growth inhibition was seen with these ODNs (data not 
shown), and we conclude that it is indeed the 26mer sequences, not the 60mers, that 
should be considered as the candidate aptamers. 
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CD spectra of GT cap suggests formation of the guanine-quaduplex conformation 
We have previously discussed the limitations of CD data, but CD is well suited to 
offer initial insight into the secondary structures of nucleic acids given consideration for 
ease and cost. In terms of G-quadruplexes, it is generally accepted that positive peaks 
close to either 260 nm or 290 nm are indicative of this conformation (133,134). The 
relative height of these peaks is influenced by the proportion of "parallel" to 
"antiparallel" G-quadruplexes QQ). To assess the molecular structure of our ODNs and 
their parent libraries we studied the CD spectra in three different solutions: 100 mM KCI, 
100 mM NaCI, and water (Figure 5). 
As before, the N 26mer spectra are classic for unstructured nucleic acid with a 
negative peak at 250 nm, a positive peak at 275 nm, and only small changes with 
differen,ces in solution. The N cap ODN, however, does exhibit polymorphism with 
solution. The peaks of the N cap spectra are of highest magnitude in potassium buffer, 
and the spectrum in this solution appears very similar to the unstructured N 26mer 
library. With water, however, the spectrum is suggestive of G-quadruplex formation with 
peaks at 240 nm and 260 nm wavelengths, and a positive peak at 290 nm (.ill). The 
spectrum ofN cap in sodium buffer appears to be intermediate between the spectra of the 
other two solutions. While the sequence of the N cap is not G-rich containing less than 
50% guanines (9 guanines out of 26 bases) and is not particularly suggestive for G-
quadruplex formation, it does contain a guanine-rich stretch that could contribute to this 
structure, especially should multiple molecules assemble. As the positive peak at 290 nm 
is less pronounced in potassium than in water, one could argue against the formation of 
the G-quadruplex by this sequence. Alternatively, these data may be due to simpler 
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Figure 5. CD spectra of candidate aptamers and parent libraries. 
Green - 100 mM KGI. Red - 100 mM NaGI. Blue - water. Ncap and its 
parent library exhibit spectra suggestive of unstructured DNA. GTcap 
and its parent library exhibit spectra characteristic for G-quadruplex 
formation. 






ii~ ~ -: 0.8 
.. > 
~ c: 0.6 
> Q) 
.- U ~ ~ 0.4 
.2 -












Figure 6. Stability of candidate aptamers and parent libraries. End-
labeled libraries incubated with either cell culture media containing 10% 
FBS or PG3 whole cell lysate for up to 24 hours. In the cell lysate 
samples, GT cap has modestly enhanced stability compared to parent 
library, while Ncap has decreased stability. Assay performed once. 
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secondary structures such as hairpins or duplexes. 
For the GT 26mer library, the CD spectra were similar to those previously seen 
(Chapter 2) and are in accordance with our previous conclusion thatthe GT library has a 
high proportion of molecules that adopt a G-quadruplex structure (a mixture of the 
"parallel" and "antiparallel" forms). We reach the same conclusion for the GT cap 
sequence, as the spectra exhibit peaks at the characteristic wavelengths for "antiparallel" 
G-quadruplexes and are most enhanced in the presence of potassium. The spectra of both 
the GT cap and GT 26mer library exhibit substantial polymorphism between the different 
solutions, again consistent with G-quadruplex formation. 
GT cap has modestly enhanced stability relative to parent library 
In our manuscript (Appendix A), we show that maximal degradation of our libraries was 
achieved before 24 hours with no further degradation seen as far out as 72 hours. We 
therefore tested the nuclease resistance of our candidates and their parent libraries for up 
to 24 hours (0, 1, 4, and 24 h). We tested both complete cell culture medium (containing 
10% heat-inactivated FBS) and PC3 cytoplasmic extract (Figure 6) in order to mimic the 
SELEX conditions in which the candidate aptamers were selected. With the cell culture 
medium, little degradation was seen for any of the samples. These data for the libraries 
are consistent with our previously published stability assay (Chapter 2). As the parent 
libraries themselves are largely stable under these conditions, we are unable show 
enhanced stability from our candidate aptamers. We do demonstrate that unlike some of 
our previously studied samples (e.g. AT 26mer, C 26mer) our candidates are not 
appreciably less stable than their parents under these conditions. 
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In the PC3 extract samples, the N cap was clearly less stable than the parent library, and 
was fully degraded by 24 hours while the parent library persisted at that time point. Both 
the GT cap sequence and the GT library exhibited stability for all time points tested. 
Although it is difficult to demonstrate enhanced stability by our GT cap OON because the 
parent library itself was largely stable even at 24 hours, densitometric analysis of the 
bands did indicate that the GT cap sequence was slightly more stable at 24 hours (81 % of 
o hr versus 54%). 
Candidate aptamers have more complex protein binding than parent libraries 
Radiolabeled OONs were incubated with PC3 whole cell extract and subjected to 
an electrophoretic mobility shift assay (EMSA) to study protein binding. ASI411 is 
included for comparison. Samples were analyzed alone (without protein) to examine 
labeling and molecular integrity (Figure 7). The labeling appears unequal across samples, 
and the protein binding data must accordingly be interpreted with caution. As before, we 
observed a difference in migration due to base composition, with the N library and N cap 
migrating faster than the G-rich samples. 
In general, our candidate aptamers displayed more shifted bands than their parent 
libraries. We observe that the band marked "B 1" is present in all samples. A similar band 
was previously seen for both the Nand GT libraries in four different celllysates (Chapter 
2). In our prior study we proposed that this band may represent a general nucleic acid-
binding protein which may incur molecular stability, and these new data are consistent 
with that postulate. The less distinct band/region labeled as "B2" is perhaps very faintly 
visible in all samples, but is certainly most intense in the candidate aptamer samples. This 
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Figure 7: Protein binding of candidate aptamers and parent 
libraries in PC3 cytoplasmic extract. ODNs alone (with no protein) 
and with extract. ODNs alone remain intact from degradation, migrate 
at slightly different speeds, and exhibit some differences in labeling 
efficiency. Candidate aptamers have stronger and more complex 
patterns of protein binding than their parent libraries. AS1411 is 
included for comparison as a representative G-rich, G-quadruplex-
forming ODN. "0" denotes origin of the gel. 
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may be due to the heterogeneity of the libraries (which are comprised of millions of 
possible sequences) versus the single species of each of the candidates; the libraries may 
contain only a fraction of molecules that bind the proteins seen in the B2 band whereas 
likely all the molecules in the candidate aptamer samples will bind. 
As both the EMSA and the nuclease-resistance assay was performed in PC3 
extract, and all OONs were present at the earlier time points that would correlate to the 
time required to perform the EMSA, we are confident that the absence of shifted bands in 
a given sample as seen on EMSA is not due to OON degradation. We conclude that our 
isolated candidates have more complex and more intense (though qualified by the 
difference in labeling efficiency across samples) protein binding in comparison with the 
originating libraries. In our previous work involving OON libraries, we suggested that 
protein binding may be responsible for resistance to nucleases, and these data are 
consistent with our prior results. 
CONCLUSIONS 
Although we were initially gratified to have a single clear candidate from our cell-
SELEX using the N library after only five rounds of SELEX, we were unable to show 
enhanced uptake with the N cap sequence. Though we also examined molecular stability 
and anti proliferative activity, N cap did not display enhancement of these features. The N 
cap was eventually the only 26mer present in our sequencing samples, and we therefore 
conclude that the N cap is an artifact. In the time since we have performed these studies, 
newer literature reveals that a major shortcoming of SELEX is its vulnerability to 
amplification of artifactual error (ill, 130, 136, 137). If even a single molecule of a 
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sequence that binds to an unintentional target is present, it will be amplified by the PCR 
reaction and will become enriched should the false target persist. Although not considered 
necessary at the time, many researchers now incubate the ODN library with the target in 
the presence of salmon sperm DNA, transfer RNA, and/or bovine serum albumin to block 
nonspecific binding. In addition to contamination with an unintended target, there are 
many other potential sources of artifact. One source in particular is the method that we 
employed to separate single- from double-stranded ODNs in the PCR product. Though 
the use of biotinylated primers and streptavidin beads was at the time believed to be 
sound, a subsequent report illustrated significant contamination of the "purified" PCR 
product by double-stranded DNA molecules, streptavidin, and biotin (137). The free 
streptavidin molecules were associated with the formation of cell and ODN aggregates. 
The researchers had previously identified aptamers with high binding affinity from a cell-
SELEX procedure, but when these candidates were ordered for verification and further 
testing, no binding was observed. They concluded that the SELEX procedure was 
confounded by the contamination, particularly the presence of streptavidin which, in 
addition to stimulating the formation of aggregates, may act as an unintentional protein 
target. 
Another source of artifact particular to cell-SELEX is the presence of dead cells 
in the target sample. It is well known that dead cells are more likely to have permeable 
cell membranes, and it has been reported that free ODNs are fifty-fold more likely to 
associate with dead cells than live cells (138). Consistent with this, a recent study found 
that dead cells preferentially bound fluorescently-Iabeled ODNs during the SELEX 
process. Virtually all cells that stained with the viability marker 7-AAD were also 
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strongly positive for ODNs. The authors report the failure in their hands of previous 
experiments (i.e. enrichment of sequences that did not exhibit enhanced binding) that 
neglected the issue of dead cells (136). 
We attempted the SELEX method using a novel GT library and indeed, we were 
able to selectively evolve a candidate aptamer that had enhanced antiproliferative activity 
and nuclease resistance relative to the parent library. Consistent with our previous work 
using ODN libraries, the activity of the GT cap ODN may be dependent upon G-
quadruplex formation, protein binding, and stability. However, despite our identification 
of the GT cap sequence, performing SELEX with the GT library was associated with a 
number of difficulties. The first was the problem of identifYing candidate aptamers. Few 
ODN sequences were repeating by round 5, and the artifact sequences (on the order of 
400 bases in length) were increasingly prominent and likely depleting reagents in the 
PCR reactions. We were forced to resort to an unconventional method of motif-searching 
to find a candidate 26mer. For libraries such as the GT, a pattern analysis software 
program to score sequences and motifs that are becoming enriched could provide some 
clarity. Discussions with the UL biostatistics department indicated that it is possible to 
design such a program for this specific purpose. We would test this program on our data 
set to see if it identified the same motifs/candidates that we identified by hand, and then 
use it on subsequent SELEX experiments (after addressing the issues of artifact). 
Another problem unique to the GT library lies with the PCR reaction, a critical 
step of the SELEX protocol. G-rich ODNs are notoriously difficult to PCR, such that the 
GC content of primers and sequences is an important factor in designing the PCR 
thermocycler program. Variables such as the concentration of magnesium in the buffer 
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must be adjusted in order to effectively amplify GC-rich stretches. In genotyping 
reactions, one group reports that the presence of G-quadruplexes and i-motif sequences in 
the DNA to be amplified consistently produces preferential amplification of one allele 
over the other resulting in error in diagnostic testing (133). Though we did not appreciate 
any differences in the quantity of artifact in the N versus GT SELEX, the high number of 
guanines in the GT library may have been a contributing factor. We used the same PCR 
program for both the Nand GT SELEX, but the GT SELEX PCR could have been 
optimized independently. We expect this procedure would be cumbersome and costly in 
both time and funds as on the order of 25-50 sequences would likely have to be cloned 
for each set of conditions tested. An alternate way to explore this issue is to perform 
SELEX as before with additional samples in which the libraries are applied to no target. 
These controls would help illustrate differences in PCR amplification of the N versus GT 
library. 
Our SELEX protocol was intended to select for cellular uptake, operating under 
the widely accepted premise that increased uptake of our molecule would translate to 
increased activity. Recently published developments from Dr. E. M. Reyes-Reyes from 
our laboratory regarding the mechanism of action of AS 1411 have called this basic 
premise into question (92). At early time points (2 h) the levels of uptake of AS 1411 
actually appears to be higher in benign cells than in cancerous cells, despite the fact that 
AS 1411 has minimal effect on the growth of benign cells while strongly inhibiting the 
growth of cancer cells. Upon further investigation, it was discovered that initial uptake of 
AS 1411 in the cancer cells (but not the nonmalignant cells) is by a unique endocytic 
mechanism called macropinocytosis. Macropinocytosis, as the name suggests, is a 
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process by which cells ruffle the cell membrane and extend a relatively large appendage 
to engulf a sample of their immediate environment. By this endogenous method of 
uptake, cells are able to internalize large volumes of the surrounding media (along with 
any nearby molecules such viruses, bacteria, or drugs) in vacuoles termed 
macropinosomes (139). Macropinocytosis has been shown to occur routinely in a variety 
of cell types, including epithelial cells, fibroblasts, and macrophages. At later time points 
in the cancer cells, AS 1411 triggers hyperstimulation of macropinocytosis by a nucleolin-
dependent mechanism. According to these new data, the absolute level of cellular uptake 
may be less important than the method of uptake by the cell. Therefore, in addition to 
technical improvements to the SELEX protocol, the selection of sequences that are able 
to stimulate macropinocytosis rather than merely internalized by cancer cells may be 
more apt in the study ofG-rich ODNs. A preliminary study in that case would be to study 
the method of uptake of our ODN libraries (N 26mer, GT 26mer, GC 26mer) and to 
investigate which libraries, if any, are able to hyperstimulate macropinocytosis. 
Despite many hurdles, with the utilization of the G-rich GT library we have 
identified a new anticancer aptamer with enhanced antiproliferative activity that is 
selective for cancer cells versus normal cells relative to its parent library. This aptamer 
also exhibited moderately enhanced nuclease resistance and complexity of protein 
binding than its parerit library. The data from the GT cap sequence are consistent with our 
previous conclusions from studying ODN libraries, namely that the cancer-selective 
antiproliferative activity we have observed likely requires nuclease-resistance and 
binding to a specific protein or proteins. As others have also postulated, we believe that 
ODN stability may be necessary for antiproliferative cancer activity, but it is not 
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sufficient in and of itself (37). Although GT cap does appear to form the G-quadruplex 
structure, we reiterate that the causal relationship between G-quadruplexes and 
anti proliferative activity is not yet determined. 
There are now several biotechnology companies that are developing automated 
SELEX procedures (N). As the technology improves, it may soon be possible to order 
aptamers against a particular target as one is currently able to order antibodies against an 
antigen of interest. In terms of commercial generation, SELEX has many advantages over 
antibodies. Not only are aptamers generated ex vivo with the associated simplification in 
standardization and purification, but the random SELEX starting library typically 
contains more different molecules by several orders of magnitude than a mouse possesses 
in its antibody spectrum (136). Screening of so many more different possible molecules 
may lead to greater specificity and selectivity in the evolved aptamers compared to 
antibodies. Alternatively, some reviewers suggest that it may eventually be possible to 
order commercial microtluidic kits for SELEX that would allow the rapid generation of 
target-specific aptamers in individual laboratories (20, 140). 
F or these reasons and with consideration for the cost and effort that would be 
required for optimization in our hands, we chose not to repeat this project. However, one 
variation that we believe would be worthy of pursuit as a pilot study is in vivo SELEX. 
As whole cells are arguably a more clinically relevant target than purified proteins, 
aptamers selected against cancer cells in a true physiological environment may be the 
most applicable variation of SELEX in the development of new cancer drugs. To date, 
very few reports of in vivo SELEX exist. The majority involve the use of plants as the 
target (141,142). A single recent report has generated an RNA aptamer with selective 
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uptake in liver metastases in a mouse model after fourteen rounds of SELEX (143). The 
target of this aptamer has been identified as p68, an intracellular protein that functions as 
an RNA helicase. We suggest an in vivo SELEX proof of principle protocol in mice as 
follows: implant subcutaneous DU145 prostate cancer tumors to athymic nude mice, 
allow tumors to grow until palpable, intravenously inject SELEX starting library (GT 
26mer, N 26mer, or negative vehicle), euthanize animals after one hour, harvest tumors, 
homogenize the tissue, purify nucleic acid from the homogenate, and peR. A new in vivo 
process such as this would likely require a great deal of optimization, but should it prove 
successful would comprise an early and significant contribution to the field of SELEX, 
aptamers, and potentially cancer therapeutics. 
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CHAPTERS 
EVIDENCE THAT AS1411 (A G-RICH APTAMER) INHIBITS 
THE GROWTH OF TUMOR INITIATING CELLS 
INTRODUCTION 
The cancer stem cell hypothesis 
Perhaps the most revolutionary new concept to impact clinical and experimental 
oncology in recent years is the cancer stem cell (CSC) hypothesis GJ,44,49,50,144). 
Though first proposed decades earlier, this hypothesis has truly risen to prominence since 
the mid-1990's. The central postulate is that a self-renewing subpopulation of cells within 
a cancer is responsible for its initiation and perpetuation. A popular representation of the 
CSC hypothesis is the "dandelion model": the malignancy is represented by a dandelion 
weed with the bulk of the tumor comprising the visible portion of the plant and the CSCs 
representing the hidden roots (145, 146). Cutting off the weed at the surface is analogous 
to cancer therapies that merely debulk the tumor. According to the CSC hypothesis, if the 
CSCs are not targeted and destroyed, they will, with time, reestablish the weed of 
malignancy. In theory, this correlates with clinical relapse, which is all too commonly 
seen even after dramatic initial tumor regression. Conversely, a therapy that destroys the 
CSC roots beneath the surface may initially appear to have no effect on the weed, but 
eventually the dandelion would wither away. This is a stark contrast to both classic 
oncology goals of therapy and cancer research end points which include rapid reduction 
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in tumor volume. Should the CSC hypothesis hold true, it will have (and is already 
having) fundamental effects on how cancer is studied and how new cancer therapies are 
developed. 
It has been known for many years that cancer patients in remission routinely have 
cancer cells spread throughout their bodies, yet the vast majority of these cells will not 
proliferate (147-150). This phenomenon suggests the possibility that while many cancer 
cells may be shed from the primary tumor, not every cancer cell is able to establish a 
metastasis. In animal studies, millions of cells from immortalized cancer cell lines are 
routinely injected per mouse in order to establish a xenograft, which implies that not all 
cancer cells within the injection are able to engraft. Although as of yet there are no 
reports showing that CSCs are directly responsible for relapse, a recent study of breast 
cancer patients have shown that following treatment, CSCs make up a higher percentage 
of the residual tumor population and correspond to a poorer prognosis (ill). Another 
group reports a statistically significant relationship between the number of CSCs 
remaining in multiple myeloma patients following treatment and progression free-
survival (152). Though at this point such reports may be considered anecdotal, these 
articles contribute to a growing body of work that supports the CSC hypothesis. 
Clinical implications of the CSC hypothesis 
Current cancer treatments are able to decrease tumor burden and thus morbidity in 
patients. However, response to treatment does not necessarily translate into an increase in 
survival. It is well-known that although most patients with advanced cancer do initially 
respond to oncology treatment (typically a combination of surgery, chemotherapy, and/or 
radiation), the majority of these will relapse and eventually die from their disease, and the 
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difference in time until death for responders and non-responders is often not statistically 
significant. Cancer types for which this has been shown include prostate, pancreas, 
lymphoma, and multiple myeloma (152,153). This phenomenon is in accordance with the 
CSC hypothesis. CSCs are believed to have many features that distinguish them from 
bulk tumor cells and make them intrinsically more resistant to classic cancer therapies, 
including those that target rapidly cycling cells, induce DNA damage, and are substrates 
for transmembrane efflux pumps. This means that current treatments may be effective 
only at mowing down the dandelion at surface level. Such efficacy against bulk tumor 
cells but not CSCs is the logical result of the standard cancer research models - for which 
decrease in tumor volume is a primary research endpoint - used to develop cancer 
therapies. According to the CSC hypothesis, if the CSCs are not destroyed they will 
divide, differentiate, and with time reestablish the malignancy. Worse, the treatment may 
have increased the proportion of cells that are resistant to treatment and/or more 
malignant. In prostate cancer it has been proposed that androgen ablation (castration) 
may stimulate a castration-resistant CSC compartment from quiescence to proliferation. 
This may trigger the development of a castration-resistant phenotype; that is to say, 
castration treatment of prostate cancer patients may actually hasten the progression to 
CRPC (154). To use the CSC analogy, castration is like denying the dandelion nutrition 
and causing it to wither only to stimulate the regrowth of a hardier, starvation-tolerant 
specimen. 
Conversely, targeting the CSC subpopulation alone may also prove clinically 
insufficient depending on the lifespan of the non-CSC population. Although the 
terminally differentiated tumor cell population will, in theory, eventually senesce or 
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apoptose, it is possible that the overall tumor burden may become clinically 
overwhelming to the patient before the tumor regresses. Destroying CSCs without taking 
steps to address the bulk tumor cells may thus result in unacceptable morbidity and 
mortality. Another possibility is that from among the genetically unstable cancer cells 
will evolve a new self-renewing population that can reestablish a CSC compartment. In 
all probability, leaving the bulk tumor cells untreated would increase the chance of such a 
mutation occurring. 
Ultimately, cancer therapeutics will likely evolve into a multi-pronged, 
combinatory approach in which a cytotoxic agent will be combined with drugs that 
targets CSCs. This strategy theoretically will decrease the current tumor burden from 
bulk tumor cells as well as inhibiting regrowth from the stem-like subpopulation. A trial 
recently described for multiple myeloma patients studied the effects of a classic cytotoxic 
chemotherapy drug (cyclophosphamide) in combination with a drug aimed at destroying 
myeloma CSCs (rituximab). In addition to the significant relationship between CSC and 
progression-free survival mentioned above, the researchers found that the surviving CSCs 
had surface-bound rituximab, indicating that the drug was targeting the CSCs 
appropriately but was unable to destroy them in certain patients (152). This report 
strengthens support for the CSC hypothesis of cancer and encourages further study in the 
combinatorial therapy field. 
Theoretical ways to target cancer stem cells 
The most basic strategy in the treatment of cancer is to find the cancer cells and 
kill them, typically by identifying tumor-specific functions or antigens and exploiting 
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them with targeted therapies. Destruction of the CSC subpopulation will likewise involve 
the identification of CSC-specific features. As CSCs are believed to have a unique stem 
cell-like biology, a variety of theoretical strategies to target and neutralize them take 
advantage of stem cell capabilities or requirements. Should such targets be found, a single 
anti-CSC therapy may potentially be effective against many different types of cancer. 
One of the defining characteristics of CSCs is the ability to self-renew. It is this 
ability that allows the CSC compartment to maintain a malignancy. Therefore, one 
therapeutic strategy is to block self-renewal, forcing CSCs to either senesce or divide into 
two differentiated daughter cells with no self-renewal capabilities. With the loss of the 
self-renewing roots of the tumor, the cancer as a whole will eventually wither away. A 
possible complication is that if differentiation is induced, the ex-CSCs would join the 
pool of transit (or "transient") amplifYing cells. Transit amplifYing cells exist in a 
transitory state between stem cells and fully differentiated cells, and are characterized by 
a proliferative capacity that is more limited yet typically more rapid that stem cells. Thus, 
by forcing the differentiation of the entire CSC subpopulation, the global effect on the 
tumor could actually be accelerated growth. This effect should be self-limited, because 
with the loss of the CSC compartment, the terminally differentiated cells will eventually 
senesce. This is a situation in which combination therapy to control the overall tumor 
burden could be employed and keep this transient aggravation of tumor burden within 
clinically acceptable limits. 
Another potential stem cell characteristic that may be exploited in the treatment of 
CSCs is the protected microenvironment known as the stem cell niche. The relationship 
between stem cells (benign or malignant) and their niches is complex and poorly 
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elucidated, but it is certainly highly interactive. It is likely that the stem cells themselves 
contribute to the formation of their niche, and it is known that in normal, benign 
physiology the niche is critical to maintaining the stem cell phenotype. Disruption of the 
niche may mean that the CSCs can no longer survive or function as stem cells and could 
translate into loss of the CSC compartment. An alternate scenario is that an endogenous 
disruption in the regulation of the balance of the niche may have contributed to the 
formation of the cancer in the first place. In the prostate, it has been reported that stroma 
from prostate cancers may actually induce malignancy in previously benign epithelial 
cells (154). That is to say, the niche may not only protect CSCs, but may have caused 
them to develop in the first place. Correction of the aberrant biology of the niche may 
restore benignity to the stem cells within it. The interactions between the CSC and the 
niche is of great therapeutic interest, but should be studied with caution and rigor before 
interventions are attempted. 
As the development of anticancer therapeutics specifically targeted against CSCs 
progresses, it will be important to minimize clinical side effects by sparing benign stem 
cells which share many markers, pathways, and characteristics (e.g. self-renewal and 
niche dependence) with their malignant counterparts. Anticancer therapy of any type 
should have high specificity for cancerous versus normal cells, but the stakes may be 
even higher when considering stem cells. Consider the hematopoietic stem cell; it would 
be wholly unacceptable to target leukemia stem cells only to cause life-threatening 
complications due to compromised immunity or hemostasis. However, in certain organ 
systems the distinction between CSC versus normal stem cell may be of little import 
depending upon the relative significance of the normal stem cell. As an example, breast 
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cancer is most common in older women who have typically undergone menopause and 
have no particular need for the normal breast stem cell population. A therapy that targets 
breast CSCs could therefore also affect the normal breast stem cells with virtually no 
impact on the patient's quality of life. This also holds true for the prostate. Indeed, as 
benign prostatic hyperplasia (BPH) is a common medical condition that negatively 
impacts quality of life in the vast majority of the elderly male population, nonspecificity 
in targeting prostate stem cells could actually be beneficial even outside the field of 
oncology. If a PrCSC-targeting drug is easily tolerated, it could potentially also be used 
as a treatment for this notoriously inconvenient and widespread disease. 
A final caveat is that the CSC compartment may comprise a "moving target" in 
clinical oncology; elimination of CSCs does not rule out the possibility that another CSC 
compartment may arise. One potential source for CSCs is the bulk tumor cells, which are 
notoriously genetically unstable and may undergo mutations that translate into de-
differentiation to achieve a more primitive phenotype. This could perhaps occur when 
subjected to unknown external stimuli from CSC-targeted therapies, similar to the natural 
selection of drug-resistant clones following chemotherapy. Also, the question of the cell 
of origin for cancer in general must be considered. It is possible that a CSC may arise 
from benign stem cells, transit amplifying cells, or fully differentiated somatic cells. A 
recent report from the University of Louisville describes a combination of genes that may 
be manipulated to convert benign mouse fibroblasts to a CSC-like phenotype (155). In 
leukemia, it has been shown that both hematopoietic stem cells and non-stem bone 
marrow cells may act as the cell of origin for cancer (156,157). Another group reported 
that a series of oncogenic insults converted benign prostate basal cells (which likely 
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includes the stem cell compartment) to CSCs, but the same mutations applied to benign 
prostatic luminal cells were insufficient to create a similar effect (158, 159). The 
researchers argue that in the prostate, one possible cell of origin for prostate cancer is the 
benign prostate stem cell. These studies provide insight regarding the fundamental 
question of how cancers develop. Although this question has yet to be answered, factors 
clearly exist that cause one person rather than another to develop cancer in the first place, 
and elimination of CSCs does not remove the potential for another CSC developing from 
other cells with the same environmental exposures and genetic risk factors. 
Cancer stem cells versus tumor initiating cells 
As discussed in the introduction (Chapter 1), the definitions, terminology, and 
methodology of the study of CSCs is far from standardized. For this body of work, we 
will utilize the American Association of Cancer Research definition of "cancer stem cell," 
whereby a CSC is characterized by the ability both to self-renew and to differentiate so as 
to establish and maintain a tumor. (50) The feature of self-renewal translates into the 
long-term survival of the CSC and therefore of the cancer. Asymmetric division allows 
the CSCs to proliferate into a diversity of cells that typically divide rapidly at the outset 
(as transit amplifying cells) and are ultimately responsible for clinical symptoms. 
We observe that many reports involving the characterization of "CSCs" do not 
address the issue of self-renewal. We hold that the more appropriate term for this type of 
cell is "tumor initiating cell" (TIC). TIC refers most simply to a cancer cell type that has 
the capacity for tumorigenesis. Although this property implies the capacity for 
differentiation (i.e. the TIC can give rise to daughter cells that comprise the heterogenous 
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bulk tumor population), TICs mayor may not possess the ability to self-renew; in other 
words, CSCs are a subclass within the broader category of TICs. The general 
characterization of TICs is far from complete and sometimes hotly debated, but in 
addition to the defining characteristic of tumorigenesis, several features have come to be 
widely accepted. These include primitive, stem-like characteristics such as transient 
quiescence, membrane efflux pumps, and enhanced DNA repair mechanisms. Features 
such as these translate into resistance to classic anticancer treatments, and CSC/TICs 
have been strongly correlated to drug resistance and poor clinical outcome in a variety of 
settings (64,160-163). 
One particularly interesting topic in the field of TICs is the discussion of the 
existence of different TIC subtypes. It is known that within the total cellular population of 
a given cancer, there exist subpopulations of cancer cells with different capacities for 
malignant characteristics such as tumorigenicity, proliferation, invasion, DNA repair, and 
drug resistance. In addition to a CSC class within the TIC compartment, perhaps enough 
heterogeneity exists such that some TICs are more tumorigenic than others or some are 
important in certain physiologic settings but not in others. For example, one subclass of 
TICs may be essential to the primary tumor while another variation of TIC is responsible 
for the formation of distant metastases. Information regarding TICs and variations within 
the TIC compartment may prove essential in the treatment of cancer. 
Regardless of the precise definitions of CSCs versus TICs, the degree to which 
these cancer cell classes overlap, and their relative prominence in the total cancer cell 
populations, ultimately it is likely that complete cures from cancer will require specific 
targeting of unique subpopulations and their unique features. This makes the 
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identification of pharmaceuticals that can target these cell types highly relevant in 
oncology research. 
Methods to study tumor initiating cells 
Surface markers 
The first and most common method to characterize TICs is by dividing cancer 
cells into subtypes based on cell surface markers. These markers sometimes have no 
known function, but may descriptively divide the cancer cell population until a signature 
is identified that is enriched in TICs in a process that is similar to the fractionation of an 
organic chemical solution (such as a plant extract) with anticancer activity. The chemical 
solution is divided into fractions that are tested for anticancer activity and the fraction 
with the highest activity identified. This fraction may then be subfractionated and the 
process repeated until in theory a single anticancer molecule may be identified. In the 
case of TICs, the criterion for fractionating cancer cells is tumorigenicity. 
In our project, we investigate the following surface markers: 
• CD24-/CD44+ - CD44+ primary prostate cancer cells have been shown to have 
higher proliferation, tumorigenicity, and metastatic potential than CD44- cells. 
This feature also holds true in prostate cancer cell lines routinely used in cancer 
research (DUI45, PC3 cells) (164,165). The CD24-/CD44+ signature was 
originally described as enriched in CSCs for breast cancer (166). In the prostate, 
cancer cells with this signature have been shown to have higher soft agar colony 
formation, higher tumorigenicity in a limiting dilution nude mouse model, 
differentiation capacity in vivo, and gene expression patterns that are predictive of 
poor outcome (ill). CD44 has also been reported as a predictive factor for 
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prostate cancer recurrence (Qi). 
• C0133 - a marker of sternness in many different benign and malignant cancer 
types, C0133 (in combination with C044 and a2~1 integrin) was among the first 
markers described for prostate CSCs (167-169). 
• Tumor-associated calcium signal transducer 2 (Trop2) - Also known as 
TACST02, MISI, and GA733-1, Trop2 is a transmembrane protein of the 
EpCAM family with unknown function. Trop2 is enriched in prostate tissue 
samples after castration, in benign prostate spherocytes, and in the basal fraction 
of prostate epithelium. It has been reported as a marker for both prostate TICs and 
benign prostate stem cells (170). It has also been suggested that Trop2 plays an 
active role in the tumorigenicity and invasion of prostate cancer. 
Functional markers 
• Side population 
• Aldehyde dehydrogenase 
Side population: ATP-binding cassettes (ABCs) comprise a large family of 
nucleotide-binding molecules, with on the order of 50 types in humans organized into 
seven families (ABCA to ABCG). Most ABCs contain characteristic membrane-spanning 
domains and are believed to be involved in the transmembrane movement of small 
molecules. More specifically, they function by using energy from ATP to constitutively 
and non-specifically eject small molecules from the cytoplasm of cells. Particular ABC 
subtypes that are enriched in normal stem cells and CSCs include ABCG2 and ABCB 1. 
(55) Prostate TICs have been reported to be enriched specifically in the ABCG2. 
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One class of substrate for these pumps is small fluorescent dyes including 
Hoescht 33342 and rhodamine 123 (rho123). (171,172) These molecules freely diffuse 
across the plasma membrane, such that all cells will fluoresce by default when exposed to 
these dyes. However, cells that express high levels of these efflux pumps will remain 
dark. When subjected to flow cytometry, this population of unstained cells lie literally to 
the side of the main population and comprise the side population (SP). A SP, by 
definition, must disappear in the presence of a pump-inhibitor such as verapamil. 
SPs have been shown to be enriched in TICs for many cancer types in both 
primary and established human cultures by a variety of methods (173-179). Moreover, 
SPs are clinically relevant. One small study of clinical samples of ovarian cancer found 
that recurrent cancers were more likely to have a SP than primary cases, and that cancer 
cells harvested from ascites fluid or from peritoneal metastases (i.e. no longer localized) 
had a larger SP than cells from the primary tumor. More importantly, even with this small 
sample size, the authors report a statistically significant difference in prognosis for 
patients whose tumors had a SP versus non-SP cancer (160). The authors add that a 
significantly greater percentage of cells lie within the SP for chemoresistant ovarian 
cancer cell lines versus chemosusceptible lines. The level of ABCG2 expression has also 
been reported as a predictor of poor outcome indicator for esophageal squamous cell 
carcinoma (163). In neuroblastoma cell lines derived from patients at presentation and at 
relapse, the size of the SP was significantly increased for cells from the relapse samples 
(162). 
Aldehyde dehydrogenase (ALDH): ALDH is an intracellular enzyme highly 
expressed by stem-like cells. ALDH is believed to be a marker of TICs in many cancer 
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types including liver, breast, and prostate. For prostate cancer, ALDH has been described 
as a marker for clonogenic, migratory, tumorigenic, and metastatic potential in both cell 
lines and primary human cells (180,ill). Even more exciting, subtypes of ALDH have 
been reported as clinical prognostic indicators in breast (182, 183 ), ovarian, (184) and 
prostate cancer (185). To measure ALDH activity, a commercial molecule called 
ALDEFLUOR which freely diffuses into cells and is a substrate for the ALDH enzyme 
may be used. Cells that express ALDH will cleave ALDEFLUOR, yielding a fluorescent 
product that can no longer diffuse across the cell membrane. Therefore, ALDHbr cells 
(some of which presumably will be TICs) will fluoresce more brightly than ALDK cells. 
As a negative control, samples containing cells and ALDEFLUOR are co-incubated with 
an ALDH inhibitor (DEAB). As with the side population assay, the ALDHbr population is 
defined as those cells that are fluorescent with ALDEFLUOR, but not fluorescent with 
ALDEFLUOR plus the ALDH enzyme inhibitor. 
Sphere assays 
Among cancer cells that are typically cultured as mono layers, the vast majority 
require cell adhesion for survival. However, it is known that a subpopulation of cells will 
survive when grown in non-adherent culture conditions (with or without growth factors to 
stimulate sternness pathways such as bFGF and EGF). These cells may proliferate 
robustly under these conditions to form spheres (dense round clusters) of cancer cells up 
to on the order of a millimeter in diameter. Cancer spheres have been reported for many 
tissue types including breast (mammosphere), brain (neurosphere), and prostate 
(prostasphere, or prostatosphere) (186-189). It has been reported by many groups that 
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sphere culture conditions enrich the total cell population for cells with stem-like features. 
The term spherocyte refers to a cell from a sphere. Spherocytes have been shown to have 
an increased proportion of TICs for many different cell types including both primary 
prostate cancers and prostate cancer cell lines (DUI45, PC3) (190-192). 
Different ways to utilize spheres in the study of TICs exist. As CSCITICs are 
typically believed to comprise a small percentage of the total cancer cell population, 
some researchers culture spherocytes simply for the purpose of having a larger population 
of TICs to analyze. Another method is to plate cells in sphere culture to see if an 
experimental agent is able to block the formation of spheres. Still another is to allow 
spheres to form, and test different components or conditions to observe for dissolution of 
the spheres. The sphere culture model at this time is widely held to be the most applicable 
in vitro method in the study of TICs. 
In vivo tumorigenicity assays 
In the identification of TICs, the gold standard is tumor growth of limiting 
dilutions of cancer cells in vivo; in theory every single cell of a stringently fractionated, 
pure TIC population will have the ability to establish a complete and heterogeneously 
populated tumor (50). Researchers use dilutions of cells of different signatures (e.g. 104, 
103, 102, 101 CD44+ cells versus CD44- cells) and observe whether fewer cells of a 
particular signature are required for tumor growth. This implies that selecting for that 
signature enriches for CSCs. 
For the study of CSC-targeting drugs, two main approaches have been described 
(193-195). The first is pretreatment of cancer cells with the experimental drug ex vivo 
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followed by transplantation to mice. The rationale is that treatment will deplete the TIC 
sub population and that tumor growth will require a greater number of total cancer cells. 
This requires that the bulk tumor cells are not greatly affected by treatment with the 
experimental drug. The pretreatment approach may also employ the limiting dilution 
concept; pretreated and untreated cells may be implanted in varying numbers. The second 
approach is more powerful, involving establishing tumors in mice and then treating them 
with the experimental drug, alone or perhaps in combination with currently used 
chemotherapy. A TIC targeting drug should inhibit tumor growth, an effect that may be 
rapidly evident or may require a longer period of time in order for the bulk tumor cells to 
senesce and the tumor to regress. These models may be used in combination, and for this 
project we performed both the pretreated and long-term models. 
Rationale for this project 
Our hypothesis is that ASI411, a G-rich, quadruplex-forming aptamer that was 
studied in Phase II clinical trial as treatment for cancer, is effective at eliminating TICs. 
To test this, we used an established prostate cancer cell line and investigated whether 
AS 1411 is capable of eliminating the TIC sub-population within these cancer cells. As 
discussed in Chapter 1, our hypothesis involving the effect of AS 1411 on TICs arose 
from the clinical observation that treatment with the aptamer resulted in markedly 
delayed (rather than immediate) but durable tumor regression in a number of patients. A 
study of the scientific literature at the time revealed further correlates between aptamers 
and CSCs that suggest aptamers may be especially appropriate in the targeting of CSCs; 
aptamers may be more effective than other chemotherapy types at targeting quiescent 
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cells, drug-resistant cells, cells able to repair DNA damage, and cells protected by their 
microenvironment (Chapter 1). Additionally, in our own laboratory, gene expression 
microarrays were performed on DU145 prostate cancer cells treated with ASI411 for 2 
and 18 hours. This study found that, of the genes with the greatest difference in 
expression, a large number of those downregulated were implicated in stem cell biology. 
(unpublished data, Appendix C). This is consistent with our hypothesis. 
Despite the uncertainties and controversial nature of the field, we undertook this 
high-risk project because the potential implications for aptamers, CSCs, and clinical 
oncology are great. Not only would this work shed light on the target of AS 1411, but a 
clear corollary between AS 1411 and CSCs could help elucidate the mechanism of action 
of AS 1411, contribute to the rapidly growing knowledge of CSC biology, and further 
validate the field of aptamers, especially in the field of clinical oncology. It was decided 
that the possibility of high impact results validated the discovery-driven efforts that we 
describe in this chapter. 
The question of studying primary prostate cancer samples versus established 
prostate cancer cell lines was considered. While primary specimens are clearly more 
representative of clinically relevant prostate cancer, much of the literature supports the 
concept of a TIC popUlation existing (albeit in questionable percentages) in virtually all 
the established cancer cell lines studied. Many of the reports of TICs from a variety of 
cancer types employ cancer cell lines for their studies. For this preliminary project, we 
decided that use of established cancer cell lines is appropriate. As discussed in the 
previous section, DU145 TICs in particular have been relatively well characterized in 
vitro and in vivo. We therefore felt justified in utilizing this cell line for our experiments. 
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We acknowledge the difficulty in definitively proving that a drug targets 
CSCs/TICs given the dearth of well-established methodology and rampant controversy in 
the field. For this reason, we employ a wide variety of methods and assays, each of which 
has been reported to distinguish TIC-targeting agents from non-TIC agents. While each 
assay will imperfectly overlap the TIC compartment, we propose that the accumulation of 
a large body of data exhibiting decrease in a purported TIC-enriched population in a 
multitude of ways will strengthen our hypothesis thatAS1411 acts by targeting TICs. 
MATERIALS AND METHODS 
Oligodeoxyn ucleotides 
Oligomers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) or 
from Invitrogen (Carlsbad, CA). Lyophilized oligomers were resuspended in filtered-
sterilized water, then heated at 65°C for 10 minutes and vortexed vigorously to dissolve. 
For in vivo studies, AS1411 was ordered in large-scale batches and resuspended in 10 
mM potassium phosphate buffer (pH 7.4). 
Cells and monolayer culture conditions 
Three cell lines were studied: DU145 and PC3 prostate adenocarcinoma, and MCF7 
breast adenocarcinoma. All cell lines were acquired from ATCC. Cells were grown in 
complete cell culture medium of DMEM (DU145 and MCF7) or F-12K (PC3) 
supplemented with 10% heat-inactivated FBS (15 minutes at 65°C) and 1 % 
penicillin/streptomycin. The MCF7 cell line alone was grown with insulin (0.01 mg I 
mL). All cells were cultured at 37°C in 5% CO2• 
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MTT anti-proliferative assay 
AS 1411 and the chemotherapy drug doxorubicin were tested in triplicate at a range of 
concentrations in DU145 prostate cancer cells for 72 hours. We modified previously 
published MTT [3-( 4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay 
protocol. Briefly, cells were seeded in 96-well tissue culture plates and incubated 
overnight. Cells were plated at 1000 cells per well. Drug stock solutions were then added 
to each well to yield the desired final concentration. Plates were incubated with the 
oligomer for three days, during which the cell culture medium was not changed. On day 
3, cell viability was determined and the background corresponding to medium alone (no 
cells) was subtracted. For each concentration, the average of the three wells was 
calculated and plotted. 
Stem cell marker staining 
Antibodies against human surface antigens along with coordinating isotype 
control antibodies were purchased from BD Biosciences (San Jose, CA) or Miltenyi 
Biotech (Auburn, CA). All antibodies were directly conjugated to fluorophores save the 
antibody against Trop2. For this antibody, appropriate secondary antibodies conjugated to 
fluorophores were used, and the secondary alone was used as the negative control. 
For antibody staining of surface epitopes, cells were resuspended with TrypLE 
Express (GIBCO). The cell suspension was washed twice with cold staining buffer (1 % 
FBS in sterile PBS), then resuspended in 100 J.lL of staining buffer at a final 
concentration of approximately 5 x 105 cells / mL. Appropriate antibodies were added 
directly to cells at concentrations recommended by the manufacturers. Samples were 
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protected from light and incubated on ice (4°C) for 30 minutes, and mixed occasionally 
by tapping during the incubation. Samples were then washed twice and resuspended in 
cold stain buffer for analysis. Samples requiring a secondary antibody were washed once 
incubated and with the secondary antibody for 30 minutes more, then washed and 
resuspended for analysis. Propidium iodide (2 Ilg per sample) was added as a marker of 
viability. Cells were kept on ice and protected from light until analysis. Flow cytometry 
was performed using a FACScan flow cytometer. 
For staining of internal stem cell markers, we used the BD Human and Mouse 
Pluripotent Stem Cell Analysis Kit with additional antibodies (Nanog, SOX 2) from BD 
Biosciences. We modified the manufacturer's protocol slightly as follows: up to 106 cells 
were resuspended in 100 /-lL of BD Fix buffer, then incubated at room temperature for 20 
minutes. Cells were washed once with Ix Perm/Wash buffer, then resuspended in 100 /-lL 
Ix Perm/Wash buffer and incubated for 10 min at room temperature. Appropriate 
antibodies were added directly to cells in stain buffer in volumes recommended by the 
manufacturer. Samples were protected from light and incubated at room temperature for 
30 minutes. Samples were mixed occasionally by tapping during the incubation. After 
staining the samples were spun down, washed once with Ix Perm/Wash buffer, then 
resuspended in approximately 500 /-lL stain buffer (1 % FBS). As we could not use 
propidium iodide as a marker of viability, we counted cells with Trypan blue before 
fixing and permeabilizing cells. Cells were protected from light until analysis. Flow 
cytometry was performed using a FACScan flow cytometer (BD Biosciences). 
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Side population assay (Rhodamine 123 dye exclusion assay) 
MCF7 breast cancer cells were grown to approximately 80% confluence in the 
appropriate cell culture medium, washed, and harvested with TrypLE Express. Cells were 
spun down and resuspended in prewarmed (37°C) OMEM + 2% FBS + 10 mM HEPES 
to make a final concentration of 106 cells / mL. One to two mL of cell suspension were 
placed in darkened 15 mL tubes. The inhibitor verapamil was added to the control 
samples (10 f.lM final concentration) followed by 0.1 f.lg / mL of Rho 123 added to each 
sample. Samples were placed in a 37°C water bath for 30 minutes with regular mixing by 
inversion of the tubes. Cells were spun down at 4°C and resuspended in 500 f.lL ice cold 
HBSS + 2% FBS + 10 mM HEPES. Propidium iodide (2 Ilg per sample) was added as a 
marker of viability. Cells were kept on ice and protected from light until analysis. Flow 
cytometry was performed using a LSR II flow cytometer (BO Biosciences). 
To study the effect of ASI411 treatment on the size of the side population (e.g. 
percentage of cells that remained unstained in treated versus untreated cells), MCF7 cells 
were treated with 10 f.lM AS 1411 or negative vehicle for 24 hours. Cells were washed, 
harvested, and stained with Rho 123 as above. 
ALDEFLUOR assay 
The aldehyde dehydrogenase (ALDH)-positive population was assayed using a 
commercial kit (ALOEFLUOR, Stem Cell Technologies) according to manufacturer's 
directions. OU145 cells were grown to approximately 80% confluence in the appropriate 
cell culture medium, washed, and harvested with TrypLE non-trypsin enzyme 
(Invitrogen). Cells were spun down, then resuspended in room temperature Aldefluor 
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Assay Buffer to make a final cell concentration of 106 cells / mL. Aldefluor reagent was 
added to the cell suspension at a ratio of 5 IlL per mL. Without delay, the sample was 
mixed and a portion of this sample added to a fresh tube containing the DEAB inhibitor. 
Another portion was placed in a fresh tube for staining with propidium iodide. Samples 
were incubated in 37°C water bath for 30 minutes, mixing occasionally by inversion. 
Cells were spun down and resuspended in ice-cold Assay Buffer to make a final 
concentration of 106 cells / mL. Propidium iodide (2 /lg per sample) was added as a 
marker of viability. Cells were kept on ice and protected from light until analysis. Flow 
cytometry was performed using a FACScan flow cytometer. 
To study the effect of AS 1411 treatment on the size of the ALDHbr population 
(defined as cells negative for ALDH in the presence of ALDEFLUOR and DEAB, but 
positive with ALDEFLUOR alone) cells were treated with ASI411 at a range of 
concentrations and time points (0-20 /lM ASl411 for 24-72 hours). Cells were washed, 
harvested, and stained with ALDEFLUOR as above. Experiments were performed thrice 
to ensure reproducibility. 
Soft agar colony formation 
DU145 cells were plated in soft agar as follows: a lower, cell-free layer of noble 
agar and cell culture medium (0.6% agar and 70% complete cell culture medium final 
concentrations) was plated in 60 mm tissue culture plates and allowed to solidify at room 
temperature. DU145 cells were resuspended with trypsin. An upper layer of agar (0.3% 
agar and 86% complete cell culture medium final concentrations) containing 2000 
DUl45 cells plus 10 /lM AS1411, 2 /lM doxorubicin, or no drug was plated over the 
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solid lower layer. Plates were incubated at 37°C and 5% CO2 for 10-18 days until 
colonies grew to an appropriate size. Feeder layers of agar (including fresh drug) were 
applied weekly. Plates were stained with 500 ilL of MTT [3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] (1 mg / mL) solution, then photographed and scanned 
(EPSO Expression 1680 scanner at 1000 dpi). Average colony size and total colony area 
for each sample was analyzed using Image-J software (National Institute of Health). 
Experiment was repeated thrice to ensure reproducibility. 
Prostate cancer sphere (prostasphere) culture 
DU145 prostate cancer cells were sorted for a subpopulation held to be enriched 
in TICs (CD241o/CD44hi), then grown in non-adherent conditions supplemented with 
growth factors to promote sphere formation and enrichment of stem-like cells. Serum-
free sphere culture media was made fresh on the day of sorting consisting of: DMEIF-12 
(Thermo Scientific), Ix B27 (Invitrogen), insulin (4 Ilg/mL, Millipore), bFGF (20 ng/mL, 
Millipore), and EGF (20 ng/mL, Millipore). DU145 cells were stained for CD24 and 
I h" CD44 as described above, and the top 2.5% of CD24 o/CD44 I cells were sorted at the 
University of Louisville cell sorting core facility using a MoFIo flow cytometer 
(Beckman Coulter). These cells were spun down, washed twice with 50% sphere culture 
media (diluted 1:1 with DMEMIF-12), and plated in T75 low-adherence flasks (Coming). 
The media was changed weekly. Cells were additionally supplemented with bFGF and 
EGF weekly. 
To harvest spheres, the cell culture medium containing spheres in suspension was 
passed through a 70 micron nylon filter (BD Biosciences) to remove single cells and 
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small cell clumps. Spheres were washed with PBS. The filter containing retained spheres 
was inverted over a clean 6-well dish and the spheres washed out with PBS. The spheres 
in PBS were spun down, resuspended in 1 mL TrypLE, and mixed by pipetting for 10-20 
seconds to dissociate them into single cells. An equal volume of complete sphere media 
was added to neutralize the enzyme. Samples were counted with trypan blue; typical 
viability for primary spherocytes harvested and resuspended in this way was on the order 
of80%. 
To study the effect of AS 1411 treatment on spherocytes, DU145 CD241o/CD44hi 
cells were sorted and plated as described with the addition of 10 /-1M AS 1411 or negative 
vehicle for up to three weeks. For spheres grown in the presence of drug, fresh AS 1411 
was added at the time that the media was changed. 
Sphere survival assay 
To study the effect of AS 1411 treatment on prostasphere survival, freshly sorted 
CD241o/CD44hi DU145 cells were plated in complete sphere culture media in 6-well ultra 
low attachment plates (Stem Cell Technologies, 2000 cells per well). Wells were treated 
with 10 /-1M AS 1411, 1 /-1M doxorubicin, or negative vehicle. The media was changed 
weekly with fresh drug added at that time. Cells were additionally supplemented with 
bFGF and EGF weekly. Cells were cultured until an effect on sphere survival was seen, 
generally three weeks. Spheres were photographed in these plates. For quantification, the 
media and cells from each well were passed through a 70 micron nylon filter to remove 
any spheres/cells smaller than that diameter. Spheres washed into fresh wells with PBS 
and counted under the microscope. 
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Ex vivo pretreatment of cells followed by tumor growth in vivo 
This experiment was performed four times with slight variations in cell number and 
technique. Data are clearly marked with the variations. In general, DU 145 prostate cancer 
cells were grown to approximately 50% confluence. Fresh medium was added, and 
AS 1411 was added to a final concentration of 10 )lM versus negative vehicle. Cells were 
incubated for 72 hours. Cells were washed, trypsinized, and counted, then resuspended in 
PBS at a concentration of 1 or 2 x 106 per mL. Just prior to injection, the cells were 
mixed at a ratio of 1: 1 with Matrigel (growth factor reduced, without phenol red (BD 
Biosciences)). Two hundred microliters of this suspension (containing 0.5 - 1 x 106 cells) 
were implanted subcutaneously to the right flank or the midline back of 5-8 female 
athymic nude mice (DU145 cells do not require androgen for growth, and therefore 
female mice may be used for in vivo experiments). Tumor size was monitored thrice 
weekly until animals were euthanized due to tumor burden. Tumor volume was 
determined by measuring the greatest linear dimensions in length and width (calculated 
by the equation V = 1 x w2 x (n / 6)). The tumors were allowed to grow until tumor 
volume reached 10% of the total body mass of the animal, approximately 2 cm3 (2000 
mm
3) for a 20 gram animal, at which point the animal was euthanized. Approval of this 
protocol was granted by the University of Louisville Institutional Animal Care and Use 
Committee. 
Long-term growth in vivo 
DU145 prostate cancer cells were grown to 90-100% confluence. Cells were 
washed, trypsinized, and counted, then resuspended in PBS at a concentration of 107 per 
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mL. One hundred ilL of this suspension (containing one million cells) were implanted 
subcutaneously to the right flank of twenty female athymic nude mice. Tumors were 
allowed to grow until palpable, then measured, and mice stratified into two equivalent 
groups. 
The test group received intraperitoneal injections of AS 1411 (10 mg/kg/day) in 10 
mM potassium phosphate buffer (pH 7.4) while the control group received intraperitoneal 
injections of negative vehicle. Injections were given once daily for 21 days. Tumor size 
was monitored twice weekly from the start of the injections until animals were sacrificed 
due to tumor burden. Tumor volume was determined by measuring the greatest linear 
dimensions in height, width and length (calculated by the equation V = I x w x h x (n / 
6)). The tumors were allowed to grow until tumor volume reached 10% of the total body 
mass of the animal, approximately 2 cm3 (2000 mm3) for a 20 g animal, at which point 
the animal was euthanized. Approval of this protocol was granted by the University of 
Louisville Institutional Animal Care and Use Committee. 
RESULTS AND DISCUSSION 
MTT assay used to assess test doses for AS1411 and doxorubicin 
The purpose of this project is to study the effect of AS 1411 on TICs. As a 
negative control, we also tested the chemotherapy drug doxorubicin which is used as 
second line treatment for CRPC, widely used in other cancer types, and has been reported 
to have little effect on TICs (196-198). To minimize confounding effects on bulk tumor 
cells with doxorubicin treatment, we decided to select doses of doxorubicin that have 
only modest effects on the proliferation ofDU145 cells for the timeframe we intended to 
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study. In order to select an appropriate dose, we performed the MTT assay on DU145 
cells at 72 hours using different concentrations of both AS 1411 and doxorubicin (Figure 
1 ). 
In the majority of our TIC assays, the dose of AS1411 used is 10 /-lM. This dose 
was determined empirically, and was selected to illustrate the maximum effect of the 
aptamers on TICs. According to this MTT assay, at 72 hours As 1411 inhibits the growth 
ofDU145 cells by about 30%. From these data, we also decided upon the dose of2 /-lM 
doxorubicin, which inhibits the growth of DU145 cells by about 15%. This range of 
doses is also supported by the literature in the study of CSC/TICs. (193, 198-200) We 
decided that these doses of doxorubicin and AS 1411 were comparable in terms of 
anti proliferative effect on bulk tumor cells, and could thus be used to illustrate 
differences in efficacy against TICs. 
AS1411 treatment induces cell cycle arrest but is not toxic to DU145 monolayer cells 
As a preliminary experiment to study the effects of AS 1411 in our hands, we 
treated DU 145 cells with 5 or 10 /-lM AS 1411 for 24 hours, prepared cells for flow 
cytometric analysis, and stained them with 7-AAD or propidium iodide. (Figure 2) We 
observed that AS 1411 treatment results in modest accumulation of cells in the S phase of 
the cell cycle. (Figure 2A) This datum is consistent with previous reports (H.,.2.l). We 
also observed, again consistent with previous reports, that AS 1411 causes only a minimal 
increase in cell death under these conditions. (Figure 2B) While previous studies have 
reported GIso values of about 3 /-lM, those data were generated under different conditions, 
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Figure 1: MTT assay of experimental drugs on DU145 cells 
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Figure 2: Cell cycle and cytotoxic effects of AS 1411 on bulk DU 145 cells. 
A.Cell cycle analysis - 7-AAD. 
B.Ceil death analysis - propidium iodide 
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our experimental conditions validates our methodology in preparing our samples, as well 
as aids in the interpretation of subsequent assays that study the effects of AS 1411 on the 
TIC compartment. Because "the bulk tumor cells are only marginally affected by AS 1411 
under these conditions, we can better determine whether or not any changes in cell 
growth and/or survival we see with our later assays are particularly targeting TICs. 
Though the data are reassuring, we did routinely stain samples with propidium iodide 
and/or trypan blue as a marker for viability for all subsequent experiments. 
CD2410/CD44hi sorted cells and spherocytes are enriched for prostate TIC markers 
As discussed previously in this chapter, CD241o/CD44hi prostate cancer cells are 
believed to overlap the TIC compartment. A similar argument has been made for prostate 
cancer cells that have been grown in non-adherent sphere culture conditions. To establish 
and validate the methodology in our hands, we analyzed three classes ofDU145 cells: 1) 
unsorted monolayer cells, harvested by a trypsin analogue to make a single cell 
suspension ("monolayer" cells) 2) freshly sorted CD241o/CD44hi DU145 cells ("sorted" 
cells), and 3) cells from DU145 spheres that have been digested to form a single cell 
suspension ("spherocytes"). Our results are summarized in Figure 3. 
We observed that a much greater percentage of sorted cells were CD24-/CD44+ 
compared to unsorted cells (86.0% versus 15.4%). As this is the cell surface marker 
signature for which we sorted, these data support the validity of our sorting procedure. 
We also observed that a greater number of sorted cells are ALDHbr than seen in 
monolayer DU145 cells (20.1% versus 7.51%, P < 0.05). To our knowledge, this is a 
previously unpublished finding that provides additional evidence that prostate TICs are 
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CD 24144 ALDH Trop2 Nanog 
Monolayer 15.4± 1.0% 7.51 ± 0.4% - -
Sorted 86.0% 20.1 ± 3.2% - -
Spherocyte 62.5 ± 6.9% N/A 12.4% 41.5 ± 10.4% 
Figure 3: Baseline levels of TIC markers in different types of DU145 cells. All 
cells analyzed in suspension by flow cytometry. Monolayer - unsorted DU145 
cells. Sorted - CD24-/CD44hi. Spherocyte - cells from spheres grown from 











Figure 4: Heterogeneity of DU145 monolayer versus spherocytes cells 
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contained within the CD2410/CD44hi compartment. As another assessment, we sorted the 
CD241o/CD441o double negative subpopulation at the same time as the CD24-ICD44+ 
cells. When stained with ALDEFLUOR, these double-negative cells had fewer ALDHbr 
cells (4.21 %) than not only the sorted cells, but also the unsorted monolayer cells. 
Though not statistically significant, this finding was not unexpected; if the CD24-ICD44+ 
subpopulation is enriched in stem-like cells, it follows that at least some other 
subpopulations are depleted. We studied both sorted and monolayer cells for several other 
reported TIC markers (Trop2, CD133, Nanog, Oct3/4, Sox2) but did not find detectable 
levels by flow cytometry. 
Spherocytes were found to be enriched in CD24-ICD44+ compared to monolayer 
cells (62.5% versus 15.4%), but not compared to sorted cells. We reasoned that the sorted 
cells are most enriched in this surface marker signature because they are sorted based on 
these markers, and that once in sphere culture conditions some of the cells lose this 
signature via cell division and differentiation. We did find positive subpopulations of both 
Trop2 (12.4%) and Nanog (41.5%) in spherocytes versus undetectable levels in 
monolayer and sorted cells by flow cytometry. Taken together the data suggest that of the 
three prostate cancer cell types studied, it is the spherocytes that are most enriched in 
TICs. CD133 was once again undetectable. 
Spherocytes were more challenging to assess due to limited viability and 
heterogeneity. The viability of freshly harvested spherocytes was typically around 80% as 
measured by trypan blue. Upon flow cytometric analysis, we observed a large degree of 
heterogeneity as seen by widely diffuse forward and side scatter clusters, and even clear 
subpopulations with different markers. For example, with ALDEFLUOR staining we 
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observed two distinct groups of cells in spherocyte samples, while monolayer samples 
had a much more uniform population (Figure 4). We suggest that these phenomena are 
due to the physical structure of the prostasphere. Our spheres routinely grew to several 
hundred microns in diameter. It is therefore likely that cells embedded deep within the 
sphere are less able to receive nutrients, oxygen, and growth factors, and that cells in 
different positions within the sphere receive different growth signals that affect their 
protein expression. Because of these issues, we decided not to use the ALDH assay for 
these cells. 
Our rationale for plating sorted cells was that a greater number of sorted cells 
would have the ability to form a sphere, and that we could perform our assays involving 
spheres more quickly by plating sorted cells rather than unsorted monolayer cells. The 
question has been raised whether or not unsorted DU145 cells would form spheres as 
robustly as those from sorted cells, and whether spheres grown from unsorted cells would 
show a similar enrichment of stem cell markers. We plan to undertake experiments to 
assess these questions in the near future. Nevertheless, these data show that, consistent 
with the literature, many markers for TICs are enriched in both the CD241o/CD44hi 
subpopulation of DU145 cells and in cells grown in non-adherent sphere culture 
conditions. We therefore utilized the sphere culture method to assess the effect of AS 1411 
on the TIC subpopulation. 
Treatment with AS1411 decreases surface and internal markers believed to be 
associated with TICs 
Data from the functional markers (SP and ALDH) are discussed In separate 
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sections below. We studied the effect of AS1411 on TICs by generating dose and time 
curves of on DU145 monolayer cells. Cells were treated at 24, 48, and 72 hours with 5 
and 10 /lM AS I 411, then stained for CD24 and CD44. The data are summarized in Figure 
5. We quantified the percentage ofDU145 cells that lay in the CD24-ICD44+ quadrant as 
well as a subpopulation (about 5%) that was negative for CD24 and brightest for CD44 
(CD2410/CD44hi). The flow cytometry graphs for 10 /lM AS1411 at the three time points 
is shown in Figure 5A to illustrate the populations of interest. The smaller subpopulation 
demarked with a rectangle within the upper left quadrant is believed to be most enriched 
in TICs. In all cases, we found that ASI411 decreased the percentage of cells in both the 
whole quadrant of interest and the subpopulation (Figure 5B). The difference between 
untreated and treated samples was statistically significant, while the difference between 
the lower and higher dose was not. We concluded from this that the 5 /lM dose is 
sufficient to achieve maximal effect on the TICs at these time points. We repeated this 
experiment using lower doses of AS 1411 (Figure 5C) at 72 hours and found that the 
decrease in these populations was in general dose dependent and can be seen with as little 
as 4 /lM AS 1411. 
Due to the resources and time required to generate prostaspheres, we limited our 
studies of the effect of AS 1411 on prostaspheres to a single dose of 10 /lM. To assess this 
effect, we developed an assay whereby freshly sorted CD241o/CD44hi cells were plated in 
sphere culture conditions with or without AS 1411. Media was changed and fresh drug 
added weekly until any signs of senescence (less dense, less well-defined borders, more 
single cells) were seen. At this time all samples were harvested and analyzed. With this 























Figure 5: Effect AS1411 on percentage of CD24-/CD44+ DU145 cells at 
various time points and concentrations. 
A. Flow cytometry of unsorted DU145 monolayer cells treated with 10 
11M AS1411 for up to 72 h. 
B. Summary of effect of 5 or 10 11M AS141"1 upon CD24-/CD44+ 
subpopulation (upper left quadrant) and on CD24-/CD44hi 
subpopulation (inset. upper left quadrant). 
C. Summary of effect of 72 h treatment with 0-10 11M AS1411 upon 
CD24-/CD44+ and CD24-/CD44hi subpopulations. 
118 
B. CD24-/CD44+ 
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Figure 5, continued 
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/CD44+, Trop2, and Nanog (Figure 6). Due to the time required for prostaspheres to 
mature, replicate experiments are ongoing. In addition, we plan to repeat certain key 
experiments with additional controls. We will repeat the treatment of DU145 monolayer 
cells for 72 hours and of spherocytes for approximately three weeks with 10 /lM AS 1411 
using doxorubicin as a non-TIC targeting control and a cytosine-rich analogue of AS 1411 
(CRO) as a control oligomer. 
Treatment with AS1411 eliminates the side population of breast cancer cells 
We attempted the SP assay using DU145 cells, but found that this cell line did not 
have a measurable side population either by Hoechst 33342 or by Rho123 staining. These 
data are consistent with reports from other researchers (201). We therefore employed the 
MCF7 breast cancer cell line to study the effect of AS 1411 on this TIC-enriched 
subpopulation. Cells were treated with and without 10 /lM AS 1411 for 24 hours, 
harvested and stained with Rho123. (Figure 7) Upon analysis, untreated MCF7 cells had 
a small SP (0.406%) which did not stain with Rho123 and disappeared (i.e. became 
fluorescent) in the presence of the pump-inhibitor verapamil (0.007% SP). MCF7 cells 
treated with ASI411 for 24 hours had virtually no cells in the side population (0.004%). 
AS 1411 had minimal effect on overall cell viability as measured by PI staining (data not 
shown). 
As discussed previously in this chapter, SP cells have been shown to be enriched 
III TICs in a number of different cancer types. These data therefore support our 
hypothesis that AS 1411 is an inhibitor of TICs. One caveat is that we cannot conclude 
from our data whether or not AS 1411 is inhibiting the survival SP cells, and it is possible 
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A. Untreated 10 /-lM AS1411 
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Figure 6: Effect of 10 /-lM AS1411 on DU145 spherocytes, treated for 2-3 
weeks in sphere culture. 
A. CD24-/CD44+: 43.4% untreated, 17.9% treated. 
B. CD133: 6.29% untreated, 0.11 % treated 
C. Nanog: 51 .8% untreated, 24.2% treated 
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Rhodamine123 Alone Rhodamine123 + Verapamil Rhodamine123 + AS1411 
Rhodamine123 (FITC A) ______ _ 
0.406% 0.007% 0.004% 
Figure 7: Effect of 24 h treatment with 10 IlM AS 1411 on Rhoneg side 
population MCF7 cells. 
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that AS 1411 is not frankly decreasing the number of cells in the population, but rather 
inhibiting the pumps that efflux the fluorescent dye. These pumps are known to act upon 
chemotherapeutic molecules of many types and have been implicated as the mechanism 
of drug resistance in cancer cell subpopulations (52, 160, 163, 171 ). Therefore, if AS 1411 
acts by inhibiting the ABC pumps it could decrease drug resistance and potentiate the 
effects classic cytotoxic chemotherapies as combination therapy. Regardless of which 
case is true in actuality, we argue that both cases (decrease in cell survival and inhibition 
of ABC pumps) support the utility of AS 1411 in the targeting of TICs. 
Treatment with AS1411 decreases the size of ALDHbr populations 
We assessed ALDH activity in DU145 prostate cancer cells treated with different 
doses of ASI411 or negative vehicle. (Figure 8) Untreated cells had a small and 
consistent ALDHbr population of 7.51 % ± 0.81 %. Treatment with 10 11M ASI411 for 24 
hours decreased the ALDHbr population to 1.34% ± 0.68% (P < 0.001). We also studied 
the effect of a smaller dose of AS 1411. After 24 hours of treatment with 5 11M AS 1411, 
we found that the ALDHbr population decreased to 0.43% ± 0.29%, a value even smaller 
than seen with 10 11M AS 1411. Although the difference between 5 11M and control treated 
DU145 cells was statistically significant (P < 0.01), the difference between 5 and 10 11M 
AS 1411 was not. We conclude from this that 5 11M at 24 hours is sufficient to 
significantly inhibit the ALDHbr population, and that the higher dose of AS 1411 has no 
additional effect. Unlike classic cytotoxic chemotherapies, for which higher doses 
translates into higher efficacy and doses are limited only by the patient's ability to 
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Figure 8: Effect of 24 h treatment with 5 or 10 /-lM AS 1411 on ALDHbr 
unsorted DU 145 monolayer cells. 
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chemotherapies may be most efficacious at moderate doses. Possible further experiments 
include the study of lower doses of AS 1411 (e.g. 1-5 J...lM) for different time points. 
Treatment with AS1411 decreases the formation of DU145 colonies in soft agar 
Predating the emergence of the CSC field, the ability of cancer cells to proliferate 
and survive in soft agar culture is a classic model for tumorigenicity (202). We plated 
DU 145 cells in soft agar with no treatment, AS 1411, or the classic chemotherapy 
doxorubicin which has been reported not to inhibit the growth of TICs (196-198). Cells 
were cultured for three weeks with new top layers of agar with cell culture medium and 
additional drug added weekly. (Figure 9A) Cells grown in the presence of ASI411 
developed significantly fewer colonies than untreated cells (366 ± 92 versus 1371 ± 68, 
P<O.OO 1). (Figure 9B) The average size of colonies grown with AS 1411 was also 
significantly smaller than with no treatment (0.23 ± 0.03 mm2 versus 1.00 ± 0.17 mm2, 
P<O.OI). (Figure 9C) Additionally, doxorubicin had a markedly smaller effect on colony 
number as compared to untreated cells (793 colonies ± 84, P<0.05). Colonies with 
doxorubicin and with no treatment were the same size (1.00 ± 0.13 mm2) while the 
difference in colony size between AS 1411 and doxorubicin was statistically significant, 
(P<0.005 compared toASI411). 
The soft agar assay has not yet been as clearly linked to the TIC subpopulation as 
other assays (such as sphere formation/survival). Despite this lack of association, this 
assay does illustrate the effect of treatment upon cells that do not require adhesion to 
matrix to proliferate. The soft agar assay may thus be considered as a functional marker 
for a more tumorigenic, invasive, and prone to metastasis cancer cell subpopulation. The 
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Figure 9: Soft agar colony formation of DU145 cells. 
A. Light microscopy of colonies stained with MTT. 
B. Analysis of colony number. Untreated vs. AS 1411, *** P < 0.001. 
Untreated VS. doxorubicin, *P < 0.05. 
C. Analysis of colony size. Untreated VS. AS1411, **P < 0.01. AS1411 VS. 
doxorubicin, **P < 0.01. 
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data we have generated, that AS 1411 strongly inhibits the growth of colonies in soft agar 
while doxorubicin modestly inhibits their growth, is therefore noteworthy and supports 
our hypothesis that AS 1411 is targeting a TIC compartment. 
Treatment with AS1411 inhibits prostasphere survival 
Freshly sorted CD241o/CD44hi DU145 cells were plated in sphere culture media 
with no treatment, AS 1411, or doxorubicin. At the end of the experiment, all spheres 
greater than 70 microns were counted for each sample. (Figure 10) We found a decrease 
in the number of spheres that survived AS1411 treatment versus no treatment (5.7 ± 4.3 
versus 42.7 ± 12.3 spheres, respectively per 2000 cells plated). Even more exciting, as 
with the soft agar assay we found that doxorubicin had a much more attenuated effect on 
sphere survival (34.7 ± 14.8 spheres). These data approached statistical significance, but 
additional replicates with our refined sphere culture techniques will be required. 
Other putative TIC-targeting drugs have been reported to inhibit sphere formation 
(193,194). We observe that AS1411 did not inhibit the formation of cancer spheres, but 
rather promoted their demise. This is in contrast to the soft agar assay where colonies are 
inhibited from forming by AS 1411 treatment. A decrease in sphere survival may more 
accurately model the common clinical scenario in which an existing tumor must be 
treated, i.e. a newly diagnosed cancer patient with frank disease. As CSCs are a subclass 
of TICs, so other subclasses may exist, such as primary TICs that are responsible for the 
growth and maintenance of the primary tumor and metastatic TICs that are responsible 
for tumor growth at distant sites. It is possible that these two assays (colony formation 
and sphere survival) distinguish different types of TICs. It may be that different classes of 
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Figure 10: Sphere survival assay. 
A. Light microscopy. 
B. Total number of spheres retained after passing through 70 micron filter. 
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TIC-targeting drugs will ultimately prove necessary to both cure the initial malignancy 
and prevent recurrence. AS 1411 appears to be effective against both the malignant 
subpopulation that can grow in soft agar and the subpopulation that can maintain a 
prostate cancer sphere. 
For this assay we used I f.lM doxorubicin. When this assay was performed we had 
not yet assessed the effect of doxorubicin on the bulk tumor cells. As discussed 
previously, a higher dose (2 f.lM) would give us a fairer comparison with this dose of 
AS 1411. We plan to repeat this assay in order to achieve statistical significance. At that 
time we plan to study the higher dose of doxorubicin. We also plan to test oligomer 
libraries and candidate anti-prostate cancer aptamers from our previous work: N 26mer, 
N cap, GT 26mer, GT cap, GA 26mer, GC 26mer, and a C-rich analogue of AS 1411 in 
which all guanines are replaced by cytosines (CRO: 5'- CCT CCT CCT CCT TCT CCT 
CCT CCT CC -3 '). 
Pretreatment of cancer cells with AS1411 before implantation to mice results in 
slowed or delayed tumor growth 
We performed an in vivo experiment in which DU 145 prostate cancer cells were 
treated ex vivo for 72 hours with AS 1411, washed, and equal numbers of viable cells 
implanted subcutaneously to nude mice. This pretreatment model has been described in a 
number of different reports that study the potential TIC-targeting ability of 
pharmaceuticals (193-195). While certainly less clinically pertinent than the treatment of 
established tumors with long term follow up, we undertook this method to see if the 
molecular results we have generated thus far in vitro would translate into an effect in the 
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complexity of the murine physiologic environment. In essence, the mouse acts as a more 
physiologically relevant cell culture system. We felt comfortable employing this model 
because it is known that cells treated with AS 1411 for up to 72-96 hours will recover if 
the drug is removed (34). 
The tumor growth curves from the pretreatment model experiments are shown in 
Figure 11. We performed this experiment four times, and each time experienced technical 
difficulties with the injections which resulted in different artifacts in tumor growth for 
some mice. A number of mice of the first two experiments developed tumors that grew 
within the peritoneal cavity rather than subcutaneously (Figure llA and B). Some of the 
mice of the second experiment developed ascites, likely due to inadvertent direct 
injection of tumor cells into the liver (Figure II C). We then switched the location of the 
injections to the skin of the midline back (Figure lID) which avoided the abdominal 
cavity altogether, but found that the shapes of the tumors were much more irregular; 
several mice had very elongated and narrow tumors, while others grew two distinct 
masses instead of one. 
For analysis, we eliminated data for any mouse with tumor growth that was 
clearly not limited to the subcutaneous area as we reasoned there must be tumor present 
that was not measurable by calipers. Because of these issues, the experiments finished 
with fewer mice than we intended and we did not achieve the significance that we hoped. 
However, for every data point that was statistically significant, tumors from the 
pretreated cells were smaller than the control treated cells (marked with asterisks), and in 
general all the curves indicate that pretreatment with AS 1411 inhibits the growth of 
tumor, either by blocking tumor take or slowing tumor growth. We conclude that 
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Figure 11: In vivo tumor growth curves of DU145 cells pretreated with 10 
J.l.M AS1411 for 72 hours. Number of cells and site of implantation as noted. 
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pretreatment of prostate cancer cells with AS 1411 inhibits tumor growth in vivo. With 
better in vivo injection technique, we feel confident that this difference will be 
statistically significant for most if not all time points. 
Long-term treatment with AS1411 in vivo showed no difference in tumor growth or 
outcome 
We attempted to mimic the delayed tumor regression seen in the AS 1411 Phase I 
clinical trial by establishing DU 145 subcutaneous tumors in nude mice and, once 
palpable, treating mice with daily intraperitoneal injections of AS 1411 (10 mg/kglday) or 
negative vehicle for three weeks. We observed no significant difference in tumor volume 
between treated versus untreated mice (data not shown). We also analyzed survival in the 
two groups and again found no difference. 
AS 1411, as well as other aptamers, is known to be rapidly cleared from systemic 
circulation via the kidneys with a half-life on the order of minutes. Due to this 
pharmacokinetic feature, in clinical trials AS 1411 was given by continuous infusion for 
seven days. The daily intraperitoneal injection model that we used for this experiment 
may thus not be an effective method to study aptamer pharmaceuticals. An experiment 
using an infusion method of drug delivery would likely be more appropriate, and we are 
planning to pursue this in the near future. Once a modified research protocol is approved, 
we will use implantable intraperitoneal pumps to deliver appropriate amounts of AS 1411 
over the course of 7 days. 
CONCLUSIONS 
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Cancer research in recent years has seen the advent of numerous new therapies 
with efficacy in decreasing tumor volume, yet there have been relatively few 
breakthroughs leading to improvement in survival. This quandary may be due to CSCs. 
CSCs and TICs comprise an exciting new field of study experiencing exponential growth 
with far reaching implications in clinical oncology and cancer research. Tumor 
heterogeneity in general is an increasingly relevant concept. The field of oncology has 
moved historically from considering cancer to be a single disease, to believing every 
cancer within an organ to be the same, to realizing different cancer types exist within a 
given tissue type. Now the dawning realization is that the differences between cancer 
cells within a single malignancy must also be addressed. It is likely that in the near future 
there will be even more refined medical subdivisions in cancer histology and diagnosis 
that guide clinical treatment. 
Given the growth in the study of TICs, a steady increase in the identification and 
development of TIC-targeting therapies is likely to follow. At present, only a handful of 
agents have been reported to deplete TICs. They include small molecule inhibitors of 
certain signaling pathways (e.g. Hedgehog, Akt, NF-KB, Notch), salinomycin, 
aurothiomalate, temozolamide, and a few oncolytic viruses. Our preliminary data suggest 
that AS 1411 is effective in targeting and inhibiting TICs in prostate cancer cells. We have 
generated in vitro and in vivo data supporting our hypothesis. We have studied baseline 
levels of prostate TIC surface markers in DU145 prostate cancer cells and shown that 
AS 1411 decreases them. Using the SP and ALDH assays we have shown that AS 1411 
also decreases functional markers. We have provided evidence that AS 1411 decreases the 
clonogenicity of DU 145 cells via demonstrating decreased colony formation in soft agar 
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and decrease sphere survival in non-adherent culture. These markers and functional 
assays have all been described in the study of prostate TICs. Although the precise 
definitions of TIC versus CSC are still being shaped, cancer cells with these signatures 
have been shown repeatedly to be more tumorigenic, more invasive, and more drug 
resistant than other prostate cancer cells. Therefore, regardless if AS 1411 only targets 
TICs rather than the true CSC compartment, or inhibits only a subtype of TICs, or, with 
changing definitions, does not target "TICs" at all, we are still providing evidence that 
AS 1411 inhibits particularly clinically important and malignant subpopulations of 
prostate cancer cells. 
The ex vivo pretreatment of cancer cells followed by subcutaneous implantation is 
a model that has recently been reported by a number of groups in the study of TICs. This 
model does not attempt to mimic the clinical scenario, but illustrates the effect of drugs 
on cancer cell growth under the complexities of mammalian physiology. Our data suggest 
that treatment with AS 1411 slows the growth of prostate cancer cells in vivo. The long-
term in vivo experiments that we performed (which are a truer model for clinical 
oncology) did not show a difference with AS 1411 treatment in the growth of established 
subcutaneous prostate cancer tumors. As discussed, we feel the lack of effect is due to 
insufficiency with administration of the drug and intend to repeat this experiment with 
implantable drug delivery pumps to achieve sustained levels of the drug and to more 
accurately mimic the clinical trial protocols. 
Although we have shown that AS 1411 decreases signatures and markers 
associated with TICs, we realize that we are not able to conclude the fate of AS 1411-
treated TICs from our data. As discussed in the introduction of this chapter, many 
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possible fates exist for TICs including cell death, blocking of proliferation (cytostasis), 
and differentiation. To shed some light on the mechanism of downregulation of the 
CD24lo / CD44hi stem cell signature with 72 hour treatment of ASI411 on monolayer 
DU145 cells, one planned experiment is to plate freshly sorted CD24lo / CD44hi cells in 
monolayer cell culture conditions with or without 10 J.!M AS 1411, then harvest after 72 
hours and stain for CD24, CD44, and with propidium iodide. The experiment will also be 
performed plating the sorted cells in non-adherent sphere culture conditions. Although 
sphere culture conditions less accurately mimic the conditions under which our assays 
were performed, at this time we are uncertain of general effects of monolayer culture 
conditions on the sorted cells. According to the literature, both serum and adhesion tend 
to induce differentiation of stem-like cells, therefore we will examine the cells under both 
monolayer and sphere culture conditions. We hope that investigations such as these using 
AS1411 on TICs will provide some insight on the fate ofthese cells. 
One technical issue that needs to be addressed is appropriate controls. Most of 
these assays have never before been performed in our laboratory. Designing and 
optimizing these protocols required a great deal of time and resources, and thus in most 
cases we restricted our experiments to AS 141 I-treated and -untreated samples. Additional 
important controls to add to our study are classic, non-TIC targeting drugs and other 
oligomers at comparable doses. The question of appropriate doses of the classic 
chemotherapy doxorubicin has been discussed. An even more relevant chemotherapy 
control would be docetaxel, the first-line chemotherapy for CRPC (Petrioli, 2008) which 
is also used for other cancer types and has been reported not to target CSCITIC 
subpopulations. In terms of oligomer controls, experts in the field opine a lack of true 
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relevant control molecules. It is not possible to use a scrambled version of AS 1411 as this 
ODN is comprised solely of guanines and thymines, and scrambling the order of these 
bases does not provide sufficient variation from the original sequence. The standard 
oligomer control that our group has used in many other publications to contrast with 
ASI411 is "CRO," a C-rich 26-base oligomer which replaces the guanines of ASI411 
with cytosines. Although CRO is limited in relevance because it is not a G-quaduplex, we 
use this molecule because it is an ODN of the same length as AS 1411 that is known to 
have no biological activity in any assay our laboratory has performed. Plans are 
underway to repeat key experiments with CRO. 
The field of CSCffICs, though exciting and rapidly expanding, is still only on the 
order of a decade old. Even younger is the field of solid tumor CSCs; the establishment 
of benign solid organ stem cells was many decades behind hematopoietic stem cells, and 
solid tumor CSCs have naturally lagged behind their leukemic counterparts as well. As in 
any new field of research, there is a high degree of controversy over virtually every 
aspect of CSCs, even their very existence. The validity of methods used to study stem-
like cancer cell populations, including the SP and ALDH assays that we describe here, 
have been proposed, questioned, and refuted in tum. We have attempted to select 
signatures and assays for which the greatest consensus has been built, but it will take time 
before the methodology in the study of TICs is universally accepted. Even more 
fundamentally, questions such as whether or not all tumors have CSCs and if neutralizing 
or destroying CSCs actually translates into clinical benefit have yet to be answered. 
In this project, we performed proof-of-principle studies to examine the effect of a 
known anticancer aptamer on TIC subpopulations. We do not attempt to prove the CSC 
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hypothesis, to answer fundamental questions in the field, or to validate the signatures that 
have been reported to identifY prostate TICs. Although we have been as rigorous as 
possible in our study of TICs, we acknowledge that we are necessarily utilizing unproven 
assays. To compensate for this issue, we tested our hypothesis that ASI411 is a TIC-
targeting drug by several different methods, each of which in actuality is likely to assess a 
slightly different yet overlapping cancer cell subset. While not conclusive, taken together 
our data support our hypothesis and provide a strong argument that AS 1411 affects TICs. 
This does not preclude effects on non-TIC cells, and indeed previous data from our group 
indicate a strong anticancer effect on bulk tumor cells for a number of different cancer 
types. 
In the future, we would like examine the effect of AS 1411 on the gene expression 
of spherocytes to see if these data provide any insight to the mechanism of action of 
AS 1411 on TICs. We have plans to perform a qPCR stem cell gene array with cDNA 
created from spherocytes that have been treated with AS 1411 versus negative vehicle. We 
plan to study the mechanism of action of this inhibition on TICs to see if it differs from 
that of the bulk tumor cells, to repeat and refine our assays to achieve statistical 
significance using appropriate controls, and to prepare a manuscript for publication. 
Ideally we would also like to repeat key experiments using clinical specimens. Our work 
will be among the very first articles to combine the fields of aptamers and TICs, and the 




Summary of major findings and their significance 
G-rich oligodeoxynucleotide libraries 
The properties of a molecular solution of any kind that contains a mixture of 
species are, most logically, a summative function of the individual molecules that 
comprise it. Thus, the properties of the solution may be argued to be representative of the 
predominance of molecules. We found that GT and GC ODN 26mer libraries, each 
containing millions of different G-rich sequences, exhibit selective anticancer activity as 
a whole. This implies that rather than being a rare occurrence, this feature is a common 
property for the different individual sequences within these particular libraries. Ours is 
the first report of a large, complex library of ODNs, rather than a single sequence or a 
few known sequences in combination, exhibiting cancer-selective antiproliferative 
activity (Chapter 2, Appendix A). 
We found that the selective antiproliferative activity against cancer cells was only 
seen in G-rich libraries (though not all G-rich libraries) and generally corresponded with 
formation of G-quadruplexes, molecular stability against nucleases, and increased 
cellular uptake. The causative relationship between the different biophysical and 
biological properties we assayed was not determined, although we suggest that protein 
binding may be required for molecular stability. Along this line of reasoning, a follow up 
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study could verify that the band "B 1" identified most strongly in the GT libraries is 
indeed nucleolin as we suspect, and that the protein is the same across the different ODN 
libraries (i.e. that B 1 contains the same protein in all samples). Although nucleolin is a 
required factor for AS 1411-mediated anticancer activity, these results suggest that factors 
other than nucleolin binding playa role in determining activity; future research could 
help us understand why some libraries exhibited this band but did not have 
anti proliferative activity against cancer cells. One method to assess the relative binding 
affinities is the competitive EMSA using radiolabeled TEL (telomerase sequence) as a 
competitor for nucleolin binding. Caveats include the possibility that different ODN 
species may bind to different sites or to different forms of nucleolin. As TEL is a known 
G-quadruplex-forming sequence, it is logical that libraries with high levels of G-
quadruplex formation would compete with TEL, but others would not. This could provide 
information about the relative importance of G-quadruplex formation versus G-richness 
to anticancer activity. 
GC library and poly-dC binding targets 
Both GC and C-rich nucleic acid sequences have important roles in cellular biology 
(discussed fully in Chapter 3). Arising from the protein binding assay of the ODN 
libraries chapter, we identified a handful of proteins that are bound by the GC 26mer 
library and the poly-dC oligomer. Some of these have been previously reported while 
some were newly identified by us. A number of the identified proteins have known effects 
in cancer biology in general and prostate cancer in particular. As discussed in the chapter, 
important follow-up experiments include foremost the verification of the protein targets 
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and a study of their biological relevance. Many other follow up projects, particularly 
involving the GC library, could stem from these data. The mechanism of the GC library's 
cancer-selective anti proliferative activity is likely different from the GT-library; this is a 
novel finding and could be an important development. Like the GT libraries, the GC 
library had potent anti proliferative activity against lung and prostate cancer cells and little 
effect on benign fibroblasts. In contrast, the GC library had markedly attenuated activity 
against the MCF7 breast cancer cells, while these cells were the most vulnerable cancer 
type to the GT libraries. Discovery of the basis of this difference in antiproliferative 
activity could be a complete research project in and of itself with implications not only in 
oncology but also basic cellular biology. Further studies with the GC library may lead to 
new strategies in the advancement of cancer-selective therapies. 
Identification of a new anti-prostate cancer aptamer via SELEX 
Despite technical hurdles, we identified a candidate aptamer evolved via SELEX 
from the GT library that has enhanced cancer-selective antiproliferative activity and 
increased nuclease resistance relative to its parent library (Chapter 4). Although our 
SELEX protocol was designed to select for sequences with efficient cellular uptake, we 
were unable to exhibit an increase in uptake by the GTcap sequence despite employing a 
variety of methods. ODN uptake is a challenging phenomenon to study, and at this time 
the mechanism of the cellular uptake of G-quadruplex ODNs is poorly understood by the 
scientific community as a whole. One technical difficulty that we encountered is intrinsic 
variation of fluorescence of ODN samples. Some of this variation may be due to 
difference in manufacturing conditions, but this issue is particularly associated with 
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quenching of the fluorophore by G-quadruplexes. Fluorescent ODNs can only be used in 
comparison if measured fluorescence is proportional to ODN concentration across 
samples. We found inconsistent fluorescence among our fluorophore-Iabeled ODN 
stocks. Though we attempted to compensate for this difference both mathematically and 
experimentally, this incongruity makes any experiment comparing these ODNs 
questionable. 
More recently, a new paradigm for AS 1411 cellular uptake has developed from 
our laboratory (92). In short, evidence suggests that it is not the degree of cellular uptake 
that is the key to the cancer-selective anti proliferative activity of AS 1411, but the method 
of cellular uptake. The major mechanism of uptake for cancer cells is macropinocytosis 
while the predominant mechanism for benign cells is non-macropinocytic endocytosis. 
AS 1411 triggers hyperstimulation of macropinocytosis only in the cancer cells, and this 
hyperstimulation appears to require nucleolin though the mechanism of this interaction is 
incompletely understood at this time. In accordance with the literature, we saw increased 
cellular uptake with our "active" G-rich samples in our study of ODN libraries, and the 
degree of uptake appeared to correlate with antiproliferative activity (Chapter 2). 
Although we were unable to demonstrate increased cellular uptake with the GTcap 
sequence, enhanced cellular uptake is a known general characteristic of GROs. Higher 
uptake is a valuable pharmacokinetic property that may have many clinical and 
experimental applications, but the new data regarding macropinocytosis and AS 1411 
suggests that the paradigm of higher intracellular uptake corresponding with higher 
efficacy is overly simplistic. We now believe that both the specific mechanism of uptake 
as well as high intracellular concentration play important roles in the selective anticancer 
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activity of AS 1411 and perhaps GROs in general. 
Of note, our newly evolved aptamer (GTcap) is G-rich and does appear to form a 
G-quadruplex, have enhanced resistance to nuclease degradation relative to its parent 
library, and exhibit greater complexity of protein binding. This finding is in agreement 
with our previous results using ODN libraries, namely that selective anti proliferative 
activity against cancer cells may correspond with and require all these features. 
Therefore, it is possible that we have inadvertently selected the GTcap sequence based on 
its superior nuclease-resistance, rather than increased cellular uptake. 
AS 1411 inhibits prostate cancer tumor initiating cells 
We studied the effect of AS 1411, a known G-rich, G-quadruplex-forming aptamer, 
on subpopulations of prostate cancer cells reported to have enhanced tumorigenicity (i.e. 
TICs; Chapter 5). By all assays tested, AS 1411 decreased prostate TIC signatures. Most 
excitingly, prostaspheres treated with AS 1411 had shorter survival than both negative 
vehicle and the classic chemotherapy doxorubicin. This trend also translated to the in vivo 
realm; preliminary studies showed that cancer cells pretreated with AS 1411 exhibited 
slowed tumor growth compared to control treated samples. 
We acknowledge the limitations of the field, for CSCITICs in general and solid 
tumor and prostate TICs in particular, but believe that our data collectively support the 
hypothesis that one of the ways by which AS 1411 acts against cancer is by inhibiting 
TICs. We are interested to study whether or not this effect is exclusive to ASI411, or 
rather a general property of other GROs as well. Experiments to test the effect of other G-
rich samples including ODN libraries (GA, GC, and GT 26mers) and well as our selected 
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GTcap aptamer on prostasphere survival are underway. We are also testing some non-G-
rich libraries and ODN s in parallel. We know that some of these samples form G-
quadruplexes and some do not; we may thus be able to correlate G-richness versus G-
quadruplex formation with inhibition of prostasphere survival. 
Overall conclusions and future directions 
Our hypothesis is that guanine-rich oligonucleotides are optimal for the 
development of new aptamers for use in the treatment of cancer. We have performed 
experiments using GRO libraries correlating G-quadruplex formation with cancer-
selective antiproliferative activity. Following from this study we undertook and identified 
unique GC library-binding proteins. We performed SELEX and managed to evolve a G-
rich aptamer with more potent anticancer activity and greater nuclease resistance than its 
G-rich parent library. And lastly, we generated evidence that a first in class G-rich 
anticancer aptamer inhibits TICs. Taken as a whole, this body of work supports the 
hypothesis that GROs have great potential in the development of cancer therapies. 
For context, we have discussed specific possible future studies for each subproject 
(ODN libraries, protein target identification, SELEX, and TIC) in depth within each 
chapter. Clearly much more work could be done in every aspect of this project. Our 
immediate plans are to strengthen our data involving AS1411 and prostate TICs to 
prepare a manuscript for submission. We also plan to study the effect of other G-rich and 
non-G-rich libraries and ODNs via the sphere survival assay. The results may have 
implications on the anticancer activity of the libraries, and if sphere survival correlates 
with the previous anticancer acti vity seen, further study will be warranted. 
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As previously discussed, according to the literature, GROs have distinct 
properties, namely nuclease resistance and enhanced cellular uptake that appear to be 
related to G-quadruplex formation. These properties may be accountable for the cancer-
selective anti proliferative activity seen with AS 1411, GRO libraries, and the GTcap 
sequence, and could perhaps be a common feature of sequences that form G-
quadruplexes. The causative relationship between these GRO-associated properties has 
not been fully determined. It is widely held that G-quadruplexes are resistant to nucleases 
due to the intrinsic stability of their secondary structure, and that this stability affords G-
quadruplexes the opportunity to reach a protein target (e.g. nucleolin) and bind it. Our 
data suggest that it is in fact protein binding that confers molecular stability rather than 
vice versa (Chapter 2, Appendix A). We propose a new model by which GROs are more 
likely to bind to a protein such as nucleolin which provides stability against serum and 
intracellular nucleases. This protein binding mayor may not depend on G-quaduplex 
formation. Regardless, with this stability, GROs survive and are able to be taken up by 
the cell and reach other targets. 
Although the determinants of the mechanism of cellular uptake of G-quadruplex 
ODNs are unclear, it is known that GROs may be taken up by a variety of ways and have 
a number of effects, including cell death, cytostasis, and antiviral activity (li). In 
accordance with Dr. Reyes-Reyes' recent work, cancer cells take up G-quadruplexes by 
macropinocytosis, a process which may then become dysregulated by a nucleolin-
dependent mechanism and lead to a novel kind of cell death. Clearly there is more 
information to be discovered, for example why the GC 26mer library was only active 
against certain cancer cell types while GT 26mer libraries were active against all cancer 
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types tested, and whether cancer-selective hyperstimulation of macropinocytosis is 
specific to AS 1411 or a general property of GROs. 
The future of anticancer aptamers 
Aptamers as pharmaceuticals, especially in the context of oncology, are a worthy 
field of study. Aptamers have many features that make them desirable for drug 
development and commercial manufacture. The cost of drug development is notoriously 
high, and of the total potential pharmaceuticals that enter the research and development 
process, less than 1 % will ever reach market. Aptamers are inexpensive and easy to 
manufacture which is important not only in the context of providing drug to patients, but 
also in the scientific study of these molecules. Aptamers typically have low side effects as 
evidenced by the lack of dose-limiting toxicities in the clinical trials of AS 1411. Features 
that makes GROs good candidates against cancer in general also makes them good 
candidates for treatments against CSCs, and there are additional features (previously 
discussed in Chapter 1) that may make them particularly well-suited to anti-CSC therapy. 
To date, there is a single report of an RNA anti-EpCAM aptamer which may 
prove to inhibit CSCs. However, no one has yet reported using SELEX to target whole 
CSCITICs. In conclusion, we suggest that in the future it will become technically 
possible to employ SELEX using a G-rich library to deliberately develop aptamers that 
target CSCITICs. As the field of CSCs and TICs matures, the subpopulations of cancer 
cells that are enriched in tumorigenic capabilities will become better characterized. It will 
then be possible to use these clinically important subpopulations as targets of whole cell 
SELEX using a G-rich starting library as we have described here. TICs may be sorted out 
145 
from clinical tumor samples based on functional or surface markers and if necessary 
established as primary cultures at the time of surgical resection. Cancer patients typically 
require a post-surgical recovery period before beginning a chemotherapy regimen. During 
this time, automated SELEX could be performed upon each individual patient's cancer 
cells. Although automation for cell-SELEX is undoubtedly further away than for SELEX 
using a molecular target, we believe cell-SELEX would be preferable for tailored therapy 
as the SELEX could be performed without knowledge of a target on the molecular level 
which mayor may not be relevant for that particular patient. As aptamers are remarkably 
safe and non-toxic pharmaceuticals, the issue of dangerous side effects is less concerning. 
At this time, tailored oncology therapies are limited to determining which patients will 
benefit most from the available chemotherapies (e.g. giving anti-estrogen medication 
only to those breast cancer patients whose cancers are ER+). We describe a scenario of the 
future, which will involve custom made cancer therapies for each individual and their 
unique cancer. 
The overall aim of our project is to identify aptamers for use as oncology 
therapeutics (i.e. chemotherapy, drug-delivery vehicle, imaging) and to study the 
mechanisms of the unusual and potentially useful properties of GROs. A better 
understanding of how GROs work may lead to the development of specific and selective 
anticancer drugs, both vehicles (for targeted delivery of small molecules or siRNAs) and 
frank aptamer pharmaceuticals. In this body of work, we have generated and discussed a 
diverse collection of data related to GROs and their effects on cancer cells. Our work has 
contributed to the fields of G-rich oligonucleotides, aptamers, cancer therapeutics, and 
tumor initiating cells in overlapping and sometimes wholly novel ways. A number of our 
146 
findings have previously been unreported, and comprise a small yet significant 
contribution to the literature. 
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ABSTRACT 
Oligodeoxynucleotide libraries containing randomly 
incorporated bases are used to generate DNA 
aptamers by systematic evolution of ligands by 
exponential enrichment (SELEX). We predicted that 
combinatorial libraries with alternative base com-
positions might have innate properties different 
from the standard library containing equimolar 
A + C + G + T bases. In particular, we hypothesized 
that G-rich libraries would contain a higher propor-
tion of quadruplex-forming sequences, which may 
impart desirable qualities, such as increased 
nuclease resistance and enhanced cellular uptake. 
Here, we report on 11 synthetic oligodeoxy-
nucleotide libraries of various base combinations 
and lengths, with regard to their circular dichroism, 
stability in serum-containing medium, cellular 
uptake, protein binding and anti proliferative 
activity. Unexpectedly, we found that some G-rich 
libraries (composed of G + T or G + C nucleotides) 
strongly inhibited cancer cell growth while sparing 
non-malignant cells. These libraries had spectral 
features consistent with G-quadruplex formation, 
were significantly more stable in serum than 
inactive libraries and showed enhanced cellular 
uptake. Active libraries generally had strong 
protein binding, while the pattern of protein 
binding suggested that GIT and G/C libraries have 
distinct mechanisms of action. In conclusion, 
cancer-selective anti proliferative activity may be a 
general feature of certain G-rich oligodeoxynu-
cleotides and is associated with quadruplex 
formation, nuclease resistance, efficient cellular 
uptake and protein binding. 
INTRODUCTION 
Cancer is a leading cause of death throughout the 
world. Although many drugs have been developed to 
treat cancer, the majority of the oncology pharmacopeia 
causes serious, dose-limiting side effects due to damage to 
healthy cells. There exists a clear need for better, more 
specific cancer therapies, not only to increase efficacy 
against cancer cells but also to decrease the suffering of 
patients who are subjected to these drug regimens. 
Nucleic acid aptamers are emerging as a new class 
of targeted therapeutic agents and are the focus of a 
rapidly growing field of medical research (1-4). These 
small synthetic oligomers of DNA or RNA form sta-
ble three-dimensional structures and bind to defined 
molecular targets via shape-specific recognition. Thus, in 
essence, their mechanism of action is similar to that of 
protein-based monoclonal antibodies. However, due to 
their smaller size and different chemical composition, 
aptamers have a number of potential advantages over 
antibodies. These include ease of manufacture and 
storage, facile conjugation, better tumor penetration, 
more rapid systemic clearance and non-immunogenicity. 
In recent years, aptamers have been identified as potential 
treatments for a variety of diseases, including macular 
degeneration (5,6), autoimmune disease (7), disseminated 
intravascular coagulation (8,9) and prion diseases (10). 
In the oncology field, the most clinically advanced 
aptamer, and the first anticancer aptamer to be tested 
in humans, is a 26-nt G-rich DNA known as ASI411 
(formerly, AGROIOO). This nucleolin-targeted aptamer, 
which was discovered by our group, has shown promising 
clinical activity without any major side effects in Phase I 
and ongoing Phase II clinical trials (11). 
New aptamers against specific targets are most often 
engineered via systematic evolution of ligands by exponen-
tial enrichment (SELEX) (1,12,13), an iterative methodol-
ogy designed to create target-specific aptamers from a 
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A 
Repeat 
up to 20x 
B 
c 
N = A, C, G orT 
possible sequences = 426 ", 4 x 10'5 
K=GorT 
possible sequences = 226 "' 7 x 107 
Figure I. Overview of SELEX procedure and oligonucleotide libraries. (A) Schematic of SELEX procedure. (B) Diagram of N library. 
Primer-binding regions (PBR) flank a length of random sequence, for which eacb base has equal likelihood of being an A, C, a or T. In theory, 
the library contains 4" different sequences, wbere II is the length of the random sequence (in this example 11 = 26). (C) Example of a guanine-ricb 
aT library. The random sequence is restricted sucb that each base may be either a a or a T . This library should contain 2" different sequences 
(in this example II = 26). 
combinatoria l library (Figure IA). For DNA aptamers, a 
single-stranded oligodeoxynucleotide library consisting of 
two known primer-binding sequences flanking a random 
sequence of usually 20--40 nt in length (N library, where 
N = A, C, G, or T; Figure IB) is applied to the target of 
interest. The molecules that do not bind are washed away, 
and the remainder are harvested and amplified by 
polymerase chain reaction (PCR). The aptamer-enriched 
pool of single-stranded molecules is then isolated from the 
PCR product, reapplied to the target and the process is 
repeated. In this manner, highly specific aptamer 
sequences are usually evolved after 10-20 cycles. For 
RNA aptamers, a similar procedure with additional 
steps for transcription and reverse transcription can be 
utilized . Typically, the target of interest for SELEX is a 
purified protein or small molecule, but the development of 
aptamers against intact cells or organisms can be also 
achieved (1,14). 
One shortcoming of traditional SELEX is the high 
number of iterations required, which consumes time and 
resources, and increases the likelihood of artifacts (since 
every round of SELEX requires PCR and must be care-
fully protected from contamination). Moreover, for in vivo 
use, evolved sequences must typically be modified to 
enhance their pharmacokinetic properties and to increase 
resistance to serum nucleases. This can be achieved 
post-SELEX, or by incorporating modified bases or back-
bones during the SELEX procedure (1,15). However, 
these approaches have some drawbacks: post-SELEX 
modification can reduce aptamer activity or increase 
toxicity, and not all modified nucleotides are compatible 
with the polymerases used during SELEX. An additional 
shortcoming of aptamers (which is also shared by 
antibodies) is their inefficient cellular internalization, 
which generally limits their clinical targets to extracellular 
or cell surface molecules. 
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In an attempt to address some of these limitations, we 
have considered the use of alternative starting libraries for 
SELEX. Rather than the random N library containing 
billions of sequences, the vast majority of which will not 
turn out to be clinically useful aptamers, we propose 
beginning with smaller libraries, especially those which 
may be enriched in molecules that contain secondary 
structure motifs, such as hairpins or G-quartets. In par-
ticular, we hypothesized that libraries enriched in guanine 
(G) residues (for example, see Figure IC) would contain 
a higher proportion of quadruplex-forming sequences, 
which may impart increased functionality, nuclease resis-
tance and cellular uptake compared to the N library. An 
additional driving force for this study was the realization 
that very G-rich sequences such as ASI411 (5'-d[GGTGG 
TGGTGGTTGTGGTGGTGGTGG)), which was dis-
covered by chance, would rarely occur in the standard N 
library, making it unlikely to have been discovered by 
standard SELEX. Furthermore, our previous work 
involving the ' bench-to-bedside' development of ASI411 
and the preclinical research of several other groups who 
are researching a variety of different G/T-containing 
oligonucleotides (II) led us to focus on GfT DNA 
libraries for our studies on the effect of oligonucleotide 
length . 
As a prelude to SELEX studies using alternative 
oligodeoxynucleotide libraries, we have sought to estab-
lish the baseline characteristics of various libraries and to 
test our hypothesis that G-rich libraries will be enriched 
in quadruplex-forming sequences with improved nuclease 
resistance and cellular uptake. In this project, we have 
examined II oligodeoxynucleotide libraries of varying 
base compositions and lengths, as well as three monobasic 
oligomers (Figure 2). We have performed studies to 
evaluate various characteristics of the libraries, including 
a well-established colorimetric assay to determine their 
Name Length %A %C %G %T 
N28mer 26 2S 2S 2S 2S 
.r:. A 26mer 26 100 
.g 
C28mer 26 100 C, 
C: T 26mer 26 100 
0 AT28mer 26 50 50 Z 
CT26mer 26 50 50 
GT 10mer 10 50 50 
GT 18mer 18 50 50 
GT28mer 26 50 50 
.r:. GT34mer 34 50 50 ~ 
C, GT 0.33 28mer 26 33~ 
GT 0.67 26mer 26 67 33 
GA26mer 26 50 50 
GC26mer 26 50 50 
Figure 2. Oligonucleotides and libraries used in this study. Single-
stranded DNA oligonucleotide libraries and monobasic oligomers 
used in this study. Libraries with >25% guanines are considered 
'G-rich·. 
intrinsic antiproliferative activities in three different cancer 
cell lines compared to non-malignant cells. As far as we 
know, we are the first to perform such a comprehensive 
screen of oligonucleotide libraries. In addition, we report 
here the unexpected discovery that certain G-rich libraries 
have high levels of intrinsic, cancer-selective anti pro-
liferative activity. 
MATERIALS AND METHODS 
Oligodeoxynucleotides and libraries 
All oligonucleotides and oligonucleotide libraries were 
purchased from Integrated DNA Technologies, Inc. 
(Coralville, lA, USA) and are shown in Figure 2. The 
relative proportion of bases was specified for libraries, 
which can be synthesized by mixing phosphoramidite pre-
cursors in the desired ratio. The specified bases are then 
randomly incorporated into the sequence. Lyophilized 
libraries were resuspended in filter-sterilized water, then 
heated at 65°C for 10 min and vortexed vigorously to 
dissolve. For uptake studies, three thymidine bases 
(TIT) were added to the 3'-end of the library sequence 
to avoid quenching the 3'-fluorophore, which can occur 
when it is proximal to a G-quartet (Choi,E., Nayak,L. and 
Bates,P . unpublished data). A G26 oligodeoxynucleotide 
was originally proposed for study, but is not commercially 
ava ilable due to difficulties in synthesis of oligodeoxy-
guanosines of this length. 
Cell culture 
Four cell lines were comprehensively studied: A549 
lung adenocarcinoma, DUI45 prostate adenocarcinoma, 
MCF7 mammary carcinoma and Hs27 non-malignant 
skin fibroblasts . All cell lines were acquired from 
American Type Cultu re Collection (ATCC, Manassas, 
VA, USA). Cells were grown in complete cell culture 
medium of Dulbecco's Modified Eagle Medium 
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(DMEM, Invitrogen, Carlsbad, CA, USA) supplemented 
with 10% heat-treated (15 min at 65°C) fetal bovine serum 
(FBS, Invitrogen) and I % penicillin/streptomycin 
(Invitrogen). The MCF7 cell line a lone was grown using 
charcoal-stripped serum (Invitrogen). All cells were 
cultured at 37°C in 5% CO2, Methods for cell culture 
and antiproliferative assays using MCFIOA cells can be 
found in the Supplementary Data. 
Antiproliferative activity assay 
In the four cells lines, each library/oligomer was tested 
in triplicate at eight concentrations of oligonucleotide 
(0, 2, 4, 6, 8, 10, 12 and 141lM) using a modified 
previously publ ished MTT [3-( 4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay protocol (16). 
Briefly, cells were seeded in 96-well tissue culture plates 
and incubated overnight. To account for intrinsic differ-
ences in growth rate, the A549 and DUI45 lines were 
plated at 1000 cells per well , MCF7 at 2000 per well and 
Hs27 at 3000 per well. Oligomer library stock solutions 
were then added to each well to yield the desired final 
concentration. Plates were incubated with the oligomer 
libraries for 5 days, during ' which the cell culture 
medium was not changed. On Day 5, cell viability was 
determined and the background corresponding to 
medium alone (no cells) was subtracted . For each concen-
tration, the mean and standard error of triplicate wells 
was plotted . Assays were repeated at least twice in tripli-
cate to ensure reproducibility of the results. 
Circular dichroism spectroscopy 
Oligomer library stocks were diluted to a concentration 
of 5 11M (strand concentration) using either water (buffer 
was not included in order to be representative of the stock 
solutions used to treat cells), or aqueous solutions contain-
ing 100mM sodium chloride or 100mM potassium 
chloride. Samples were incubated at 95°C for 5 min, then 
cooled on ice until analysis. Circular dichroism (CD) 
spectra were collected at 20°C using a Jasco J-7 15 
spectropolarimeter between 340 and 220 nm wavelengths, 
using 200 nm/min scanning speed, 2 s response time, 5 nm 
bandwidth and I-cm pathlength . For each set of samples, 
the same solution used to prepare the oligomers was used 
as the reference. The resulting spectra in millidegrees 
(mdeg) were converted to molar CD (~e), referring 
to per mole of nucleotide. Methods for analysis of 
(dC)26 at various pH can be found in the Supplementary 
Data. 
Nuclease-resistance in serum-containing medium 
Each oligomer library was 5'-end-Iabeled with 32p using 
T4 kinase (Invitrogen) and unincorporated y_32p_ATP was 
removed from samples using TE-Midi SELECT-D G-25 
columns (Shelton Scientific, Shelton , CT, USA), according 
to manufacturers' directions. Collection tubes containing 
end-labeled libraries were kept on ice, or stored at -20°C. 
The radioactivity of end-labeled libraries was measured 
in a scintillation counter on the day of the experiment. 
For each library to be tested, four reaction tubes contain-
ing complete cell culture medium without antibiotics were 
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prepared . One million counts per minute of end-labeled 
oligomer was added to each of four tubes. Samples were 
incubated at 37°C, and tubes were flash-frozen in a dry 
ice/ethanol bath at 0, 1.5, 24 and 72 h. Frozen samples 
were stored at -SO°C until all samples had been harvested . 
Samples were then thawed on ice and run on 12% 
denaturing polyacrylamide gels. Band density was 
measured over each lane using the UN-SCAN-IT gel 
densitometry application (Silk Scientific, Orem, UT, 
USA). The percent sample remaining was calculated 
taking the signal of the zero time point lane to be 100% . 
Cellular uptake 
Uptake experiments were performed using oligomer 
libraries labeled at the 3' end with FAM 
(6-carboxyfluorescein) for representative libraries that 
were inactive (N 26mer and GA 26mer) or active (GC 
26mer and GT 26mer) . For each sample, 3 x 105 cells 
were plated and incubated overnight. The following day, 
fresh medium was added to each plate. FAM-Iabeled 
libraries were added to make a final concentration of 
5-f!M oligonucleotide and plates were incubated for I h. 
The medium containing unbound oligo was removed . 
Cells were washed twice and treated with trypsin 
(Invitrogen) to remove surface-bound oligonucleotides 
and harvest cells. Cells were kept on ice and protected 
from light unti l analysis. Propidium iodide (PI, 2 ~lg per 
sample, BD Biosciences, San Jose, CA, USA) was added 
as a marker of viability. Ten thousand cells were counted , 
after gating to exclude PI-positive (non-viable) cells from 
analysis. Cells were analyzed using a FACSCalibur 
cytometer (BD Biosciences). The relative fluorescence of 
cells was determined using the FlowJo software program 
(Tree Star, Ashland , OR, USA). 
Protein binding using electrophoretic mobility shift assay 
Libraries were end-labeled with 32p as described for the 
nuclease-resistance assay and then electrophoresed on a 
non-denaturing 20% polyacrylamide gel to check 
labeling. Whole-cell extracts from A549, DU 145, MCF7 
and Hs27 cells were prepared using a modification of a 
previously published method (17) as follows: cells were 
grown until confluent in 75 cm2 flasks . The cells 
were washed, then scraped with 100 ~I HEDG buffer 
[20mM HEPES-NaOH, pH 7.S, 0.5mM EDTA, 0.5mM 
dithiothreitol (DTT)] containing 10% glycerol, 
I x protease inhibitor cocktail (Sigma, St Louis) , and 
0.42 M NaCI. The solution was harvested and subjected 
to three freeze-thaw cycles (liquid nitrogen versus room 
temperature). Samples were centrifuged at 16000g at 4°C 
for 45 min to pellet cell debris. An equal volume of HEDG 
with glycerol and protease inhibitor but without NaCi was 
added to reach a final concentration of 0.21 M NaCi . An 
aliquot (IOOOOOc.p.m.) of radiolabeled oligomer was 
combined with 5.0 f!g of cell extract from A549, DU 145 
and MCF7 cells, or with 3.2 f!g from Hs27 cells, and 5X 
protein binding buffer [IX is 20 mM Tris-HCI, pH 7.4, 
140mM K1 , 2.5mM MgCI2, I mM dithiothreitol, 
0.2mM phenylmethylsulfonyl fluoride (PMSF), S% (v/v) 
glycerol]. Samples were incubated at 37°C for 15 min and 
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run on a non-denaturing 5% polyacrylamide gel. Gels 
were fixed in a solution of 10% (v/v) methanol + 10% 
(v/v) glacial acetic acid in water for 10min at room tem-
perature, then exposed to a storage phosphor screen for 
2 h at room temperature before scanning. Gels were also 
exposed to X-ray film overnight at -SO°C. 
RESULTS AND DISCUSSION 
GT libraries of all types and the GC 26mer library have 
selective antiproliferative activity against cancer cells 
The anti proliferative activity of II oligomer libraries and 
three monobasic oligomers at various concentrations 
against four cell lines was determined using the MTT 
assay. The results are summarized in Figure 3A, which 
shows the percentage reduction in cell number at 6-f!M 
oligonucleotide strand concentration. This format was 
selected for clarity of presentation and 6 f!M was chosen 
because it best illustrated the relative activities of the 
various libraries. 
Some libraries containing G + T or G + C were found 
to strongly inhibit cancer cell proliferation at low 
micromolar concentrations, whereas non-G-rich libraries, 
including the standard N library, had little effect on the 
cancer cells (Figure 3A). All libraries tested had minimal 
anti proliferative activity against the non-cancerous Hs27 
cells (Figure 3A and B). These novel data provide surpris-
ing evidence that some oligomer libraries possess intrinsic 
antiprolifera tive activity, even before isolation of individ-
ual aptamer sequences. 
The GT IS-mer, 26-mer and 34-mer libraries had the 
highest level of antiproliferative activity against the three 
cancer cell lines (Figure 3A). The GT 10-mer, GT 0.33 
26-mer and GT 0.67 26-mer libraries had similar 
specificity, but were less effective at inhibiting the cancer 
cells (Figure 3A). Figure 3B and C illustrate these results 
for A549 cells, and similar patterns of activity were 
observed in the other cancer cell lines (Figure 3A 
and data not shown) . The GC 26-mer library had 
potent anti proliferative activity against A549 and 
DU 145 cells, and had a weaker effect on MCF7 cells 
(Figure 3E). In contrast to the other G-rich libraries, the 
GA 26-mer library had very little antiproliferative activity 
against any cell line (Figure 3A and data not shown). 
Based on the shape of the dose-dependence curves (for 
example, see Figure 3C, which plateaus at a non-zero 
value), it appears that active libraries have a cytostatic 
rather than cytotoxic effect. This was also observed 
previously for individual antiproliferative G-rich 
oligonucleotides (J 6). 
From these data, we designated all of the GT libraries 
and the GC 26-mer library as 'active' against cancer cells. 
In the remaining experiments, we compared these active 
libraries against the remaining ' inactive' libraries in 
order to identify characteristics that were associated with 
the unexpected antiproliferative activity. To confirm 
the cancer-selectivity of the active libraries, we also 
examined all libraries and oligomers in an additional 
non-tumorigenic cell line, MCFIOA, which is derived 
from benign breast epithelial cells. The results indicated 
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Figure 3. Antiproli ferative activity of libraries and oligomers. (A) Tabulation of percent decrease in cell number at 6 11M (strand concentration), 
calcula ted taking untrea ted wells to be 100% . Dark-gray shading indicates > 50% decrease; light-gray shading indicates betwcen 30% and 50% 
decrease. (8) Growth curves showing the effects of all libraries, non-G-rich and G-rich, on non-cancerous fi broblasts (Hs27). Relative cell numbers at 
each concentration are compared to no treatment. (C) Growth curves showing the effects of GT libraries of different lengths on A549 lung cancer 
cells. The N library is shown for comparison. (D) Growth curves showing the effects of various GT libraries on A549 lung cancer cells. The N library 
is shown for comparison. (E) Growth curves showing the effects of the GC 26-mer library on fo ur cell lines. 
that although the MCF IOA cells were slightly more sensi-
tive to anti proliferative effects than the Hs27 skin 
fibroblasts, they were markedly less sensitive than the 
cancer cell lines, includi ng MCF7 breast cancer cells 
(Supplementary Figure S I). 
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Libraries with anti proliferative activity share features 
of CD spectra 
CD of DNA arises from the helical arrangement 
of the bases and therefore conformational characteris-
tics (e.g. A-, B- or Z-forms of duplexes, and C- or 
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G-quadruplexes) can often be inferred from CD spectra, 
as described in an excellent recent review article (18). 
In our experiments, we observed that the CD spectra 
of active libraries typically displayed a negative peak 
at ~240 nm, a strong positive peak at 260-265 nm and 
an additional maximum or shoulder (depending on the 
cation present) in the region 285- 290 nm (Figure 4A). In 
addition, the spectra of the active libraries changed 
significantly between different salt solutions, with the 
largest peaks seen in the 100 mM potassium chloride 
solution. While CD data alone cannot be used to abso-
lutely assign structure, it is widely accepted that positive 
peaks close to 260 nm or 290 nm are associated with 
G-quadruplex formation (18, 19). Similarly, the 
conformational polymorphism suggested by the differ-
ences in CD spectra in the presence of various cations is 






























spectrum for an oligonucleotide library is derived from 
the combined CD spectra from millions of sequences. 
Thus, the characteristic spectrum of the active GT 
libraries (Figure 4A) presumably represents contributions 
from molecules with various arra ngements of G-quartets 
(maxima at 260 and 290 nm) and non-quadruplex 
single-stranded molecules (maximum at 275- 280 nm). 
Somewhat surprisingly, the spectrum of the GC library 
(Figure 4A) was quite similar to the GT libraries and 
shared features suggestive of G-quadruplex formation , 
although the presence of duplexes or hairpins in the 
GC-library cannot be excluded. 
Most of the inactive libraries showed a negative peak 
at ~250 nm as well as a single positive peak at ~275 om 
(Figure 4B). This is typical of both ordered single-
stranded and double-stranded DNA (18) . The spectra 
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Figure 4. CD studies. Samples were prepared at a concentration of 5 ~lM in three different solutions: water (blue), 100mM NaCI (red) and 100mM 
KCI (green). (A) CD spectra of various active libraries showing a similar profile (a positive peak at 260 nm and a second positive peak or shoulder at 
290 nm), which is characteristic of G-quadruplex formation. (B) CD spectra of inactive libraries showing a similar profile (positive peak in 
270-280-nm region), characteristic of non-G-quadruplex oligonucleotides. (C) Li braries with anomalous CD. Tbe inactive GA 26-mcr library CD 
is different from botb active and inactive profiles. The GT 0.33 26-mer libra ry has some anti proliferative activity, but its CD spectrum is similar to 








































Figure 4. Continued. 
different salt solu tions, except for the CT library and 
(dAh6, which showed slightly different spectral patterns 
in water compared to the salt-containing solu tions. 
Interestingly, the (dC)26 oligomer displayed a very large 
ellipticity and the peaks were slightly phase-shifted from 
the remaining inactive libra ries, with a negative peak at 
265 nm and positive at 285 nm. This subtle shift in CD 
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spectra may be due to the formation of secondary struc-
tures called i-motifs that have been reported in 
cytosine-rich molecules (20,21), albeit usually only under 
slightly acidic conditions. Our theory was supported by 
additional experiments in buffered solutions, which 
showed that the amplitude and shape of the CD 
spectrum for (dCh6 was strongly pH-dependent a nd was 
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typical of the i-motif (18.21) at pH 5, 6 or 7, but there 
was a transition to the standard single-stranded DNA 
spectrum at pH 8 (Supplementary Figure S2). 
The two exceptions to the general trends were the 
GT 0.33 26-mer library and the GA 26-mer library 
(Figure 4C); although the GT 0.33 26-mer library is 
included in the active libraries, its spectrum resembled 
the inactive libraries, consistent with the expected much 
smaller proportion of quadruplex-forming sequences a nd 
its lower level of a nti proliferative activity. The spectrum of 
the inactive GA 26-mer library varied considerably 
between water, NaCl and KCI, but was distinct from 
any of the other libraries examined, being close to zero 
at 240 om, with a positive peak at 260 nm and a negative 
peak at 285 om. This has been reported to be typical 
of G + A containing oligonucleotides and associated 
with stacked guanosines, although it is not clear if this 
reflects the presence of quadruplexes or other ordered 
structures, such as alternatively base-paired duplexes (18). 
Libraries with antiproliferative activity are significantly 
more stable in serum than inactive libraries 
To assess nuclease resistance, oligonucleotides and 
libraries were radiolabeled at the 51-end a nd incubated 
in complete medium (which contains serum-derived 
exonucleases) for various times. The primary purpose of 
this experiment was to determine nuclease stability under 
the exact conditions used in the MTT as ays. This was 
considered essential, beca use if an oligonucleotide 
is degraded in the cell culture medium, it is unlikely to 
be active whatever other properties it has (unless the 
active component is derived from degradation of the 
oligonucleotide into nucleotides). The results (Figure SA) 
showed that libraries that did not contain any G bases, as 
well as a ll of the monobasic oligomers tested, were highly 
susceptible to degradation in serum-containing medium, 
with most being fully degraded within 90 min. Libraries 
containing guanines in any percentage had at least some 
molecules still intact at 72 h, regardless of anti proliferative 
activity. 
Although all active libraries displayed stability in the 
presence of serum nUcleases, the degree of stability 
did not correlate with antiproliferative activity. For 
example, the moderately active GT lO-mer library was 
markedly less stable than the inactive N 26-mer library. 
However, although band density did not correspond to 
anti proliferative activity for the individual libraries, the 
mean band density of the active libraries at 24 a nd 72 h 
was significantly greater (P = 0.026 using Students' 
two-tailed I-test) than the inactive libraries (Figure 5B). 
Active libraries had increased cellular uptake compared 
to inactive libraries as shown by flow cytometry 
For this assay, four representative 26-mer libraries 
(the active GT a nd GC libra ries, a nd the inactive Nand 
GA libraries) were synthesized with a fluorophore a t the 
3/-end and used to assess cellular upta ke by flow 
cytometry. Cells were washed a nd harvested with trypsin 
prior to analysis to remove any surface-bound 
oligonucleotides. The relative level of uptake in a given 
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Figure S. Nuclease-resistance in serum-containing medium. (A) Auto-
radiographs showing elcctophoretic migration of radiolaheled oligomers 
or libraries following incubation in complete cell culture medium. 
which contains serum exonucleases. (8) Mean stability of active 
versus inactive libraries. The difference in band density between 
active and inactive libraries was statistically significant at 24 and 72 h 
(0 P < 0.05 using Student's two-tailed I-test). 
cell line can be estimated by determining the percent of 
cells that are ' positive' for the fluorophore (i.e. have a 
greater fluorescent intensity than the background signal, 
which a rises from autofluorescence of the cells) after 
excluding non-viable cells. This type of analysis is espe-
cially useful for comparing the uptake of various libraries 
and oligonucleotides in a particular cell line (22), although 
its use for comparing uptake between different cell lines is 
somewhat complicated by differing levels of baseline 
autofluorescence between cell lines. 
We observed that the active libraries, GT and GC, 
consistently yielded a higher proportion of fluorescent 
cells compared to inactive libraries in all cell lines 
(Figure 6). In general, the inactive N library had the 
lowest uptake of any library examined, and the inactive 
GA library had a similar or slightly higher uptake than the 
N library, but substantially less than the active libraries. 
For the GC 26-mer library, whereas its uptake in Hs27, 
o U 145 and A549 cells was close to that of the GT library 
(albeit a different distribution), its uptake in MCF7 cells 
was considerably less than the GT library (Figure 60). 
This result is noteworthy beca use the GC library also 
has reduced anti proliferative activity in this particular 
cell line (Figure 3E). Thus, these data suggest a correlation 
between relative uptake and antiproliferative activity, 
a lthough with the caveat that, as mentioned above, this 
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Figure 6. Cellular uptake or libraries and oligomers. Fluorescently labeled oligonucleotides (5 11M strand concentration) were incubated with cells ror 
I h. Cells were harvested and stripped or surrace-bound DNA using trypsin. then analyzed by flow cytometry to determine uptake. Uptake was 
quantified by determining the percentage or cells included in the black gate (positive ror FAM arter controlling ror autofluorescence). (A) Uptake in 
Hs27 non-malignant fibroblasts . (8 ) Uptake in A549 cancer cells. (C) Uptake in DUI45 cancer cells. (0) Uptake in MCF7 cancer cells. (E) Table or 
percent or FAM-positive cells ror each -sample. 
technique may not be optimal for comparing uptake 
between different cell lines. We noted the non-uniform 
shape of the curve for the GT library compared to other 
libraries, which may indicate a non-uniform uptake of the 
GT library (some cells take up much more oligomer than 
others), but the reason for this is unclear at present. 
Active libraries and inactive libraries had quantitative 
and qualitative differences in protein binding 
The protein binding patterns of S'-radiolabeled libraries or 
oligonucleotides fo llowing incubation with cell extracts 
were examined by electrophoretic mobility shift assay 
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(EMSA) and are shown in Figure 7. To start, we first 
analyzed the libraries and oligomers in the absence of 
proteins. The results (Figure 7A) confirmed the labeling 
and integrity of each sample and showed a quite marked 
dependence of electrophoretic migration on base compo-
sition, as expected. A very general observation from the 
EMSA experiments was that inactive libraries and 
oligomers displayed fewer and less intense shifted bands, 
when compared to the active libraries across a ll samples. 
Several shifted bands of interest were noted and are 
marked in Figure 7B-F. Appearance of the band 
marked 'B" was associated for the most part with 
nuclease-resistance libraries, but not nuclease-susceptible 
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Figure 7. Protein binding or libraries and oligomers. Radiolabeled oligonucleotides were incubated with whole-cell extracts and analyzed by native 
gel EMSAs. Oligonucleotides were with: (A) no protein extracts (oligomers alone); (8 ) A549 extracts; (C) DU 145 extracts; (D) MeF7 extracts; 
(E) Hs27 extracts; or (F) representative libraries were directly compared ror binding to extracts (5 II g) rrom the rour cell types. The arrows indicate 
DNA- protein complexes or panicular interest (see text ror discussion), and '0' indicates the origin or the gel. 
libraries or oligomers (Figure 5), suggesting it may be a 
general DNA-binding protein. However, this was usually 
most intense for the most active libraries and was present 
at much higher levels in the cancer cell lines compared to 
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the non-cancer cells (Figure 7F), suggesting it may con-
tribute to the antiproliferative effects. The series of faster 
migrating bands indicated by 'B2' were much less intense 
than B I, but are of interest because they were present 
predominantly for the most active libraries (GT26 and 
GT34). However, these bands were observed for Hs27 
cell extracts, as well as for cancer cells (Figure 7F). 
The band marked 'B3' is particularly interesting because 
it is specific for the GC-library, which has strong 
antiproliferative activity, and it is present at high levels 
in all of the cancer cells, but is undetectable in the 
non-malignant cells (Figure 7F). The fastest migrating 
band we have highlighted, 'B4', is present only in 
the C26 sample. Although this sequence has no 
antiproliferative activity, this band is interesting because 
oligo--<lC sequences may form unusual structures, 
involving the i-motif, and very few proteins that bind spe-
cifically to such structures have been previously reported 
(20). We plan to follow up these studies in the future by 
attempting to identify proteins of interest using mass 
spectrometry-based techniques. 
Interpretation of the EMSA data in the presence of 
protein (Figure 7B-F) has the potential to be somewhat 
complicated because the presence of shifted bands 
may depend not only on protein binding activity, 
but on nuclease-resistance as well. The relative 
nuclease-susceptibility under these conditions was 
expected to reflect the results from our serum stability 
assay (Figure 5), but may not be exactly the same 
because cell extracts contain endonucleases, as well as 
exonucleases. To further investigate these issues, we per-
formed nuclease-resistance assays in the presence of the 
DUI45 cellular extracts that were used in the EMSA 
experiments. We examined stability after incubation 
for a short time (15min), which mimics the EMSA condi-
tions, and found no significant nuclease degradation 
(Supplementary Figure S3A). These results verify that 
the absence of a shifted band in the EMSA is due to the 
complex not being formed, rather than the oligonucleo-
tides being degraded by nucleases. After longer incubation 
(18 h), which we anticipate will reflect the persistence of 
oligonucleotides inside cells, we observed (Supplementary 
Figure S3B) relative stabilities similar to those reported 
above for long-term stability in cell culture medium 
(Figure 5). This confirms our conclusions regarding the 
relationship between nuclease resistance, protein binding 
and anti proliferative activity (i.e. that, while active 
libraries are invariably stable and display strong protein 
binding, not all libraries that are stable and display strong 
protein binding are active). Furthermore, the data also 
suggest that protein binding may be responsible for 
nuclease resistance and not vice versa. 
CONCLUSIONS 
In this study, we have examined the biological properties 
and CD spectra of oligonucleotide libraries. The purpose 
of this exercise was primarily to test our hypothesis that 
G-rich libraries would be enriched in quadruplexes, which 
might make them useful starting points for the develop-
ment of new therapeutic aptamers using SELEX or similar 
technologies. 
The results of our analyses seem to confirm that G-rich 
oligodeoxynucleotide libraries do indeed contain large 
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numbers of quadruplex-forming sequences, and they are 
more nuclease-resistant and efficiently internalized by cells 
compared to the standard 'N library' currently used in 
SELEX. Experiments are now underway to determine if 
G-rich libraries can be used for SELEX and whether they 
will allow faster evolution of aptamers for in vivo use. 
While many of the observed properties of G-rich 
libraries were anticipated, the strong and cancer-selective 
growth inhibitory effects of some GT and GC libraries 
were unforeseen. When analyzing a library of molecules, 
it is important to remember that the results are the 
averages of the effects of all the different molecules 
within the library. Given our previous work, showing 
that several different quadruplex-forming oligonucleotides 
have cancer-selective antiproliferative activity (19,23), we 
expected that G-rich libraries might contain a small pro-
portion of active molecules. However, while we 
anticipated that a G-rich library might contain some 
very potent molecules, we presumed that the vast 
majority of the estimated 67000000 sequences in such a 
library would be ineffective, such that the library as a 
whole would display at best a modest growth inhibitory 
effect against cancer cells. Thus, the finding that certain 
GT and GC libraries have very potent and tumor-selective 
antiproliferative effects against a variety of cancer cell 
types was somewhat surprising. Remarkably, the 
antiproliferative activity of these libraries was comparable 
to some individual G-rich oligodeoxynucleotides that are 
currently in pre-clinical development or clinical trials (II). 
Although a full understanding of the anti proliferative 
properties of active libraries will require further efforts, 
the work that we have described provides some clues to 
the mechanism of action for these effects. The restriction 
of the activity to only certain GT and GC libraries indi-
cates that it cannot be a non-specific effect of 
phosphodiester oligonucleotides or simply due to the 
presence of deoxyguanosine nucleotides (either in the 
context of an oligonucleotide or as nucleobases resulting 
from oligomer degradation), because some dG-containing 
libraries, including the GA and N libraries, had no 
activity. In addition, although active libraries are generally 
more stable than inactive libraries, nuclease-resistance 
alone cannot explain the anti proliferative effects because 
some of the inactive libraries displayed comparable 
stability. 
In view of our observations, we now propose that 
antiproliferative activity requires all of the following: 
nuclease-resistance, efficient cellular uptake and binding 
to a specific protein (or proteins). It is not yet clear if 
quadruplex formation, per se, is necessary for activity, 
or whether it is simply that quadruplex-forming oligo-
nucleotides generally have the aforementioned properties. 
One possible candidate for the complex in the EMSAs that 
appears to be most relevant for activity (band 'B I' 
in Figure 7) is nucleolin. This protein is highly expressed 
in cancer cells and is a general DNA binding pro-
tein, but binds particularly strongly to a variety of 
quadruplex-forming sequences (24-27). It is also the 
molecular target of an existing G/T oligonucleotide 
aptamer (11). However, further studies will be required 
to verify this possibility and to reconcile why some 
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libraries bind to this protein (if it is indeed band B I), yet 
do not have enhanced cellular uptake or anti proliferative 
activity. Interestingly, the GC library appears to have a 
different cancer cell selectivity compared to the GT 
libraries and forms a specific protein complex (band 'B3' 
in Figure 7), suggesting that its mechanism of action 
and molecular target may be distinct from the GT 
oligonucleotides. 
In summary, the potent intrinsic and selective 
anti proliferative activity of the GT and GC libraries is 
an unexpected and wholly novel finding. Our results 
indicate that cancer-selective anti proliferative activity is 
a common characteristic of G-rich DNA oligonucleotides, 
which may explain why numerous different G-rich 
oligonucleotides have been reported as potential 
anticancer agents (II). Although many different mecha-
nisms of action have been proposed for these, our 
results suggest there may be common mechanisms 
(related to nuclease resistance, protein binding and 
cellular uptake) that contribute to the activity of G-rich 
oligonucleotides. Further research is warranted to eluci-
date the mechanism of action for these cancer-selective 
effects, as this may lead to insights into basic cancer cell 
biology, as well as to the identification of novel molecular 
targets and new oligomer-based therapies for cancer. 
SUPPLEMENTARY DATA 
Supplementary Data are available at NAR Online. 
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SUPPLEMENTARY DATA: METHODS 
Antiproliferative assay of oligomers on MCFIOA cells 
MCF10A non-malignant mammary epithelial cells were cultured in MEBM 
supplemented according to ATCC guidelines (BPE l3 mg/ml, 2 ml; hydrocortisone 0.5 
mg/ml, 0.5 ml; hEGF 10 ug/ml, 0.5 ml; insulin 5 mg/ml, 0.5 ml). Cells were incubated at 
37°C in 5% CO2 , For the MTT assays, 3000 cells were plated per well and assays were 
performed according to methods described in the manuscript. 
Circular dichroism at varying pH 
The (dCb oligomer was prepared at a concentration of 5 11M (strand concentration) in 50 
mM Tris acetate buffer that was pH-adjusted using glacial acetic acid to final values of 5, 
6, 7, and 8. Samples were incubated and analyzed according to methods described in the 
manuscript. 
Nuclease-resistance in DU145 protein extracts 
Libraries and oligomers were end-labeled as described in the manuscript. To match the 
conditions of the protein-binding assay, 50,000 cpm of oligomer was combined with 2.5 
Ilg DU145 whole cell lysate and protein binding buffer, as described for the EMSA in the 
manuscript. Samples were incubated at 37°C for 15 min, then electrophoresed on a 12% 
denaturing gel as described in the manuscript for the nuclease resistance assay. To 
examine nuclease resistance under conditions mimicking the cellular environment, 
similar experiments were carried out using 50,000 cpm of oligomer with 2.5 Ilg DU145 
whole cell lysate, but without protein-binding buffer, incubated at 37°C for l8h. 
SUPPLEMENTARY DATA: FIGURE LEGENDS 
Supplementary Figure 1: Antiproliferative activities of libraries and oligomers against 
MCFlOA cells. 
(a) Growth curves showing the effects of all libraries on non-cancerous breast epithelial 
cells (MCF1OA). Relative cell numbers at each concentration are compared to no 
treatment. For comparison, the following are also shown: (b) Hs27 non-cancerous 
fibroblasts; and (c) MCF7 breast adenocarcinoma cells. 
Supplementary Figure 2: Circular dichroism (CD) of C 26-mer oligodeoxynucleotide at 
varying pH. Samples containing 5 11M oligomer in Tris-acetate buffer were analyzed and 
the results shown are molar circular dichroism (i1E), referring to per mole of nucleotide. 
Supplementary Figure 3: Nuclease-resistance in the presence ofDU145 protein extracts. 
5' -Radio labeled libraries and oligomers were incubated with protein extracts (prepared as 
described for EMSA studies) at 37°C for the time indicated, and then electrophoresed on 
a 12% polyacrylamide denaturing gel. "0" indicates the origin of the gel. 
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APPENDIXB 
SELEX sequences from Nand GT library using PC3 prostate cancer cells 















1) ACTCGTGAGTATCGTCGTC (GACGACGATACTCACGAG) 














































6) ACTACGGAGGGGCTAGAGCAACAAGT (6+58) 
7) GTTGCACTTCTGAATTCAACTCTCGG 
8) ACTACGGAGGGGCTAGAGCAACAAGT (6+58) 
9) ACTACGGAGGGGCTAGAGCAACAAGT (6+58) 
10)ACTACGGAGGGGCTAGAGCAACAAGT (6+58) 





























3) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
4) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
5) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
6) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
7) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
8) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
9) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
10) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
II)ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
12) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
13) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
14) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
15) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
16) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
17) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
18) ACTACGGAGGGGCTAGTGCAACAAGT 
19) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
20) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
21) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
22) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
23) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
24) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
25) ACTACGGAGGGGCTAGAGCAACAAGT (23+41) 
Round 5: 
1) ACTACGGAGGGGCTAGAGCAACAAGT (35+29) 

























6) ACTACGGAGGGGCTAGAGCAACAAGT (35+29) 
7) ACTACGGAGGGGCTAGAGCAACAAGT (35+29) 




























































































































































































































5) TGGGTGTGGGTGTTGTTTGTTGTGTG (2) 
6) GGTTGGTTTGTTTGTGGGGGGGTTTG 






























































































































































Microarray Analysis of Changes in Gene Expression in 
DU145 Cells Treated with AS1411 





























calponin homology (CH) domain containing 1 
acetyl-Coenzyme A carboxylase alpha 
S-cell ClL/lymphoma 7C 
chromosome 6 open reading frame 11 
protein kinase C and casein kinase substrate in neurons 3 
chromosome 14 open reading frame 34 
peptidylprolyl isomerase (cyclophilin)-like 2 
autoantigen 
cholinergic receptor, nicotinic, epsilon polypeptide 
keratin 15 
hypothetical protein MGC5178 
hypothetical protein 24432 
transmembrane 4 superfamily member 7 
hypothetical protein FLJ22341 
host cell factor C1 regulator 1 (XP01 dependant) 
7 -dehydrocholesterol reductase 
transmembrane 7 superfamily member 2 
pleiomorphic adenoma gene-like 1 
proline dehydrogenase (oxidase) 1 
PISC domain containing hypothetical protein 
inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
jagged 2 
hepatitis delta antigen-interacting protein A 
stearoyl-CoA desaturase (delta-9-desaturase) 
filamin S, beta (actin binding protein 278) 
hypothetical protein FLJ21347 
204 








































Homo sapiens clone 24540 mRNA sequence 
RAB9, member RAS oncogene family, pseudogene 1 
nuclear antigen Sp100 
EGF-like repeats and discoidin I-like domains 3 
KIM 1068 protein 
Homo sapiens mRNA; cDNA DKFZp434J193 (from clone DKFZp434J193); partial 
cds 
thymus high mobility group box protein TOX 
HIV-1 inducer of short transcripts binding protein 
ADP-ribosylation factor interacting protein 1 (arfaptin 1) 
likely ortholog of mouse and zebrafish forebrain embryonic zinc finger-like 
I factor (complement) 
TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated 
factor, 65kDa 
21383_at 
hypothetical protein MGC11266 
hypothetical protein FLJ 11142 
macrophage stimulating, pseudogene 9 
hypothetical protein FLJ32389 
leukocyte Ig-like receptor 9 
216688_at 
zinc finger protein, V-linked 
hypothetical protein FLJ 13646 
eukaryotic translation initiation factor 4E 
APG12 autophagy 12-like (S. cerevisiae) 
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) 
polymerase delta interacting protein 46 
F-box and WD-40 domain protein 1 B 
amiloride binding protein 1 (amine oxidase (copper-containing)) 
RNA binding motif protein 3 
CD34 antigen 
nescient helix loop helix 2 
211074_at 
211506_s_at 
transient receptor potential cation channel, subfamily A, member 1 
protein tyrosine phosphatase type IVA, member 2 
hypothetical protein MGC3067 
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), 
memberA3 
superoxide dismutase 2, mitochondrial 
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achaete-scute complex-like 2 (Drosophila) 
hypothetical protein LOC 157697 
tumor-associated calcium signal transducer 2 
Homo sapiens similar to dJ309K20.1.1 (novel protein similar to dysferlin, isoform 
1) (LOC375095), mRNA 
208278_s_at 
216737 _at 
single-minded homolog 2 (Drosophila) 
217451_at 
EphA5 
Homo sapiens transcribed sequence with weak similarity to protein 
ref:NP _060219.1 (H.sapiens) hypothetical protein FLJ20294 [Homo sapiens] 
217093_at 
superoxide dismutase 2, mitochondrial 
insulin-like growth factor 1 (somatomedin C) 
Homo sapiens transcribed sequence with moderate similarity to protein 
ref:NP _060219.1 (H.sapiens) hypothetical protein FLJ20294 [Homo sapiens] 
Homo sapiens transcribed sequences 
histamine receptor H3 
alkaline phosphatase, placental-like 2 
G protein-coupled receptor 17 
cardiac ankyrin repeat kinase 
dachshund homolog (Drosophila) 
A kinase (PRKA) anchor protein 5 
ankyrin repeat domain 1 (cardiac muscle) 
estrogen receptor 1 
tight junction protein 3 (zona occludens 3) 
transmembrane protease, serine 4 
cold autoinflammatory syndrome 1 
glutathione S-transferase theta 2 
glutamate receptor, ionotropic, N-methyl D-aspartate 1 
hypothetical protein FLJ 1 0786 
CD1E antigen, e polypeptide 
zinc finger protein 157 (HZF22) 
Homo sapiens cDNA: FLJ21911 fis, clone HEP03855 
hypothetical protein FLJ22688 
tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) 




small muscle protein, X-linked 
zinc finger protein 254 
cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, 
Drosophila) 
telomerase reverse transcriptase 
Nef associated protein 1 


















































a disintegrin and metalloproteinase domain 28 
high density lipoprotein binding protein (vigilin) 
NADH:ubiquinone oxidoreductase MLRQ subunit homolog 
5-hydroxytryptamine (serotonin) receptor 2C 
family with sequence similarity 12, member B (epididymal) 
butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine 
hydroxylase) 1 
tripartite motif-containing 3 




homeo box D3 
FK506 binding protein 12-rapamycin associated protein 1 
217311_at 
ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, 
Angelman syndrome) 
dystrophin (muscular dystrophy, Duchenne and Becker types) 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 4 
tyrosine kinase with immunoglobulin and epidermal growth factor homology 
domains 
aquaporin 4 
forkhead box D3 
homeo boxA6 
adipose specific 2 
T-cell leukemia, homeobox 2 
caspase recruitment domain family, member 10 
ribosomal protein S11 
agouti signaling protein, nonagouti homolog (mouse) 
arginine vasopressin receptor 2 (nephrogenic diabetes insipidus) 
diacylglycerol kinase, epsilon 64kDa 
eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa 
Homo sapiens transcribed sequences 
granzyme A (granzyme 1, cytotoxic T-Iymphocyte-associated serine esterase 3) 
erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) 
G protein-coupled receptor 8 
potassium inwardly-rectifying channel, subfamily J, member 12 
histone 1, H4f 
leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), 
member 5 
Homo sapiens transcribed sequences 
chromodomain helicase DNA binding protein 3 
solute carrier family 22 (organic anion/cation transporter), member 11 
221018_s_at 
ATPase, H+ transporting, lysosomal 9kDa, VO subunit e 
fibroblast growth factor 18 
LOC92346 
Homo sapiens transcribed sequences 
prostaglandin D2 synthase 21 kDa (brain) 
KIM 1922 protein 
hypothetical protein LOC339047 
IMP (inosine monophosphate) dehydrogenase 2 





























transient receptor potential cation channel, subfamily C, member 3 
zinc finger protein 165 
carnitine palmitoyltransferase 1 B (muscle) 
tripartite motif-containing 31 
221720_s_at 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM 
domains), member 1 
mitogen-activated protein kinase 8 interacting protein 3 
cholinergic receptor, nicotinic, epsilon polypeptide 
chorionic somatomammotropin hormone-like 1 
UDP glycosyltransferase 2 family, polypeptide B17 
viperin 
hypothetical protein FLJ 12443 
calponin homology (CH) domain containing 1 
growth differentiation factor 11 
calcium channel, voltage-dependent, L type, alpha 1 B subunit 
CD84 antigen (leukocyte antigen) 
cysteine knot superfamily 1, BMP antagonist 1 
NAD synthetase 1 
growth arrest and DNA-damage-inducible, beta 
ribosomal protein L 17 
hypothetical protein HSPC 109 
chromosome 12 open reading frame 6 
CDC28 protein kinase regulatory subunit 1 B 
interleukin 24 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL 1-like helicase homolog, 
S. cerevisiae) 
E4F transcription factor 1 
protocadherin beta 8 
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HUS1 checkpoint homolog (S. pombe) 
hypothetical protein FLJ 1 0849 
hypothetical protein FLJ 1 0970 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 
EGF-like repeats and discoidin I-like domains 3 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 2 
hypothetical protein PRO 1853 
PTB domain adaptor protein CED-6 
SEC10-like 1 (S. cerevisiae) 
v-rei reticuloendotheliosis viral oncogene homolog (avian) 
glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease 1110) 
RAB3B, member RAS oncogene family 
golgi SNAP receptor complex member 2 
zinc finger protein 37a (KOX 21) 
hypothetical protein FLJ 12994 
prenylcysteine oxidase 1 
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
actin filament associated protein 
wingless-type MMTV integration site family, member 7B 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
zinc finger RNA binding protein 
paraneoplastic antigen 
PTK9 protein tyrosine kinase 9 
211506_s_at 
216383_at 
similar to Caenorhabditis elegans protein C42C1.9 
guanine nucleotide binding protein (G protein), alpha activating activity 
polypeptide, olfactory type 
suppression of tumorigenicity 
Homo sapiens cONA FLJ31439 fis, clone NT2NE2000707. 
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated 
death domain 
ring finger protein 125 
fumarate hydratase 
stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein) 
zinc finger RNA binding protein 
NGFI-A binding protein 1 (EGR1 binding protein 1) 
paternally expressed 10 
poly(A) polymerase alpha 
steroid sulfatase (microsomal), arylsulfatase C, isozyme S 
Homo sapiens, clone IMAGE:5294815, mRNA 
secretory carrier membrane protein 1 
endothelial and smooth muscle cell-derived neuropilin-like protein 
aryl hydrocarbon receptor nuclear translocator-like 2 
208844_at 
met proto-oncogene (hepatocyte growth factor receptor) 
SOCS box-containing WD protein SWiP-1 
PCTAIRE protein kinase 2 






















































BcI-2-associated transcription factor 
cyclin E2 
hypothetical protein H41 
cell division cycle 27 
solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 
NDRG family member 3 
progesterone receptor membrane component 1 
mitogen-activated protein kinase kinase kinase kinase 5 
zinc finger protein 426 
secretory carrier membrane protein 1 
heat shock 70kDa protein 4 
APG12 autophagy 12-like (S. cerevisiae) 
CD164 antigen, sialomucin 
AFFX-r2-Hs 18SrRNA-M_x_at 
REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 2 
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) 
septin 10 
Homo sapiens hypothetical LOC133993 (LOC133993), mRNA 
Sec23 homolog A (S. cerevisiae) 
polymerase (RNA) III (DNA directed) (32kD) 
hypothetical protein KIM 1164 
histone 1, H3h 
Ras-GTPase activating protein SH3 domain-binding protein 2 
RIO kinase 3 (yeast) 
interleukin 6 signal transducer (gp130, oncostatin M receptor) 
HIV-1 Rev binding protein 
hypothetical protein MGC3067 
calumenin 
SEC24 related gene family, member D (S. cerevisiae) 
core-binding factor, beta subunit 
insulin-like 5 
AFFX-HUMRGE/M 1 0098_5_at 
erythrocyte membrane protein band 4.1-like 1 
calumenin 
butyrate-induced transcript 1 
hypothetical protein MGC11061 
lectin, mannose-binding, 1 
NCK-associated protein 1 
RecQ protein-like (DNA helicase Q1-like) 
chromosome 20 open reading frame 30 
secretory carrier membrane protein 1 





sphingosine-1-phosphate phosphatase 1 
GM2 ganglioside activator protein 
oculocerebrorenal syndrome of Lowe 
catalase 



























Homo sapiens cDNA FLJ35853 fis, clone TEST12007078, highly similar to 
MEMBRANE COMPONENT, CHROMOSOME 17, SURFACE MARKER 2. 
DKFZP586N0721 protein 
cleavage and polyadenylation specific factor 5, 25 kDa 
leukocyte-derived arginine aminopeptidase 
transducin (beta)-like 1 X-linked 
hypothetical protein MGC14799 
ROD1 regulator of differentiation 1 (S. pombe) 
promethin 
phosphoglycerate kinase 1 
M-phase phosphoprotein, mpp8 
RIO kinase 3 (yeast) 
thioredoxin domain containing 
UDP-Gal:betaGlcNAc beta 1 ,3-galactosyltransferase, polypeptide 3 
tumor rejection antigen (gp96) 1 
PTD016 protein 
Homo sapiens transcribed sequence with weak similarity to protein 
ref:NP _060312.1 (H.sapiens) hypothetical protein FLJ20489 [Homo sapiens] 
216899_s_at 
AFFX-HUMRGE/M10098_M_at 
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), 
memberA3 
lamina-associated polypeptide 1 B 
hypothetical protein FLJ12806 
Homo sapiens transcribed sequence with strong similarity to protein 
ref:NP _055485.1 (H.sapiens) basic leucine-zipper protein BZAP45; KlAA0005 
gene product [Homo sapiens] 
adenovirus 5 E1A binding protein 
solute carrier family 16 (monocarboxylic acid transporters), member 1 





















Abbreviations and Symbols 
Acute myelocytic leukemia 
Anticancer aptamer discovered by P. Bates et. al 
Circular dichroism 
Cancer stem cells 
Castration resistant prostate cander 
Deoxyribonucleic acid 
Enzyme-linked immunosorbent assay 
Electromotility shift assay 
Fluorescent activated cell sorting 
G-rich oligonucleotide 
dye for antiproliferation assay 
Metastatic renal cell carcinoma 
National Cancer Institute 
No evidence of disease 
Nuclear magnetic resonance 
Poly-cytosine binding protein 
Prostate cancer 









Polymerase chain reaction 
Ribonucleic acid 
Systematic Evolution of Ligands by Exponential Enrichment 
Side population 
Tumor initiating cell 
Ultraviolet 
Very small embryonic-like cells 
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University of Louisville Health Outreach and Pediatric Education Clinic Louisville, KY 
Clinic Director, January 2005-June 2006 
Headed volunteer clinic staffed by students to serve indigent patients. Liaised with attending doctors and 
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submitted written evaluations for each student to the department. 
The Center for Women and Families Louisville, KY 
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Completed 5 week training program to qualify as a medical advocate and counselor for victims of sexual 
assault and domestic violence. Worked on-call sessions on a biweekly basis, volunteered with children and 
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Dance instructor, October 2004--June 2005 
Organized weekly dance lessons for medical students. Choreographed and taught classes in jazz and hip-
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to "Knit for a Cause," a local charity. 
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